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General introduction and outline
Adapted from:
Targeting white, brown and perivascular adipose tissue
in atherosclerosis development.
Eur J Pharmacol 2017; in press
Immune modulation of brown(ing) adipose tissue in obesity. 





OBESITY, ETHNICITY AND RISK OF METABOLIC 
DISORDERS
According to the World Health Organization, the worldwide prevalence of obesity, defined 
as a body mass index (BMI) > 30 kg/m2, has nearly doubled since 1980 and at least 2.8 
million people die each year as a result of obesity. This number is expected to further 
increase over the next decade. Obesity has a great impact on public health as it leads to 
disorders such as type 2 diabetes and cardiovascular disease (1, 2). It has become evident 
that besides BMI, ethnicity determines the risk of developing both type 2 diabetes (3-5) and 
cardiovascular disease (6-9). South Asians, who originate from the Indian subcontinent and 
compose 20% of the world population, have a higher risk of developing these pathologies 
compared to white Caucasians. Despite the presence of predisposing classical risk factors 
such as central obesity, insulin resistance and dyslipidemia in this population (10, 11), the 
high prevalence of type 2 diabetes and cardiovascular disease in South Asians cannot be 
explained by these factors alone (9, 12). This suggests that other, non-classical, risk factors 
underlie their increased susceptibility (13).
LIPID METABOLISM
Obesity develops as a result of a long-term positive energy balance and storage of lipids in 
several tissues. The most abundant lipid types in our diet are triglycerides and cholesterol. 
Triglycerides are the storage form of the main source of energy for the body, i.e. fatty acids. 
Fatty acids are burnt by the heart and muscle to generate adenosine triphosphate (ATP), 
a molecule that carries energy in the form of a covalent bond holding a phosphate group. 
ATP is required for many cellular and metabolic processes such as muscle contraction (14). 
Brown adipose tissue (BAT) uses fatty acids to generate heat rather than ATP (15) (Fig. 1). 
When intake of energy exceeds the body’s needs, fatty acids are stored as triglycerides 
in white adipose tissue (WAT), a process that also uses glucose to generate the glycerol 
backbone to which fatty acids are esterified (16). For humans, cholesterol does not provide 
energy, but is an essential component of cell membranes and a precursor for synthesis 
of steroid hormones, vitamin D, and bile acids. Interestingly, cholesterol from the host is 
also used by certain bacteria such as Mycobacterium bovis as energy source when they 
colonize a host (17, 18).
Lipids are hydrophobic and thus insoluble in blood, for which they are transported in 
lipoprotein particles. Lipoprotein particles exist of a lipid-rich core containing triglycerides 
and cholesteryl esters, the storage forms of fatty acids and cholesterol, respectively, 
surrounded by an amphipathic monolayer of phospholipids and unesterified cholesterol 
in which specific proteins (i.e. apolipoproteins) are embedded. Upon a meal, dietary 
triglycerides and cholesterol are taken up by intestinal cells, which assemble the lipids into 
triglyceride-rich lipoproteins carrying apolipoprotein B (apoB) named chylomicrons, that 
subsequently travel via the lymph to the blood. From the blood, they can provide tissues 
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with fatty acids. The liver secretes triglyceride-rich lipoprotein particles, named very-low 
density lipoproteins (VLDL), into the blood to supply tissues for their energy demand as 
well, which is crucial especially during times of fasting. Chylomicrons and VLDL deliver 
fatty acids mainly to heart, muscle and adipose tissues as these tissues express lipoprotein 
lipase (LPL), an enzyme essential for lipolysis of triglycerides within these lipoproteins. 
Subsequent uptake of the disengaged fatty acids is mediated by expression of cell surface 
receptors such as CD36. During lipolysis, the triglyceride-rich lipoproteins become 
enriched with apolipoprotein E (ApoE). ApoE binds the low density lipoprotein receptor 
(LDLR) or LDL-related protein (LRP) on the liver, ensuring hepatic clearance of the remnant 
particles (14, 19).
Figure 1. Schematic representation of triglyceride-rich lipoprotein metabolism. See text for explanation. 
ATP, adenosine triphosphate; B, apolipoprotein B; BAT, brown adipose tissue; E, apolipoprotein E; LDLR, 
low density lipoprotein receptor; LPL, lipoprotein lipase; LRP, low density lipoprotein-related protein; TRL, 




Adipose tissue is the main site for energy storage during obesity. WAT is the most abundant 
adipose tissue type, found throughout the body in different subcutaneous and visceral 
depots (20). WAT is a major participant in energy regulation of the body, not only by storing 
excess ingested glucose and fatty acids in the form of triglycerides in the adipocytes but 
also by releasing fatty acids as a result of intracellular lipolysis to meet the energy needs of 
other organs. In addition, WAT is an endocrine organ. It responds to hormonal signals and 
signals from the nervous system and it expresses and releases endocrine factors including 
leptin, adiponectin, cytokines, chemokines and components of the complement system. 
This endocrine function of WAT influences essential metabolic processes, including lipid 
and glucose homeostasis (21). The spherical adipocytes within WAT characteristically 
contain a single large lipid droplet and a few mitochondria that are dispersed in a thin 
surrounding layer of cytoplasm.
Another type of adipose tissue is BAT. This tissue is found in the neck, above the 
clavicles and around the spine in humans (22-24). In contrast to WAT, which stores energy, 
BAT combusts fatty acids to generate heat and maintain body temperature, a process that 
is defined as non-shivering thermogenesis. Hence brown adipocytes, that are smaller 
than white adipocytes, contain many mitochondria and typically hold multiple small lipid 
droplets (20). Thermogenesis is induced by catecholamine signaling. Catecholamines 
signal via all types of adrenergic receptors including β1, β2, β3, α1 and α2, although not 
all of these have stimulatory effects on thermogenesis. Expression of the stimulatory β3-
adrenergic receptor on brown adipocytes is likely the most specific and relevant for heat 
production (25). Apart from adrenergic receptor expression, thermogenesis is dependent 
on intracellular lipolysis and the presence of uncoupling protein 1 (UCP1). Intracellular 
lipolysis of triglycerides yields fatty acids, which are used as substrates for heat production 
and can directly activate UCP1. UCP1 resides in the inner mitochondrial membrane and, 
upon activation, facilitates proton leak, which disturbs the proton gradient that is generated 
by oxidative phosphorylation resulting from fatty acid oxidation. This “uncouples” electron 
transport from synthesis of ATP and leads to production of heat (25, 26). From rodent 
studies, it is known that besides classical brown adipocytes with high UCP1 expression, 
brown-like cells with very low basal but highly inducible UCP1 expression exist. These cells 
usually reside in WAT and are called beige adipocytes, and considerable evidence suggests 
that human BAT is mainly composed of beige adipocytes (27-29).
In addition to adipocytes, adipose tissue is composed of pre‐adipocytes, endothelial 
cells, fibroblasts, nerve tissue and immune cells. This contributes to the complexity and 
metabolic and endocrine functions of adipose tissue. Adipose tissue not only responds 
to hormonal and neural signaling, it also expresses and secretes a range of factors named 
adipokines. These factors include cytokines, chemokines and complement components 
(21). The secretion of adipokines accounts for the role of adipose tissue in systemic signaling 
pathways, such as regulation of energy balance and inflammation (30, 31). Differences exist 
in the complexity and endocrine functions of adipose tissue depots. For example, BAT is 
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more densely vascularized and innervated than WAT (20) whereas the transcript levels of 
inflammatory genes in BAT are generally lower than in WAT (32, 33).
WHITE ADIPOSE TISSUE INFLAMMATION IN OBESITY
Increased storage of lipids in WAT during obesity leads to hypertrophy of adipocytes, 
hypoxia, and eventually cell death, causing adipose tissue dysfunction and fibrosis. 
Dysfunctional and dying adipocytes change the local microenvironment by leakage of fatty 
acids and other products. The altered microenvironment causes release of adipokines (e.g. 
IL-6, TNF, CCL2) and recruitment of inflammatory cells by WAT (31, 34).
In WAT of lean mice, 10-15% of the cells are macrophages, whereas WAT of obese 
mice contains 45-60% macrophages (35). Resident macrophages in lean WAT have a 
predominant anti-inflammatory or M2 phenotype. In obesity, inflammatory monocytes are 
recruited to WAT, where they differentiate, acquire a pro-inflammatory or M1 phenotype 
and form the majority of macrophages (35, 36). Other myeloid cells that play a role in WAT 
include neutrophils and eosinophils. Neutrophils are very short-lived cells that infiltrate the 
WAT within 3 days after exposure to a high-fat diet (37, 38). The amount of eosinophils is 
inversely correlated with adiposity, and depletion of eosinophils in mice results in obesity 
and insulin resistance (39).
The repertoire of immune cells found in WAT also comprises lymphoid cells. More 
specifically, 10% of the stromal vascular fraction of lean WAT consists of T cells. During 
obesity, the total amount of T cells, CD8+ cytotoxic T cells and CD4+ effector T cells in 
WAT increase, whereas CD4+ Tregs decrease (40). Furthermore, pro-inflammatory Th1 T 
cells increase while more anti-inflammatory Th2 T cells decrease, altogether resulting in 
increased inflammation in obese WAT (39, 41-43). The chronic low-grade inflammation in 
obese WAT includes the recruitment of B cells, natural killer cells and mast cells (44, 45). 
Overall, a variety of immune cells infiltrate WAT during obesity, inducing a switch from a 
homeostatic anti-inflammatory environment to a state of chronic low-grade inflammation.
Due to the extensive communication between adipocytes and immune cells, chronic 
inflammation as occurs in obesity disturbs insulin signalling in the tissue (34, 46) thereby 
contributing to development of type 2 diabetes as will be further described below.
IMMUNE MODULATION OF BROWN AND BEIGE ADIPOSE 
TISSUE
In contrast to the well-established presence of different immune cell types in WAT, the 
presence and role of the immune system in the development, function and activity of BAT 
is still largely unknown. Interestingly, many factors that modulate energy expenditure, 
the hallmark of BAT activity, affect inflammation too, all in all suggesting that the immune 
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system is involved in BAT function. These factors include environmental temperature (47, 
48), the biological clock (49, 50), hormones (51, 52) and food intake (53).
Macrophages, the most abundant immune cells in WAT, are present in BAT as 
demonstrated by flow cytometry and qPCR (54). Evaluation of gene networks in BAT shows 
that immune cell trafficking is upregulated upon high-fat diet feeding (55). Furthermore, like 
WAT, BAT secretes adipokines (e.g. IL-6). Although the transcript levels of pro-inflammatory 
cytokines in BAT are lower compared to WAT, augmented expression of pro-inflammatory 
cytokines has been found in obese compared to lean BAT. These pro-inflammatory factors 
are thought to diminish BAT function (30).
The limited research that has been done into the role of immune cells in BAT may suggest 
that macrophages play a role in non-shivering thermogenesis. Cold exposure increases M2 
macrophages in both WAT and BAT, which release the catecholamine noradrenaline that in 
turn activates BAT and induces browning of WAT (54, 56). Eosinophils indirectly contribute 
to thermogenesis by promoting activation of M2 macrophages within adipose tissue (56, 
57). Besides macrophages, type 2 innate lymphoid cells are important mediators of beiging 
of WAT (58). So, although knowledge about the role of immune cells in BAT and beiging WAT 
lags behind, inflammation is probably an important player in brown adipocyte function as 
well.
INFLAMMATION SIGNIFICANTLY CONTRIBUTES TO TYPE 2 
DIABETES AND CARDIOVASCULAR DISEASE
A key mechanism by which inflammation leads to insulin resistance is inhibition of insulin 
signaling pathways in several metabolic tissues (59). After a meal, insulin is released by 
the pancreas and acts on its target tissues including muscle, liver and adipose tissues. 
Stimulation of the insulin receptor induces the uptake of glucose by these tissues (60, 61). 
The inflammatory cytokines TNF and IL-6, and the acute phase protein C-reactive protein 
(CRP) can directly inhibit the insulin pathway and thereby induce insulin resistance (62-
64). Moreover, inflammation activates a number of intracellular serine/threonine kinases 
such as c-Jun N-terminal kinases (JNKs) and IκB kinase (IKK) which inhibit insulin signaling. 
Inhibition of insulin signaling leads to peripheral insulin resistance and subsequent 
hyperglycemia, which can result in development of type 2 diabetes (59). On top of that, 
since insulin normally reduces VLDL production, decreased insulin sensitivity in the liver 
leads to enhanced production of VLDL and thereby to hyperlipidemia (65).
Atherosclerosis is the pathology underlying cardiovascular disease, and the main risk 
factor for the development of atherosclerosis is hypercholesterolemia. Atherosclerosis 
development is initiated by retention of low-density lipoproteins (LDL) and very-low-
density lipoprotein (VLDL) remnant particles in the vessel wall. In response, the vessel wall 
releases oxidative and pro-inflammatory factors that modify these particles, for example 
by oxidation, resulting in oxidized LDL (oxLDL) (66, 67). LDL is also modified by hydrolyzing 
enzymes that are present in the lesions (68, 69). Immune cells, mainly monocytes, are 
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recruited from the circulation upon the expression of chemoattractants like tumor necrosis 
factor (TNF) (70) and monocyte chemoattractant protein-1 (MCP-1) in the lesions (71). 
Locally produced factors, such as monocyte-colony stimulating factor (M-CSF) (72), 
promote the differentiation of monocytes into macrophages. Macrophages scavenge the 
accumulating and modified lipoproteins thereby developing into foam cells. Foam cells 
augment the inflammatory response, resulting in additional recruitment of immune cells 
Figure 2. The proposed role of white and brown adipose tissue in the development of insulin resistance 
and atherosclerosis during obesity. In obesity, both energy storage and fatty acid release are enhanced 
in white adipose tissue (WAT). Immune cells infiltrate the WAT, causing systemic inflammation. Brown 
adipose tissue (BAT) displays a whitened phenotype in obesity, resulting in decreased combustion of fatty 
acids. Therapeutic strategies to reduce insulin resistance and atherosclerosis should on the one hand 
focus on activation of brown adipocytes and beiging of white adipocytes to reduce circulating triglyceride-
rich lipoproteins, and on the other hand on reducing adipose tissue and systemic inflammation. BAT, brown 
adipose tissue; FA, fatty acid; TRL, triglyceride-rich lipoprotein; WAT, white adipose tissue.
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into the atherosclerotic plaque (66, 67). Ultimately, plaques can rupture and/or occlude the 
vessel, leading to a cardiovascular event in e.g. the heart (myocardial infarction) or brain 
(stroke) (71). In many cell types that are involved in buildup of the atherosclerotic plaque, 
intracellular inflammatory pathways (e.g. JNK and IKK) and transcription factors (e.g. nuclear 
factor κ-light-chain-enhancer of activated B cells; NFκB) control the expression of adhesion 
molecules and inflammatory chemokines and cytokines. Besides local inflammation in the 
vasculature, other peripheral sources of inflammation can augment the development of 
atherosclerosis, including chronic infection (73, 74) and obese liver and WAT (75).
Taken together, inflammation is an important factor in the development of both type 2 
diabetes and cardiovascular disease. Together with therapeutic interventions that activate 
BAT or induce browning, resulting in enhanced nutrient combustion, strategies that reduce 
inflammation may help to mitigate these pathologies (Fig. 2).
OUTLINE OF THIS THESIS
As is evident from this chapter (chapter 1) of this thesis, inflammation plays an important 
role in the development of insulin resistance and atherosclerosis by disturbing both WAT 
and BAT, and targeting inflammation may thus hold therapeutic potential. Although widely 
used compounds to treat type 2 diabetes and cardiovascular disease, such as respectively 
metformin and statins, have pleiotropic anti-inflammatory effects (76-78), no strategies 
currently exist that primarily target inflammation in the treatment of these disorders. A better 
understanding of the interaction between inflammatory pathways in metabolic tissues and 
metabolic derangements is a prerequisite for the development of novel compounds that 
dampen inflammation to treat individuals with these pathologies.
The research described in this thesis was performed to address three key objectives: 
1) gain more insight into the role of the immune system in obesity, insulin resistance, 
dyslipidemia and atherosclerosis, 2) study inflammation in a human population with a 
particularly high risk to develop type 2 diabetes and cardiovascular disease, and 3) study 
the therapeutic potential of reducing inflammation by pharmacological strategies on 
obesity and glucose and lipid metabolism in pre-clinical models, with emphasis on BAT and 
WAT.
To address the first key objective, we studied the effect of a potent inflammatory 
trigger on lipid metabolism and atherosclerosis. Bacille-Calmette-Guérin (BCG), prepared 
from attenuated live Mycobacterium bovis, is the only licensed and widely used vaccine 
against tuberculosis and modulates atherosclerosis development via immunomodulatory 
mechanisms. However, previous studies are conflicting with regards to whether  BCG 
protects against or enhances atherosclerosis and did not take into account the effect 
of  BCG on metabolism of cholesterol, the main driver of atherosclerosis. The aim of 
chapter 2 therefore was to elucidate the effect of  BCG on cholesterol metabolism and 
atherosclerosis development. In the next chapter, we switched our focus from immune 
modulation of lipid metabolism and atherosclerosis to glucose metabolism and type 
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2 diabetes. During the development of obesity, B cells accumulate in WAT and produce 
pathogenic IgG antibodies, which contribute to the development of glucose intolerance. 
IgG antibodies signal by binding to Fcγ receptors (FcγR) and by activating the complement 
system. In chapter 3, the purpose was to investigate whether activation of FcγR and/or 
complement pathway mediate the development of glucose intolerance in WAT.
To meet our second key objective, we performed a human study in which we compared 
Dutch South Asians and Dutch white Caucasians. These ethnic groups were selected 
because of the strikingly elevated risk of developing type 2 diabetes that South Asians 
have when compared to white Caucasians. Even though their increased risk of type 2 
diabetes is well-established and inflammation is known to contribute to the development 
of this disease, inflammatory pathways in South Asians have not been extensively studied 
previously. The intent in chapter 4 was therefore to investigate the inflammatory state of 
blood and metabolic tissues in Dutch South Asians compared to Dutch white Caucasians.
In the final part of this thesis, studies are described that focus on the treatment of 
metabolic inflammation and disease by targeting BAT and WAT (key objective 3). Salsalate 
is an anti-inflammatory drug that improves glucose intolerance and dyslipidemia in type 
2 diabetic patients, but the mechanisms behind these effects are unclear. The research 
in chapter 5 was designed to unravel these mechanisms. We assessed the effects of 
salsalate on lipid metabolism and adipose tissue inflammation in vivo, and investigated the 
molecular pathways mediating direct effects of salsalate on brown adipocytes in vitro. We 
then aspired to assess the therapeutic potential of targeting GPR120, a fatty acid receptor 
that mediates anti-inflammatory and insulin-sensitizing effects. Interestingly, cold exposure 
markedly increases the expression of GPR120 in BAT and WAT. These immunomodulatory 
and fat-related properties of GPR120 prompted us to investigate the effects of GPR120 
deficiency and treatment with a GPR120 agonist on obesity and lipid metabolism in chapter 
6.
Finally, the results from these studies and their implications for the development of 
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Bacille-Calmette-Guérin (BCG), prepared from attenuated live Mycobacterium bovis, 
modulates atherosclerosis development as currently explained by immunomodulatory 
mechanisms. However, whether  BCG is pro- or anti-atherogenic remains inconclusive 
as the effect of  BCG on cholesterol metabolism, the main driver of atherosclerosis 
development, has remained underexposed in previous studies. Therefore, we aimed to 
elucidate the effect of  BCG on cholesterol metabolism in addition to inflammation and 
atherosclerosis development in APOE*3-Leiden.CETP mice, a well-established model of 
human-like lipoprotein metabolism. To this end, hyperlipidemic APOE*3-Leiden.CETP mice 
were fed a Western-type diet containing 0.1% cholesterol and were terminated 6 weeks 
after a single intravenous injection with  BCG (0.75 mg; 5x106 CFU).  BCG-treated mice 
exhibited hepatic mycobacterial infection and hepatomegaly. The enlarged liver (+53%, 
p=0.001) coincided with severe immune cell infiltration and a higher cholesterol content 
(+31%, p=0.03). Moreover,  BCG reduced plasma total cholesterol levels (-34%, p=0.003), 
which was confined to reduced nonHDL-cholesterol levels (-36%, p=0.002). This was due 
to accelerated plasma clearance of cholesterol from intravenously injected [14C]cholesteryl 
oleate-labelled VLDL-like particles (t½ -41%, p=0.002) as a result of elevated hepatic uptake 
(+25%, p=0.05) as well as reduced intestinal cholestanol and sterol absorption (up to -37%, 
p=0.003). Ultimately, BCG decreased foam cell formation of peritoneal macrophages (-18%, 
p=0.02) and delayed atherosclerotic lesion progression in the aortic root of the heart. BCG 
tended to decrease atherosclerotic lesion area (-59%, p=0.08) and reduced lesion severity. 
In conclusion, BCG reduces plasma nonHDL-cholesterol levels and delays atherosclerotic 




Cardiovascular disease is the leading cause of death in Western countries, and 
atherosclerosis is the pathology underlying most cardiovascular events. The main 
risk factor for the development of atherosclerosis is hypercholesterolemia, as excess 
cholesterol initiates foam cell formation in the arterial wall. Subsequently, inflammatory 
processes including recruitment of innate and adaptive immune cells contribute to 
further development of the plaque, which may eventually lead to plaque rupture and/or 
vessel occlusion (1). A variety of bacteria and viruses (2), but also bacterial components 
such as lipopolysaccharide (3), have been suggested to be implicated in atherosclerosis 
development. In this respect, Bacille-Calmette-Guérin (BCG), prepared from attenuated live 
Mycobacterium bovis and the only licensed vaccine against tuberculosis (4), is of special 
interest since BCG is used worldwide for vaccination.
Interestingly, animal studies have shown that  BCG modulates atherosclerosis 
development. However, the data on whether  BCG reduces or enhances atherosclerosis 
development are conflicting.  BCG injection in rabbits in which plasma cholesterol levels 
were maintained constant (i.e. by individual adjustment of the percentage of cholesterol 
in the diet) increased lymphocyte and monocyte activation and hence atherosclerosis 
development (5). In contrast, repeated injections of killed BCG reduced atherosclerosis in 
LDL receptor-knockout (Ldlr-/-) and apolipoprotein E-knockout (Apoe-/-) mice, but did not 
significantly modulate plasma cholesterol levels. The reduced atherosclerosis development 
was accompanied by enhanced circulating IL-10 levels and reduced serum levels of pro-
inflammatory cytokines (6). Although these pro- and anti-atherogenic effects have been 
attributed to immunomodulatory effects of BCG, the effect of BCG on the metabolism of 
cholesterol, the main driver of atherosclerosis development, has remained underexposed.
Therefore, in the current study we aimed to elucidate the effect of BCG on cholesterol 
metabolism and atherosclerosis development in APOE*3-Leiden.CETP (E3L.CETP) 
transgenic mice. These mice have a humanized lipoprotein profile due to expression of 
human cholesterol ester transfer protein (CETP), which transfers cholesteryl esters from 
HDL to LDL and VLDL in exchange for triglycerides, and a mutation of the human APOE*3 
gene, which attenuates clearance of cholesterol-enriched lipoprotein remnants without 
abrogating the apoE-LDLR clearance pathway (7-9). We show that BCG markedly reduces 
plasma cholesterol levels as a result of accelerated hepatic uptake of cholesterol-enriched 
lipoprotein remnants and reduced intestinal cholesterol absorption. Finally,  BCG reduces 




Mice, diet and BCG treatment
Female E3L.CETP mice were obtained as previously described (7, 8). At the start of the 
experiment mice were 10-12 weeks of age and housed under standard conditions with 
a 12:12 h light-dark cycle and free access to food and water. Mice were fed a Western-
type diet containing 0.1% cholesterol (WTD; Hope Farms, The Netherlands). After a run-
in period of 3 weeks with WTD, mice were randomized according to body weight, plasma 
total cholesterol (TC) and plasma triglycerides (TG), and received an intravenous injection 
with a human dose of Bacille-Calmette-Guérin (BCG) vaccine SSI (0.75 mg; 5x106 CFU in 
100 μL PBS; SSI Denmark) (10). Mice were terminated 6 weeks after the injection. Mouse 
experiments were performed in accordance with the Institute for Laboratory Animal 
Research Guide for the Care and Use of Laboratory Animals and had received approval from 
the University Ethical Review Board (Leiden University Medical Center, The Netherlands).
Mycobacterial culture
Blood, splenocytes and bone marrow were incubated both in BBL Bactec MGIT tubes 
(245113, BD and Company, NJ, USA) and on Lowenstein-Jensen + PACT plates (220501, 
BD and Company, NJ, USA) at 36°C. Bacterial growth in the BBL Bactec MGIT tubes was 
measured weekly using the BD BACTEC™-MicroMGIT Fluorescence Reader according to 
the manufacturer’s instructions. Lowenstein-Jensen plates were checked once a week for 
growth of colonies. When positive, standard Ziehl-Neelsen (ZN) staining [z1] was performed 
to confirm presence of mycobacteria.
Liver histology
Livers were fixed in 4% paraformaldehyde, dehydrated in 70% EtOH, and embedded in 
paraffin. Hematoxylin-eosin (HE) and ZN stainings were performed on sections (5 µm) 
using standard protocols. Immunohistochemical detection of F4/80 was done on paraffin-
embedded sections that were treated with proteinase K, by using a primary rat anti-










Table 1: Primer sequences of forward and reverse primers (5’ → 3’).
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mouse F4/80 monoclonal Ab (MCA497; 1/600, Serotec, UK) and a secondary goat anti-rat 
immunoglobulin peroxidase (MP-7444, Vector Laboratories Inc., CA, USA). The peroxidase 
activity was revealed with NovaRed (SK-4800, Vector Laboratories Inc.) and slides were 
counterstained with hematoxylin. The area positive for F4/80 was quantified using ImageJ 
Software.
RNA purification and quantitative RT-PCR
RNA was extracted from snap-frozen mouse livers using Tripure RNA Isolation reagent 
(Roche, The Netherlands) according to manufacturer’s instructions. RNA concentrations 
were measured using NanoDrop and RNA was reverse transcribed using Moloney Murine 
Leukemia Virus Reverse Transcriptase (Promega, The Netherlands) for quantitative RT-PCR 
(qRT-PCR) to produce cDNA. Expression levels of genes were determined by qRT-PCR, 
using gene-specific primers (Table 1) and SYBR green supermix (Biorad, The Netherlands). 
mRNA expression was normalized to Gapdh mRNA content and expressed as fold change 
compared with control mice using the ΔΔCT method.
Flow cytometry
Circulating white blood cells were analysed using flow cytometry. After lysis of red blood 
cells, pelleted cells were resuspended in FACS buffer and stained for 30 minutes at 4°C in 
the dark with the fluorescently labelled antibodies listed in Table 2. Cells were measured 
on an LSR II flow cytometer (BD Biosciences, CA, USA). Data were analysed using FlowJo 
software (Treestar, OR, USA).
Isolation and ex vivo stimulation of cells
Resident peritoneal macrophages were isolated from mice by washing the peritoneal cavity 
with ice-cold sterile PBS. Pelleted cells were resuspended in RPMI 1640 Dutch-modified 
culture medium (Life Technologies/Invitrogen, The Netherlands) supplemented with 10 
Antibody Fluorochrome Dilution Clone, supplier
CD45.2 FITC 1:100 104, BioLegend
CD3 APC 1:100 145-2C11, eBioscience
CD4 Qdot605 1:1000 RM-4-5, BioLegend
CD8a PerCPCy5.5 1:100 53-6.7, BioLegend
CD25 PeCy7 1:300 PC61.5, eBioScience
CD44 eFluor450 1:300 IM7, eBioScience
CD22.2 PE 1:200 Cy34.1, BD Biosciences
Cd11b Pacific Blue 1:150 M1/70, BioLegend
Cd115-Biotin n.a. 1:100 AFS98, eBioScience
Streptavidin PeCy5 1:100 SAV, eBioScience
Gr-1 PeCy7 1:1500 RB6-8C5, Biolegend
Table 2: Antibodies used for flow cytometry.
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mM glutamine, 10 mM pyruvate (Invitrogen) and 10 µg/mL gentamicin (Centrafarm, The 
Netherlands) and stimulated with 10 ng/mL LPS (E. coli serotype 055:B5, further purified as 
described previously (11); Sigma-Aldrich, MO, USA) for 24 h. Supernatants were collected 
for determination of cytokine secretion.
Splenocytes were resuspended in RPMI and stimulated with 10 ng/mL LPS or heat-
inactivated C. albicans (MYA-3573 UC 820, ATCC, Germany). Supernatants were collected 
at 48 h or 5 days for measurement of innate or adaptive cytokines.
Bone marrow cells were resuspended in Dulbecco’s Modified Eagle Medium (Gibco, 
Invitrogen, CA, USA) supplemented with 30% L929 medium, 10% FCS, 1% nonessential 
amino acids, 1% 100 U/mL penicillin and 100 mg/mL streptomycin for differentiation into 
macrophages. On day 6, the bone marrow-derived macrophages (BMDMs) were harvested 
and stimulated with 10 ng/mL LPS for 24 h. Supernatants were collected for cytokine 
measurements.
Cytokine measurements
Mouse IL-6 (CMC0063, Life technologies, The Netherlands), IL-10 and interferon γ (IFNγ; 
DY417 and DY485, R&D Systems Europe, UK) were measured using commercial ELISA kits 
according to manufacturers’ instructions. Mouse tumor necrosis factor alpha (TNF) and 
IL-1β were measured using specific radioimmunoassays (RIA) as described previously (12).
Food intake and body weight and composition measurements
Food intake and body weight were measured weekly with a scale, and body composition 
was measured using an EchoMRI-100 analyzer (EchoMRI, TX, USA).
Determination of plasma and liver lipids
At the indicated time points, 4 h-fasted (from 8:00 am to 12:00 pm) blood samples were 
collected through tail vein bleeding and isolated plasma was assayed for TC and TG by using 
commercially available enzymatic kits (Roche Diagnostics, Germany). For determination 
of HDL-cholesterol, apoB-containing particles were precipitated from plasma with 
20% polyethylene glycol in 200 mM glycine buffer (pH 10) and TC was measured in the 
supernatant.
Lipids were extracted from the liver following a protocol modified from Bligh and Dyer 
(13). Liver samples were homogenized in 10 µL ice-cold CH3OH/mg tissue. Lipids were 
extracted into an organic phase by the addition of 1,800 µL CH3OH:CHCl3 (1:3 v/v) to 45 
µL homogenate and subsequent centrifugation. The lower organic phase was evaporated, 
lipids were resuspended in 2% Triton X-100, and TC and TG content was assayed as 




In vivo clearance of VLDL-like particles
VLDL-like TG-rich particles (80 nm) labelled with glycerol tri[3H]oleate (TO) and [14C]
cholesteryl oleate (CO) were prepared and characterized as described previously (9, 14). 
Mice were fasted for 4 h (from 8:00 am to 12:00 pm) and injected with 200 µL of VLDL-like 
particles (1.0 mg TG per mouse) via the tail vein. Blood samples were drawn from the tail 
vein at the indicated times after injection to determine the plasma decay of [3H]TO and 
[14C]CO. After 15 min, mice were killed by cervical dislocation and perfused with ice-cold 
PBS through the heart. Organs were harvested and weighed, dissolved in Tissue Solubilizer 
(Amersham Biosciences, The Netherlands) overnight at 56°C and analysed for 3H- and 
14C-activity.
Extraction and analysis of hepatic cholestanol and sterols
Total cholesterol, markers for hepatic cholesterol synthesis (i.e. lanosterol, desmosterol 
and lathosterol) as well as markers for intestinal cholesterol absorption (i.e. cholestanol, 
campesterol and sitosterol) were extracted from liver by chloroform-methanol and analysed 
by GC-flame ionization detection and GC-MS as reported previously (15). Dry weight of liver 
samples was determined after they were dried to constant weight overnight in a Speedvac 
(Servant Instruments Inc., NY, USA). Data are expressed as ratio to hepatic total cholesterol 
levels.
Western blot
Pieces of snap-frozen liver tissue (~50 mg) were lysed, protein was isolated, and Western 
blots were performed as previously described (16). Primary antibodies and dilutions are 
listed in Table 3. Protein content was corrected for the housekeeping protein Tubulin.
Assessment of foam cell formation
Foam cell formation was assessed by culturing 1x105 cells/well either in control medium 
or medium supplemented with 50 μg/mL oxidized human LDL (oxLDL, prepared as 
described previously (17)) for 48 h. Supernatants were removed and cells were lysed (0.5% 
Triton-X100). Uptake of oxidized LDL was assessed by measuring intracellular human apoB 
with ELISA as described before (17).
Primary antibody Dilution Supplier
LDLR 1:1000 AF2255, R&D Systems
SR-BI 1:1000 Ab396, Abcam Inc
α/β-Tubulin 1:1000 #2148, Cell Signaling




Hearts were collected, fixed in 4% paraformaldehyde, dehydrated in 70% EtOH, embedded 
in paraffin and cross-sectioned (5 µm) perpendicular to the axis of the aorta throughout 
the aortic root area, starting at the point where the open aortic valve leaflets appear. Per 
mouse, four sections with 50 µm intervals were used for atherosclerosis measurements. 
Sections were stained with haematoxylin-phloxine-saffron (HPS) for histological analysis. 
Lesions were categorized for lesion severity according to the guidelines of the American 
Heart Association adapted for mice (18). Various types of lesions were discerned: mild 
lesions (types 1-3), severe lesions (types 4-5) and valve lesions. Lesion area was determined 
using ImageJ Software (9). Detection of macrophage-positive area was performed with rat 
monoclonal anti-MAC-3 antibody (BD Pharmingen, CA, USA) and Vector Impress anti-rat 
(Vector Laboratories Inc.). The immunostaining was amplified using Vector Laboratories 
Elite ABC kit and peroxidase activity was visualized with NovaRed (Vector Laboratories 
Inc.). Sirius red (Chroma, Germany) was used to stain for collagen. The stability index was 
determined by dividing the Sirius red-positive area by the MAC-3-positive area.
Statistical Analysis
All data are expressed as means ± SEM. Groups were compared with a two-tailed unpaired 
Student’s t-test unless stated otherwise. Groups were considered statistically significant 
if p<0.05.
RESULTS
BCG induces mycobacterial infection in hyperlipidemic mice
E3L.CETP mice were fed a Western-type diet containing 0.1% cholesterol (WTD) and 
received a single intravenous  BCG injection. After six weeks, blood and various organs 
were cultured to investigate whether viable  BCG was still present. Blood of  BCG-treated 
mice tested negative for mycobacteria. However, livers, spleens and bone marrow of BCG-
treated mice were positive for mycobacteria (Suppl. Fig. 1 and data not shown), indicating 
ongoing infection.
BCG induces hepatic inflammation
Since  BCG induced hepatic mycobacterial infection and the liver plays a key role in lipid 
metabolism, we further studied the livers of the  BCG-treated animals. Liver weight was 
increased in BCG-treated mice (+53%, Fig. 1A). In these livers, severe leukocyte infiltration 
(Fig. 1B) and accumulation of F4/80-positive cells (Fig. 1C) was observed. This coincided 
with increased expression of inflammatory markers including F4/80 and Tnf as well as the 
T cell markers Cd3, Cd4 and Cd8 (Fig. 1D). Besides hepatomegaly, BCG-treated mice also 
exhibited an enlarged spleen (+149%, Fig. 1A).
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BCG induces overall immune activation
Given the inflammatory state of the liver, we assessed the effect of BCG on circulating white 
blood cells by flow cytometry. Within the CD45+ white blood cells, BCG did not significantly 
affect the relative monocyte or granulocyte content (Suppl. Fig. 2A, B), but did reduce 
the percentage of B cells (-33%, Suppl. Fig. 2C). The percentage of total T cells remained 
similar upon BCG vaccination (Suppl. Fig. 2D), but BCG increased T helper cells (+11%, Fig. 
2A) without altering cytotoxic T cells (Fig. 2D). Activation of T helper cells was not affected 
by BCG (Fig. 2B), but the memory T helper cells tended to be higher (+59%, Fig. 2C). More 
pronounced effects on activation and memory were found within the cytotoxic T cells, 
as BCG induced both activation (+204%, Fig. 2E) and memory (+84%, Fig. 2F) of cytotoxic 
T cells. Overall, these findings suggest that BCG induces activation of circulating immune 
cells.
To determine the inflammatory status of tissue macrophages, we performed ex 
vivo stimulation of peritoneal macrophages, splenocytes and bone marrow-derived 
macrophages and measured cytokine secretion. BCG increased the number of macrophages 
in the peritoneal cavity (+37%, Fig. 2G). Even after correcting for the number of cells, the 
peritoneal macrophages of  BCG-treated mice produced more inflammatory cytokines 
upon LPS stimulation than macrophages from untreated animals (i.e. TNF, IL-1β; Fig. 2H-K), 
























































































Figure 1. BCG induces hepatic inflammation. E3L.CETP mice fed a WTD were treated with PBS or BCG 
(0.75 mg; 5x106 CFU; i.v.). Upon sacrifice after 6 weeks, liver and spleen were collected and weighed (A). 
Haematoxylin and Eosin (B) and F4/80 staining (C) of liver sections was performed. Representative pictures 
are shown. The relative content of F4/80 positive cells was quantified (C). Hepatic mRNA expression of 
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Figure 2. BCG increases immune activation. E3L.CETP mice fed a WTD were treated with PBS or BCG 
(0.75 mg; 5x106 CFU; i.v.). After 6 weeks, blood, peritoneal macrophages and bone marrow were collected. 
Within the CD3+ T cell fraction, percentage of CD4+ (A) and CD8+ (D) cells were determined. Within the 
CD4+ and CD8+ T cell fractions, percentages of activated T cells (CD44+CD25+; B, E) and memory T cells 
(CD44+CD25-; C, F) were determined. Peritoneal macrophages were counted (G) and stimulated with LPS. 
Production of IL-6 (H), TNF (I), IL-1β (J) and IL-10 (K) was measured. Bone marrow cells were counted before 




Splenocytes from  BCG-treated mice also produced more inflammatory cytokines 
upon LPS stimulation (i.e. IL-6, TNF, IL-10; Suppl. Fig. 2E-G), confirming the inflammatory 
phenotype. Interestingly, upon adaptive immune response stimulation (i.e. with C. Albicans) 
splenocytes also produced more IFNγ (Suppl. Fig. 2H), suggesting that BCG activates CD4+ 
and CD8+ T cells in the spleen, in line with our observations on circulating cells.
Bone marrow cell counts were lower in mice treated with  BCG (-28%, Fig. 2L). After 
adjusting for the number of cells, bone marrow-derived macrophages (BMDMs) from BCG 
treated mice did not exhibit lower capacity to proliferate (Fig. 2M), suggesting that 
the reduced bone marrow cell counts reflect hematopoietic stem and progenitor cell 
exhaustion. LPS stimulation of BMDMs did not reveal alterations in cytokine production 
(data not shown). Taken together,  BCG infection resulted in increased overall immune 
activation.
BCG lowers body fat but increases liver lipid content
To assess the effect of BCG on the metabolic phenotype of E3L.CETP mice, body weight 
and composition were measured over the 6-week period after  BCG administration. Total 
body weight (Fig. 3A) and food intake (Fig. 3B) were not affected by BCG. After 6 weeks, lean 
body mass remained unaffected (Fig. 3C), but fat mass tended to be lower in BCG-treated 
















































































































Figure 3.  BCG increases liver 
lipids. E3L.CETP mice fed a 
WTD were treated with PBS 
or  BCG (0.75 mg; 5x106 CFU; 
i.v.). Body weight (A), food intake 
(B), lean mass (C), fat mass (D), 
gonadal white adipose tissue 
weight (E) were measured 
at the indicated time points. 
Lipids were extracted from 
liver and liver triglycerides (TG), 
liver total cholesterol (TC) and 
liver phospholipids (PL) were 
measured (F). Values represent 
means ± SEM (n=5-6). *p<0.05 




fat pads (-36%, Fig. 3E). In line with the increase in liver weight, BCG-treated mice exhibited 
increased liver lipid content (i.e. TG, cholesterol and phospholipids), although the increase 
in TG content did not reach statistical significance (Fig. 3F).
BCG lowers plasma cholesterol by accelerating hepatic uptake 
of cholesterol-enriched lipoprotein remnants and reducing 
intestinal cholesterol absorption
As hypercholesterolemia is the main risk factor for atherosclerosis development, we 
studied the effect of BCG on plasma lipid levels. BCG tended to decrease plasma TG levels 
after 6 weeks (-34%, Fig. 4A), and consistently reduced plasma total cholesterol (TC) levels 
during the study (-34% at the endpoint, Fig. 4B) when compared to the PBS-treated group. 
This reduction in TC was confined to lowering of the nonHDL-cholesterol fraction (Fig. 
4C). To investigate whether the reduced plasma TC levels were due to increased clearance 
of lipoprotein remnant cholesterol, we assessed the plasma clearance and organ uptake 
of glycerol tri[3H]oleate (TO)- and [14C]cholesteryl oleate (CO)-double-labelled VLDL-like 
particles in vivo. Plasma clearance of [3H]TO was comparable between the groups (Fig. 4D, 
t½ = 3.0 vs. 3.4 min, p=0.09), and no obvious effects on organ uptake of 3H-activity were found 
apart from an increased uptake by the spleen (+109%, Fig. 4E). In contrast, BCG markedly 
accelerated plasma clearance of [14C]CO (Fig. 4F, t½ = 5.0 vs. 8.5 min, p=0.002), mainly due 
to increased uptake of [14C]CO by the liver (+25%, p=0.05) and to a lesser extent also by the 
spleen (+214%, Fig. 4G). The increase in liver and spleen weight are key to this increased 
[14C]CO-uptake, as uptake of [14C]CO by liver and spleen did not differ when expressed per 
gram organ (data not shown). These data support the notion that BCG reduces plasma TC 
levels by enhancing hepatic uptake of cholesterol-enriched lipoprotein remnants.
Besides increased cholesterol clearance, reduced hepatic cholesterol synthesis or 
intestinal cholesterol absorption could underlie the reduced plasma cholesterol levels. To 
assess whether BCG affects hepatic cholesterol synthesis, we determined the cholesterol 
precursors lanosterol, desmosterol and lathosterol in the liver (Fig. 4H). The ratios of 
lanosterol and desmosterol to total cholesterol were increased (+53 and +79%) upon BCG 
treatment, whereas the ratio of lathosterol to cholesterol remained unchanged. This 
suggests increased rather than decreased hepatic cholesterol synthesis. As measures of 
intestinal cholesterol absorption, we measured cholestanol, campesterol and sitosterol in 
the liver (Fig. 4I). Interestingly, the ratios of cholestanol and campestanol to total cholesterol 
were decreased (-28% and -37%), whereas the ratio of sitosterol to total cholesterol 
remained similar. These data indicate that BCG reduces intestinal cholesterol absorption.
We next assessed gene expression and protein content in the liver upon  BCG 
treatment.  BCG did not affect genes involved in cholesterol metabolism, including Ldlr, 
Apob and Hmgcoar, nor LDLR and SR-BI protein content (data not shown).
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Figure 4.  BCG increases plasma cholesterol clearance towards the liver and reduces intestinal 
cholesterol absorption. E3L.CETP mice fed a WTD were treated with PBS or BCG (0.75 mg; 5x106 CFU; 
i.v.). Plasma triglycerides (A) and total cholesterol (B) were analysed at the indicated time points. After 6 
weeks of treatment also plasma nonHDL-cholesterol and HDL-cholesterol were determined (C). After 6 
weeks, mice were injected with glycerol tri[3H]oleate and [14C]cholesteryl oleate double-labelled VLDL-like 
particles and clearance from plasma (D, F) and uptake by organs and tissues at 15 min after injection were 
determined by analysing 3H- and 14C-activity (E, G). Cholestanol and sterols were extracted from liver and 
expressed as ratios to cholesterol or per mg dry tissue weight (H, I). Values represent means ± SEM (n=4-6). 
Interaction between plasma clearance of 3H- and 14C-activity and time was analysed by two-way ANOVA. 
*p<0.05 **p<0.01 vs. PBS. nonHDL-C, nonHDL-cholesterol; HDL-C, HDL-cholesterol; gWAT, gonadal white 
adipose tissue; sWAT, subcutaneous white adipose tissue; BAT, brown adipose tissue.
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Figure 5.  BCG decreases atherosclerosis development. E3L.CETP mice fed a WTD were treated with 
PBS or  BCG (0.75 mg; 5x106 CFU; i.v.). After 6 weeks, peritoneal macrophages (A) and bone marrow-
derived macrophages (B) were incubated with oxLDL and uptake was measured. Hearts were collected 
and slides of the valve area of the aortic root of were stained with haematoxylin – phloxine – saffron (C). 
Atherosclerotic lesion area as a function of distance was determined (D) and the mean lesion area was 
calculated from the four cross-sections from D (E). Lesions were categorized according to lesion severity 
(F) and the percentage of non-diseased segments was scored (G). The macrophage (H) and collagen 
(I) content of the lesions was determined, and the stability index (collagen/macrophage content of the 
lesions) was calculated (J). Values represent means ± SEM (n=6). *p<0.05 vs. PBS.
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BCG delays atherosclerosis development
Since  BCG markedly increased immune activation, but lowered plasma cholesterol 
levels, we investigated the effects of  BCG on foam cell formation and atherosclerosis 
development. BCG reduced the ex vivo uptake of oxLDL by peritoneal macrophages (-18%, 
Fig. 5A) and BMDMs (-27%, Fig. 5B), suggesting reduced foam cell formation and an overall 
anti-atherogenic phenotype of macrophages after BCG treatment.
We therefore determined atherosclerotic lesion area of the lesions in the aortic 
root of the heart 6 weeks after  BCG administration. Interestingly,  BCG tended to reduce 
atherosclerotic lesion area throughout the aortic root (Fig. 5C, D) as well as the mean 
atherosclerotic lesion area (-59%, Fig. 5E). Although lesion severity was generally mild, BCG 
still induced a shift towards a reduced lesion severity (Fig. 5F). In addition, the number of 
non-diseased segments tended to be higher after BCG treatment (+155%, Fig. 5G). In line 
with the reduced lesion severity,  BCG increased the macrophage content of the lesions 
(+43%, Fig. 5H). Collagen content (Fig. 5I) and lesion stability (ratio collagen/macrophage 
area, Fig. 5J) were not affected by  BCG. When only type 3 lesions were compared 
between groups, the macrophage content and lesion stability were unaffected (data not 
shown), indicating that  BCG did not induce a more inflammatory or unstable phenotype 
of the lesions. Together, our findings indicate that  BCG administration decreases plasma 
cholesterol levels and delays atherosclerosis development.
DISCUSSION
BCG has been shown to modulate atherosclerosis development through immunomodulatory 
mechanisms (5, 6), but its effect on cholesterol metabolism, the main determinant of 
atherosclerosis, has not been investigated before. In the current study, we show that BCG 
administration in hyperlipidemic E3L.CETP mice induced an overall inflammatory phenotype, 
as shown by hepatic infection and inflammation, and activation of circulating T cells as well as 
peritoneal macrophages and splenocytes. Furthermore, BCG markedly decreased plasma 
nonHDL-cholesterol levels by enhancing hepatic clearance of cholesterol and reduced 
foam cell formation ex vivo. As a result of these anti-atherogenic characteristics,  BCG 
delayed atherosclerosis progression and reduced lesion severity.
We found  BCG to be present in the liver, spleen and bone marrow 6 weeks after 
administration, indicating that the mycobacterium disseminated to these organs. In humans, 
dissemination of BCG can occur upon vaccination (19-21) and disseminated BCG infections 
can manifest in bladder cancer patients as a side effect of intravesical treatment with BCG 
(22). Our finding that the liver and spleen were enlarged in the BCG-treated group has also 
been observed in humans upon disseminated BCG infection (21, 23) and extrapulmonary 
tuberculosis (24, 25). Together, these reports indicate that our study can be translated to 
the human situation.
Besides increased immune activation, we observed a large reduction of plasma nonHDL-
cholesterol levels upon BCG administration, which was accompanied by elevated hepatic 
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uptake of circulating cholesterol-enriched lipoprotein remnants and reduced intestinal 
cholesterol absorption. Since plasma HDL-cholesterol nor hepatic SR-BI content were 
altered, it seems unlikely that BCG influences reverse cholesterol transport. An underlying 
mechanism for the reduced plasma nonHDL-cholesterol levels could be that accumulated 
immune cells (26) as well as mycobacteria (27-30), both of which we detected in the liver, 
are responsible for the increased hepatic lipoprotein remnant uptake. Immune cells use 
lipids as an energy source and cholesterol is indispensable as a membrane component 
for cell growth, proliferation and membrane remodelling (26, 31, 32). Mycobacteria use 
host cholesterol for entry into macrophages and as a source of carbon and energy, as 
they cannot synthesize cholesterol themselves (27, 28, 33). Therefore, host cholesterol 
is essential for the persistence of infection (27-29). For mycobacterium leprae, which 
also infects macrophages and uses host cholesterol for survival, it was recently shown 
that infected macrophages take up LDL by upregulation of LDLR (34). Furthermore, Ldlr 
expression was shown to be upregulated in caseous human pulmonary tuberculosis 
granulomas (35), supporting the possibility that upregulation of LDLR specifically in 
infected tissue macrophages underlies the increased cholesterol uptake in our study. 
An additional cause of the reduced plasma nonHDL-cholesterol levels is the reduced 
intestinal cholesterol absorption as evidenced by reduced cholestanol and plant sterol 
levels in the liver. Intestinal absorption can be dysregulated by systemic or intra-abdominal 
inflammation, which is also observed in coeliac disease, Crohn’s disease (36) and cystic 
fibrosis patients (37, 38). Evidently, BCG infection and subsequent inflammation also lead 
to reduced cholesterol absorption.
Several pieces of evidence suggest that mycobacteria modulate lipid metabolism in 
humans as well. For instance, cholesterol levels in Nigerian adults with tuberculosis are 
lower when compared to healthy controls (39). Deniz et al. (40) also show that serum total 
cholesterol, HDL-cholesterol and LDL-cholesterol concentrations are lower in patients with 
pulmonary tuberculosis. Moreover, M. tuberculosis uses fatty acids from host triglycerides 
as a lipid source (41) and tuberculosis patients exhibit lower serum medium-chain fatty 
acids (42). Unfortunately, to our knowledge, no data exist on plasma cholesterol levels in 
patients with disseminated BCG infection.
Ultimately,  BCG tended to reduce atherosclerotic lesion area by more than half, and 
delayed the onset and progression of atherosclerosis evidenced by 1) the increased 
number of non-diseased segments; 2) the higher percentage of mild type 1 lesions; 3) 
the increased macrophage content of the lesions, indicative for mild type 1 and 2 lesions. 
Although the latter could also point to a more inflammatory phenotype of the lesions, this 
was contradicted by the fact that the macrophage content and lesion stability index within 
type 3 lesions only did not differ between the groups. Previous studies that investigated 
the effect of BCG on atherosclerosis focussed on the immunomodulatory effects of BCG 
and were not properly designed to investigate the effect of BCG on cholesterol metabolism. 
In one study performed in rabbits, plasma cholesterol level of each individual rabbit was 
maintained at a specific level by adjusting the cholesterol content in the diet (5), excluding 
the possibility to investigate the effects of BCG on cholesterol metabolism. Ovchinnikova et 
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al. (6) studied the effect of BCG that was killed by extensive freeze-drying on atherosclerosis 
and did not find changes in plasma cholesterol levels upon BCG treatment in Apoe-/- mice 
and Ldlr-/- mice. However, even though Apoe-/- and Ldlr-/- mice are the most widely used 
atherosclerosis models, they lack a functional hepatic ApoE-LDLR axis, the predominant 
route by which cholesterol-enriched lipoprotein remnants are cleared from the circulation 
(9). Based on our study in E3L.CETP mice, with a functional ApoE-LDLR pathway for 
lipoprotein remnant clearance, we conclude that the cholesterol lowering effect of  BCG 
overrules the effect of immune activation during the development of atherosclerosis, 
resulting in delayed atherosclerotic plaque formation.
Carotid atherosclerosis is increased in patients with chronic infections and interestingly, 
the atherosclerosis risk is highest in those with the most prominent inflammatory response, 
indicating that systemic inflammation contributes to atherosclerosis (43). However, Giral et 
al. (44) compared hypercholesterolemic patients with and without a history of tuberculosis 
and found that past tuberculosis is not associated with atherosclerosis development. 
Whether mycobacterial infection has beneficial effects on atherosclerosis in humans 
related to a reduction in plasma cholesterol remains to be investigated.
In conclusion, our data demonstrate that  BCG infection lowers plasma nonHDL-
cholesterol levels by accelerating hepatic uptake of cholesterol-enriched lipoprotein 
remnants and reducing intestinal absorption of dietary cholesterol. Furthermore,  BCG 
delays atherosclerotic plaque formation despite increased immune activation, most likely 
due to lowering of nonHDL-cholesterol. Because BCG is used as a vaccine for tuberculosis 
worldwide, the effect of BCG on atherosclerosis in humans is an interesting field of future 
studies.
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Supplementary figure 1. E3L.CETP mice fed a WTD were treated with PBS or BCG (0.75 mg; 5x106 CFU; i.v.) 
at baseline (t=0 weeks). Upon sacrifice after 6 weeks, livers were collected and Ziehl-Neelsen (ZN) staining 



































































































































































A B C D
E F G H
Supplementary figure 2. E3L.CETP mice fed a WTD were treated with PBS or BCG (0.75 mg; 5x106 CFU; 
i.v.) at baseline (t=0 weeks). After 6 weeks, blood and splenocytes were collected. Within the CD45+ cells in 
the blood, percentage of monocytes (A), granulocytes (B), B cells (C) and CD3+ T cells (D) was measured. 
Isolated splenocytes were stimulated with LPS for innate cytokines or C. albicans for adaptive cytokines. 
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induce glucose intolerance 
via Fcγ-receptor or complement
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During the development of obesity, B cells accumulate in white adipose tissue (WAT) and 
produce IgG, which may contribute to the development of glucose intolerance. IgG signals 
by binding to Fcγ receptors (FcγR) and by activating the complement system. The aim of 
our study was to investigate whether activation of FcγR and/or complement C3 mediates 
the development of high fat diet-induced glucose intolerance. We studied mice lacking 
all four FcγRs (FcγRI/II/III/IV-/-), only the inhibitory FcγRIIb (FcγRIIb-/-), only the central 
component of the complement system C3 (C3-/-), and mice lacking all FcγRs as well as 
C3 (FcγRI/II/III/IV/C3-/-). These mouse models and wild-type control mice were fed a high-
fat diet (HFD) for 15 weeks to induce obesity. Body weight and composition as well as 
glucose metabolism were assessed. The adipose tissue was characterized for adipocyte 
functionality and inflammation. In obese WAT of wild-type mice, B cells (+142%, p<0.01) 
and IgG (+128% p<0.01) were increased compared to lean WAT. Of all mouse models 
lacking IgG effector pathways, only C3-/- mice showed reduced HFD-induced weight gain 
as compared to controls (-18%, p<0.01). Surprisingly, FcγRI/II/III/IV-/- mice had deteriorated 
glucose tolerance (AUC +125%, p<0.001) despite reduced leukocyte number (-30%, 
p<0.05) in gonadal WAT (gWAT), whereas glucose tolerance and leukocytes within gWAT 
in the other models were unaffected compared to controls. Although IgG in gWAT was 
increased (+44 to +174%, p<0.05) in all mice lacking FcγRIIb (FcγRI/II/III/IV-/-, FcγRIIb-/- and 
FcγRI/II/III/IV/C3-/-), only FcγRI/II/III/IV/C3-/- mice exhibited appreciable alterations in immune 
cell infiltrate in gWAT, e.g. increased macrophages (+36%, p<0.001). In conclusion, FcγRIIb 
deficiency increases adipose tissue IgG, but FcγR and/or C3 deficiency does not protect 
against HFD-induced glucose intolerance or reduce adipose tissue inflammation. This 
indicates that if obesity-induced IgG contributes to the development of glucose intolerance, 




White adipose tissue (WAT) inflammation is a hallmark of obesity-associated insulin 
resistance (1). Expanding adipose tissue releases increased levels of fatty acids and 
inflammatory (adipo)cytokines, which impair insulin signaling proteins and thereby 
decrease insulin sensitivity (2). These inflammatory mediators originate from hypertrophic 
adipocytes as well as from several types of immune cells residing in the adipose tissue 
(3). During obesity, additional immune cells infiltrate and accumulate in the adipose tissue 
(4, 5). Macrophages are the most abundant immune cells in mouse adipose tissue. They 
acquire a more pro-inflammatory phenotype during obesity and aggregate around necrotic 
adipocytes in so-called crown-like structures (6). Neutrophils, eosinophils and mast cells 
also contribute to inflammation and insulin resistance in adipose tissue (7-9). Besides, 
T cell infiltration occurs during obesity and various T cell populations differently affect 
obesity-associated insulin resistance (10), although they mostly contribute to metabolic 
dysfunction by recruitment of macrophages (11, 12). Moreover, B cells infiltrate obese 
adipose tissue (5, 13) and promote obesity-associated glucose intolerance by several 
mechanisms (13). Firstly, they induce secretion of the pro-inflammatory cytokine IFNγ 
by T cells, which induces pro-inflammatory macrophage polarization. In addition, B cells 
themselves produce cytokines that modulate insulin resistance. However, a unique function 
of B cells is the production of antibodies that have recently also been demonstrated to 
promote insulin resistance (13).
Of the 5 classes of antibodies produced by B cells in mammals, IgG is the major class 
of antibodies in the blood. IgG activates complement, and binds Fc receptors (FcRs) on 
macrophages and neutrophils, upon which pathogens coated with IgG are phagocytosed 
by these cells (14). Intriguingly, obesity is associated with higher IgG production and IgG-
positive B cells in adipose tissue. Furthermore, transfer of IgG from obese high-fat diet 
(HFD)-fed mice to obese HFD-fed mice lacking B cells not only altered local inflammatory 
cytokine production and promoted pro-inflammatory macrophage polarization, but also 
deteriorated glucose tolerance. The latter seems to be mediated by an Fc-mediated 
process (i.e. FcRs or complement), since transfer of IgG lacking the Fc-binding portion did 
not affect glucose tolerance (13).
Innate immune effector cells express different FcRs specific for the diverse antibody 
subclasses. Fcγ receptors (FcγRs) bind IgG and the murine FcγR family includes FcγRI, 
FcγRIIb, FcγRIII and FcγRIV. FcγRI is the receptor with the highest affinity for the Fc fragment 
of IgG. FcγRI, FcγRIII and FcγRIV are activating receptors, which mediate phagocytosis, 
antigen presentation and killing of infected cells, whereas FcγRIIb is an inhibitory receptor. 
IgG also has different subclasses with varying affinity and specificity for the FcγRs (i.e. 
IgG1, IgG2a, IgG2b and IgG3) (15). In obese adipose tissue, IgG is enriched in crown-like 
structures, implicating that they are involved in the clearance of necrotic adipocytes. It is 
possible that in these crown-like structures, interactions between antibodies and FcRs on 
innate immune effector cells induce pro-inflammatory cytokine release. However, whether 
and which of the FcR are responsible for the effects of IgG on glucose metabolism remains 
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unknown (13). In addition to FcR binding and activation, antigen-bound IgG activates 
complement, which has also been shown to mediate insulin resistance by affecting adipose 
tissue macrophages (16).
In the current study, we aimed to elucidate whether activation of FcγR and/or complement 
mediates the development of adipose tissue inflammation and high fat diet-induced 
glucose intolerance. To this end, we investigated glucose metabolism in several mouse 
models lacking either all four FcγRs, only the inhibitory FcγR, the central component of the 
complement system C3, or all four FcγRs combined with C3. We show that absence of IgG 
effector pathways rather deteriorates than improves glucose intolerance. This implicates 
that if obesity-associated IgG contributes to the development of glucose intolerance, IgG 
does not seem to act via FcγR or complement activation.
MATERIALS AND METHODS
Mice and diet
Wild-type male mice (C57Bl/6J background) were purchased from Charles River 
(Maastricht, The Netherlands) and used as controls for the experiments with 
FcγRI/II/III/IV-/-, C3-/- and FcγRI/II/III/IV/C3-/- mice. FcγRI/II/III/IV-/- (Fransen & Van Maaren 2016, 
submitted) and FcγRIIb-/- (17) mice were obtained as previously described. FcγRIIbfl/fl mice 
were used as controls for the FcγRIIb-/- mice. The complement C3-/- strain (18) was kindly 
provided by Mike Carroll (Harvard Medical School, Boston, MA). This strain was crossed with 
the FcγRI/II/III/IV-/- mice to obtain FcγRI/II/III/IV/C3-/- mice. FcγRIIbfl/fl mice and all knockout 
models had a C57Bl/6J background and were bred at the Leiden University Medical Center 
(Leiden, The Netherlands). At the start of each experiment, male mice were 8-12 weeks of 
age and housed under standard conditions with a 12:12 h light-dark cycle and free access 
to food and water. Mice were fed a high-fat diet (HFD; lard, 45% kcal% fat (D12451) or 60% 
kcal% fat (D12492) in the study with FcγRI/II/III/IV-/- mice; Research Diet Services, Wijk bij 
Duurstede, The Netherlands). After 15 weeks, mice were terminated and perfused with ice-
cold PBS through the heart. Mouse experiments were performed in accordance with the 
Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals 
and had received approval from the University Ethical Review Board (Leiden University 
Medical Center, The Netherlands).
Body weight and composition measurements
At indicated time points, body weight was measured weekly with a scale and body 
composition was measured using an EchoMRI-100 analyzer (EchoMRI, TX, USA).
Adipocyte, stromal vascular fraction and leukocyte isolation
Gonadal white adipose tissue was dissected, rinsed in PBS and minced. Tissues were 
digested in a collagenase mixture (0.5 g/L collagenase (Type 1) in DMEM/F12 (pH 7.4) with 
20 g/L of dialyzed bovine serum albumin (BSA, fraction V, Sigma, St Louis, USA)) for 1 h at 
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37°C, and filtered through a 236-μm nylon mesh. Upon centrifugation of the suspension 
(10 min, 200 g), adipocytes were isolated from the surface for assessment of lipolysis. The 
pelleted stromal vascular fraction and blood samples were treated with red blood cell lysis 
buffer (BD Biosciences, CA, USA) and cells were counted using an automated cell counter 
(TC10, Bio-Rad Laboratories Inc., Veenendaal, The Netherlands). Cells were fixed in 0.5% 
paraformaldehyde and stored in FACS buffer (PBS, 0.02% sodium azide, 0.5% FCS) in the 
dark at 4°C for analysis by flow cytometry within one week.
Flow cytometry
Stromal vascular cells and circulating white blood cells were stained for 30 min at 4°C in 
the dark with the fluorescently labelled antibodies listed in Table 1. Cells were measured 
on an LSR II flow cytometer (BD Biosciences, CA, USA). Data were analysed using FlowJo 
software (Treestar, OR, USA).
Gonadal white adipose tissue histology
Gonadal white adipose tissue was fixed in 4% paraformaldehyde, dehydrated in 70% 
EtOH, and embedded in paraffin. Immunohistochemical detection of IgG and F4/80 was 
done on paraffin-embedded sections (5 µm). For detection of IgG, a biotinylated horse-
anti-mouse IgG (BA-2000, 1/1250, Vector Laboratories Inc., CA, USA) and Vectastain ABC 
(PK-6100, Vector Laboratories Inc., CA, USA) were used. Detection of F4/80 was done by 
using a primary rat anti-mouse F4/80 monoclonal Ab (MCA497; 1/600, Serotec, UK) and 
a secondary goat anti-rat immunoglobulin peroxidase (MP-7444, Vector Laboratories Inc., 
CA, USA). Peroxidase activity in both stainings was revealed with NovaRed (SK-4800, Vector 
Laboratories Inc.). Slides were counterstained with hematoxylin. The areas positive for IgG 
or F4/80 were quantified using ImageJ Software.
Determination of plasma parameters
At the indicated time points, 6 h-fasted (from 8:00 am to 14:00 pm) blood samples were 
collected by tail vein bleeding into chilled capillaries that were coated with paraoxon 
(Sigma-Aldrich) to prevent ongoing lipolysis (19) and isolated plasma was assayed for 
Antibody Fluorochrome Dilution Clone, supplier
CD45.2 FITC 1:100 104, BioLegend
CD3 APC 1:100 145-2C11, eBioscience
CD4 Qdot605 1:1 000 RM-4-5, BioLegend
CD8a PerCPCy5.5 1:100 53-6.7, BioLegend
CD19 PE 1:200 1D3, eBioscience
CD22.2 PE 1:200 Cy34.1, BD Biosciences
Cd11b Pacific Blue 1:150 M1/70, BioLegend
F4/80 PE 1:200 BM8, eBioscience
Table 1. Antibodies used for flow cytometry.
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glucose, insulin, triglycerides and free fatty acids. Glucose was measured using an 
enzymatic kit from Instruchemie (Delfzijl, The Netherlands), and insulin by ELISA (Crystal 
Chem Inc., Downers Grove, IL). TG was measured by a commercially available enzymatic kit 
(Roche Diagnostics, Germany). Free fatty acids were measured using the NEFA C kit (Wako 
Diagnostics; Instruchemie, Delfzijl, The Netherlands).
Intravenous glucose tolerance test
After 6 or 8 weeks of HFD, mice were fasted for 6 h (from 8:00 am to 14:00 pm), a baseline 
blood sample was obtained by tail vein bleeding and mice were intravenously injected with 
D-glucose (2 g/kg body weight). Additional blood samples were drawn at indicated time 
points after glucose injection and plasma glucose was measured as described above.
Adipocyte lipolysis assay
Basal and stimulated lipolysis and the anti-lipolytic effect of insulin on gonadal adipocytes 
was measured by incubating isolated adipocytes (approx. 10 000 cells/mL) for 2 h at 37°C, 
with DMEM/F12 with 2% (v/v) BSA and 8-bromo-cAMP (10-3 M; Sigma, St. Louis, MO) with 
or without insulin (10-9 M). Glycerol concentrations were determined as a measure for 
lipolysis, using a free glycerol kit (Sigma, St. Louis, MO) and the hydrogen peroxide sensitive 
fluorescence dye Amplex Ultra Red, as previously described (20).
RNA purification and quantitative RT-PCR
RNA was extracted from snap-frozen gonadal white adipose tissue using Tripure RNA 
Isolation reagent (Roche, The Netherlands) according to manufacturer’s instructions. 
RNA concentrations were measured using NanoDrop and RNA was reverse transcribed 
using Moloney Murine Leukemia Virus Reverse Transcriptase (Promega, The Netherlands) 
for quantitative RT-PCR (qRT-PCR) to produce cDNA. Expression levels of genes were 
determined by qRT-PCR, using gene-specific primers (Table 2) and SYBR green supermix 
(Biorad, The Netherlands). mRNA expression was normalized to 36b4 and mCyclo mRNA 
content and expressed as fold change compared with control mice using the ΔΔCT method.
Statistical analysis
All data are expressed as means ± SD. Groups were compared with a two-tailed unpaired 
Student’s t-test or a two-way ANOVA for repeated measurements, as indicated. Differences 
were considered statistically significant if p<0.05.











B cells and IgG are enriched in obese adipose tissue
To examine the presence of B cells and IgG in gWAT, we used flow cytometry to quantify 
the percentage of B cells (CD19+) within the leukocyte population (CD45+ cells) of the 
stromal vascular fraction (SVF) of gWAT of obese (>40 g) compared to lean (<30 g) mice 
that had been fed an HFD. In addition, we quantified IgG by immunohistochemistry in gWAT 
of these mice. The percentage of B cells was increased in gWAT of obese compared to lean 
mice (+142%, p<0.01, Fig. 1A). IgG staining in gWAT as percentage of total WAT area was 
also higher in obese versus lean mice (+128%, p<0.01, Fig. 1B). IgG was located around 
adipocytes and co-localized with cells positive for the macrophage marker F4/80 (Fig. 1C), 
suggesting that IgG primarily interacts with macrophages in the adipose tissue.
FcγRI/II/III/IV deficiency deteriorates glucose metabolism during 
HFD-induced obesity
We next studied the necessity of FcγRs in the development of HFD-induced obesity and 
glucose intolerance. Hereto, mice lacking all four FcγRs (FcγRI/II/III/IV-/-) were fed an HFD 
for 15 weeks. Body weight (Fig. 2A), fat mass (Fig. 2B) and weight of several WAT depots 
(Fig. 2C) of FcγRI/II/III/IV-/- mice were not different from control mice. FcγRI/II/III/IV-/- mice 
had slightly more lean mass upon 15 weeks of HFD (+6%, p<0.05, Fig. 1D). Fasting plasma 
levels of glucose (Fig. 2E), triglycerides (Fig. S1A) and free fatty acids (Fig. S1B) during 
HFD did not differ between the two groups. However, after 6 weeks of HFD-feeding, plasma 
insulin levels were increased (+84%, p<0.05, Fig. 2F) and glucose tolerance as measured 
by an intravenous glucose tolerance test was deteriorated (AUC +125%, p<0.001, Fig. 1G) 
in FcγRI/II/III/IV-/- mice compared to controls. To assess whether the reduced whole-body 
glucose tolerance was due to insulin resistance in white adipocytes, intracellular lipolysis 
was assessed ex vivo. Adipocytes isolated from gWAT of FcγRI/II/III/IV-/- and control mice 















































Figure 1. B cells and IgG in gWAT increase during 
HFD-induced obesity. Male wild-type C57BL/6J mice 
were fed an HFD for different amounts of time varying 
between 4 and 34 weeks. Mice were categorized by 
body weight, with <30 g defined as lean (n=6-7) and 
>40 g defined as obese (n=12-13). The percentage 
of B cells (CD19+) of CD45+ cells in SVF of gWAT was 
determined by flow cytometry (A). IgG staining of 
gWAT sections was performed and % of IgG staining 
was quantified (B). Histological IgG staining (left) and 
F4/80 staining (right) on gWAT. Values represent 
means ± SD. **p<0.01 vs. lean.
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insulin was also comparable between groups (Fig. S1C), suggesting that WAT may not be 
responsible for the deteriorated glucose tolerance in FcγRI/II/III/IV-/- mice.
FcγRI/II/III/IV deficiency increases adipose tissue IgG without 
affecting immune cell composition
To assess whether the absence of FcγRs affects adipose tissue IgG, IgG was quantified 
by immunohistochemistry on gWAT from FcγRI/II/III/IV-/- and control mice. Interestingly, 
adipose tissue IgG was increased in the FcγRI/II/III/IV-/- group (+44%, p<0.05, Fig. 2H). 
Immune cell composition in gWAT was not affected as FcγRI/II/III/IV-/- and control mice 
exhibited comparable percentages of leukocytes (CD45+ cells) within the SVF (data not 
shown), and B cells (CD19+), T cells (CD3+) and macrophages (F4/80+) within the leukocyte 
population (Fig. 2I). However, total cell count of the isolated SVF from gWAT was lower in the 
FcγRI/II/III/IV-/- group (-30%, p<0.01, Fig. 2J), indicating that the absolute numbers of immune 
cells in gWAT were lower than in control mice. This did not result in a less inflammatory 
milieu in gWAT, as expression of several inflammatory genes (Mcp1, Tnfα, Il-6, Il-10) was 
similar in FcγRI/II/III/IV-/- and control mice (Fig. S1D).
In blood, total cell count (data not shown) and percentages of B cells (CD22.2+) and 
T cells within the leukocyte population were unaffected by FcγRI/II/III/IV deficiency (Fig. 
S1E), but within the T cell population, percentage of T helper cells (CD4+) was lower (-8%, 
p<0.05) and the percentage of cytotoxic T cells (CD8+) was higher (+8%, p<0.001) in 
FcγRI/II/III/IV-/- compared to control mice (Fig. S1F). This resulted in a lower CD4:CD8 ratio in 
FcγRI/II/III/IV-/- than in control mice (-15%, p<0.001, Fig. 2K), indicating increased 
systemic inflammation. In summary, FcγRI/II/III/IV-/- mice exhibited similar body weight but 
deteriorated glucose metabolism compared to controls, together with higher IgG levels but 
similar immune cell composition in WAT.
FcγRIIb deficiency does not affect glucose metabolism during 
HFD-induced obesity
We then assessed whether deficiency of only the inhibitory FcγR (FcγRIIb) would affect HFD-
induced obesity and glucose intolerance. To this end, FcγRIIbfl/fl (control) and FcγRIIb-/- mice 
were fed an HFD for 15 weeks. Body weight (Fig. 3A) and total fat mass (Fig. 3B) were not 
different between FcγRIIb-/- and control mice, but weight of the gWAT fat pad was lower in 
FcγRIIb-deficient animals (-18%, p<0.05, Fig. 3C). FcγRIIb-/- mice showed higher lean mass 
on chow diet before the diet intervention (+9%, p<0.05, Fig. 3D), but this difference was 
nullified after HFD feeding. Fasting plasma glucose (Fig. 3E), insulin (Fig. 3F), triglyceride 
(Fig. S2A) and free fatty acid (Fig. S2B) levels did not differ between the two groups. Glucose 
tolerance after 8 weeks of HFD-feeding (Fig. 3G) and ex vivo lipolysis of gWAT adipocytes 
(Fig. S2C) were not different between the FcγRIIb-/- and control groups, suggesting that the 























































































































































































































Figure 2. FcγRI/II/III/IV deficiency deteriorates glucose tolerance, increases IgG and decreases 
immune cells in gWAT during HFD-induced obesity. FcγRI/II/III/IV-/- and wild-type control mice were fed 
an HFD for 15 weeks. Body weight (A), fat mass (B), WAT depot weight (C), lean mass (D), plasma glucose (E) 
and insulin (F) were analysed at the indicated time points. After 6 weeks, mice were injected intravenously 
with glucose and clearance from plasma was determined by measuring plasma glucose at 5, 15, 30, 60, 
90 and 120 min after injection (G). IgG staining of gWAT sections was performed and quantified (H). The 
percentage of B cells (CD19+), T cells (CD3+) and macrophages (F4/80+) of CD45+ cells in SVF of gWAT 
was determined by flow cytometry (I). Total numbers of SVF cells per gWAT were counted (J). Within the 
CD3+ T cell fraction in blood, the ratio of CD4+ and CD8+ cells was determined (K). Values represent means 
± SD. *p<0.05, **p<0.01, ***p<0.001 vs. control (n=7-8) as measured by a two-way ANOVA in D, G or by a 
two-tailed unpaired Student’s t-test in F, H, J, K. WT, wild-type; gWAT, gonadal white adipose tissue; vWAT, 
visceral white adipose tissue; sWAT, subcutaneous white adipose tissue; SVF, stromal vascular fraction.
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FcγRIIb deficiency increases adipose tissue IgG without affecting 
immune cell composition
Like in FcγRI/II/III/IV-/- mice, presence of IgG in gWAT of the FcγRIIb-/- mice was higher 
compared to controls (+94%, p<0.05, Fig. 3H), suggesting that lack of the inhibitory FcγR 
mediated this effect. FcγRIIb-/- mice had similar percentages of leukocytes (CD45+ cells) 
within the SVF (data not shown), but exhibited a higher percentage of B cells (CD19+, 
+95%, p<0.05, Fig. 3I) within the leukocyte population in gWAT. The percentage of T cells 
(CD3+) within the leukocyte population of gWAT did not differ between FcγRIIb-/- mice and 
controls, but the percentage of macrophages (F4/80+) was decreased in the FcγRIIb-/- 
group (-13%, p<0.05, Fig. 3I). Total cell count of the isolated SVF from gWAT was similar in 
FcγRI/II/III/IV-/- and control mice (Fig. 3J), as was the expression of inflammatory genes 
(Mcp1, Tnfα, Il-6, Il-10) in gWAT (Fig. S2D). Thus, FcγRIIb-/- mice had similar body weight 
and glucose tolerance compared to controls, together with higher IgG levels and slight 
alterations within the leukocyte population in WAT.
Complement C3 deficiency protects against HFD-induced obesity 
but does not improve glucose intolerance
In addition to signaling through FcγRs, IgG activates complement. To study the involvement 
of complement C3 in the development of HFD-induced obesity and glucose intolerance, 
mice lacking the central component of the complement system (C3-/-) were fed an HFD 
for 15 weeks. Lack of C3 decreased HFD-induced body weight gain compared to control 
mice (-18%, p<0.01, Fig. 4A). This effect was primarily due to decreased accumulation of 
fat mass (Fig. 4B), reflected by less weight of the various WAT depots (-23 to -11%, p<0.06, 
Fig. 4C) of C3-/- compared to control mice. Lean mass of C3-/- mice was already lower at the 
beginning of the diet intervention (-5%, p<0.05), and this difference remained throughout 
the study (-6%, P<0.01 after 15 weeks of HFD, Fig. 4D). Both triglyceride (-29%, p<0.01, Fig. 
S3A) and free fatty acid (-22%, p<0.05, Fig. S3B) levels were lower in C3-/- mice before the 
diet intervention. Despite lower body weight, fasting plasma glucose (Fig. 4E) and insulin 
(Fig. 3F) levels were not different in C3-/- mice compared to controls. C3-/- mice did not exhibit 
different glucose tolerance (Fig. 4G) or ex vivo lipolysis of gWAT adipocytes, indicating that 
C3 deficiency does not affect glucose tolerance or adipocyte lipid metabolism.
Complement C3 deficiency does not alter immune cell 
composition
Even though complement C3-/- mice showed pronounced differences in body composition 
compared to controls, C3-/- mice exhibited similar percentages of leukocytes (CD45+ cells) 
within the SVF (data not shown), and similar fractions of B cells (CD22.2+), T cells (CD3+) and 
macrophages (F4/80+) within the leukocyte population of gWAT (Fig. 4H). Total cell count of 
the stromal vascular fraction isolated from gWAT was also the same between the two groups 
(Fig. 4I), as was inflammatory gene expression (Mcp1, Tnfα, Il-6, Il-10) in gWAT (Fig. S3D).
In blood, total cell count (data not shown) and percentages of B cells and T cells 
within the leukocyte population were unaffected in C3-/- mice (Fig. S3E), but within the T 
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Figure 3. FcγRIIb deficiency does not affect glucose tolerance but increases IgG and slightly alters 
immune cell composition in gWAT during HFD-induced obesity. FcγRIIb-/- and FcγRIIbfl/fl control mice 
were fed an HFD for 15 weeks. Body weight (A), fat mass (B), WAT depot weight (C), lean mass (D), plasma 
glucose (E) and insulin (F) were analysed at the indicated time points. After 8 weeks, mice were injected 
intravenously with glucose and clearance from plasma was determined by measuring plasma glucose at 5, 
15, 30, 60, 90 and 120 min after injection (G). IgG staining of gWAT sections was performed and quantified 
(H). The percentage of B cells (CD19+), T cells (CD3+) and macrophages (F4/80+) of CD45+ cells in SVF of 
gWAT was determined by flow cytometry (I). Total numbers of SVF cells per gWAT were counted (J). Values 
represent means ± SD. *p<0.05, **p<0.01, ***p<0.001 vs. control (n=11-12) as measured by a two-way 
ANOVA in D or by a two-tailed unpaired Student’s t-test in C, H, I. gWAT, gonadal white adipose tissue; vWAT, 
visceral white adipose tissue; sWAT, subcutaneous white adipose tissue; SVF, stromal vascular fraction.
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cell population, the percentage of cytotoxic T cells (CD8+) was higher in C3-/- compared to 
control mice (+10%, p<0.01, Fig. S3F). As a result, C3-/- mice exhibited a lower CD4:CD8 ratio 
(-14%, p<0.05, Fig. 4J), representative of increased systemic inflammation. All in all, C3-/- 
mice had lower body weight but similar glucose tolerance and immune cell composition in 
WAT as compared to controls.
Deficiency of FcγRI/II/III/IV as well as complement C3 decreases 
insulin sensitivity during HFD-induced obesity
To exclude the possibility that either FcγRs or complement C3 are sufficient to mediate the 
effects of IgG signaling on glucose tolerance or that one of the pathways could compensate 
for lack of the other, mice lacking both C3 and all FcγRs (FcγRI/II/III/IV/C3-/-) were fed an HFD 
for 15 weeks. Body weight, fat mass and lean mass of FcγRI/II/III/IV/C3-/- and control mice 
was similar after 15 weeks of HFD (Fig. 5A-D), although FcγRI/II/III/IV/C3-/- mice showed a 
transient increase in fat mass compared to controls (Fig. 5B). Plasma triglyceride levels 
(Fig. S4A) were not different between the two groups and free fatty acid levels transiently 
decreased (-18%, p<0.01, Fig. S4B) in FcγRI/II/III/IV/C3-/- mice compared to controls. 
Interestingly, FcγRI/II/III/IV/C3-/- mice also had transiently higher glucose levels after 6 weeks 
of HFD (+23%, p<0.001, Fig. 5E). Plasma insulin levels were higher at baseline (+18%, p<0.05) 
and after 6 weeks of HFD (+40%, p<0.01, Fig. 5F), indicating decreased insulin sensitivity 
in FcγRI/II/III/IV/C3-/- mice. However, glucose tolerance was not different after 6 weeks of 
HFD (Fig. 5G), suggesting that the increased insulin levels sufficiently compensated for the 
reduced insulin sensitivity to maintain normoglycemia. Ex vivo lipolysis of gWAT adipocytes 
did not differ between FcγRI/II/III/IV/C3-/- and control mice (Fig. S4C), suggesting that the 
decreased insulin sensitivity was not specific to WAT.
FcγRI/II/III/IV and complement C3 deficiency increases adipose 
tissue IgG and macrophages
Similar to FcγRI/II/III/IV-/- and FcγRIIb-/- mice, the quantity of IgG in gWAT of the 
FcγRI/II/III/IV/C3-/- mice was higher compared to controls (+174%, p<0.001, Fig. 5H). 
The leukocyte fraction (CD45+ cells) within the SVF (data not shown) and percentage of 
B cells (CD22.2+) within the leukocyte population in gWAT were comparable between 
the two groups. The percentage of T cells (CD3+) was decreased (-20%, p<0.05) and the 
percentage of macrophages (F4/80+) was increased (+36%, p<0.001) in FcγRI/II/III/IV/C3-/- 
mice compared to controls (Fig. 5I), while the total number of stromal vascular cells isolated 
from gWAT (Fig. 5J) and inflammatory gene expression (Mcp1, Tnfα, Il-6, Il-10) in gWAT 
(Fig. S4D) did not differ between the groups.
In blood, no differences were found in total cell count (data not shown), percentages of B 
and T cells within the leukocyte population (Fig. S4E), nor in the ratio of T helper (CD4+) and 
cytotoxic T cells (CD8+) within the T cell population (Fig. S4F and 5K), indicating that systemic 
inflammation was not different between the groups. In summary, FcγRI/II/III/IV/C3-/- mice had 
similar body weight and glucose tolerance compared to controls, but higher IgG levels and 
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Figure 4. Complement C3 deficiency protects against weight gain but does not affect glucose 
tolerance or immune cell composition in gWAT during HFD-induced obesity. Complement C3-/- and 
wild-type control mice were fed an HFD for 15 weeks. Body weight (A), fat mass (B), WAT depot weight (C), 
lean mass (D), plasma glucose (E) and insulin (F) were analysed at the indicated time points. After 6 weeks, 
mice were injected intravenously with glucose and clearance from plasma was determined by measuring 
plasma glucose at 5, 15, 30, 60, 90 and 120 min after injection (G). The percentage of B cells (CD22.2+), T 
cells (CD3+) and macrophages (F4/80+) of CD45+ cells in SVF of gWAT was determined by flow cytometry 
(H). Total numbers of SVF cells per gWAT were counted (I). Within the CD3+ T cell fraction in blood, the ratio 
of CD4+ and CD8+ cells was determined (J). Values represent means ± SD. *p<0.05, **p<0.01, ***p<0.001 
vs. control (n=10-12) as measured by a two-way ANOVA in A, B, D or by a two-tailed unpaired Student’s 
t-test in C, J. WT, wild-type; gWAT, gonadal white adipose tissue; vWAT, visceral white adipose tissue; sWAT, 
























































































































































































































Figure 5. Deficiency of both FcγRI/II/III/IV and complement C3 elevates plasma insulin and increases 
IgG and macrophages in gWAT during HFD-induced obesity. FcγRI/II/III/IV/C3-/- and wild-type control 
mice were fed an HFD for 15 weeks. Body weight (A), fat mass (B), WAT depot weight (C), lean mass (D), 
plasma glucose (E) and insulin (F) were analysed at the indicated time points. After 6 weeks, mice were 
injected intravenously with glucose and clearance from plasma was determined by measuring plasma 
glucose at 5, 15, 30, 60, 90 and 120 min after injection (G). IgG staining of gWAT sections was performed 
and quantified (H). The percentage of B cells (CD22.2+), T cells (CD3+) and macrophages (F4/80+) of CD45+ 
cells in SVF of gWAT was determined by flow cytometry (I). Total numbers of SVF cells per gWAT were 
counted (J). Within the CD3+ T cell fraction in blood, the ratio of CD4+ and CD8+ cells was determined (K). 
Values represent means ± SD. *p<0.05, **p<0.01, ***p<0.001 vs. control (n=9-10) as measured by a two-
way ANOVA in A, B, D or by a two-tailed unpaired Student’s t-test in C, J. WT, wild-type; gWAT, gonadal 





IgG in obese adipose tissue has been shown to decrease glucose tolerance, but the 
signaling pathway mediating these effects remains unknown (13). By using mouse models 
deficient for all four FcγRs (FcγRI/II/III/IV-/-), only the inhibitory FcγRIIb (FcγRIIb-/-), only the 
central component of the complement system C3 (C3-/-), and all FcγRs combined with C3 
(FcγRI/II/III/IV/C3-/-), we show that deficiency for FcγR and/or complement C3, both of which 
are important for the effector functions of IgG, does not ameliorate the development of 
glucose intolerance in diet-induced obesity.
We observed that obese adipose tissue is enriched for B cells and IgG, as compared 
to lean adipose tissue, and we found that IgG co-localizes with macrophages in crown-like 
structures within the adipose tissue, which confirms previous reports (13, 21). It would be 
interesting to uncover to which antigens IgG responds in the adipose tissue. Adipocytes 
are known to present lipid antigens to immune cells (22) and it has also been reported 
that HFD-fed mice have higher levels of circulating IgG against modified LDL compared to 
mice fed a low fat diet (23). Winer et al. (13) searched for IgG antigens in serum of obese 
insulin-resistant vs. insulin-sensitive men and found mostly differences in intracellular 
self-antigens that are ubiquitously expressed in many tissues. Thus, the antigens to which 
obesity-induced IgG responds remain unknown and uncovering them is of high therapeutic 
value.
In our study, FcγRI/II/III/IV-/- mice lacking all IgG receptors exhibited deteriorated rather 
than improved glucose tolerance. This is in contrast to what we expected based on the data 
of Winer et al. (13). They showed that transfer of IgG from diet-induced obese wild-type 
mice to diet-induced obese B cell deficient mice deteriorated glucose tolerance whereas 
transfer of IgG lacking the Fc region did not, indicating that the pathogenic effects of IgG 
are mediated by FcγR or complement. However, the Fc region is important for extension of 
the half-life of IgG (24), raising the possibility that the lack of effect in the latter experiment 
is due to increased clearance of IgG. Since insulin sensitivity in the white adipocytes was 
not affected in our FcγRI/II/III/IV-/- mice, we speculate that other organs such as muscle 
could be responsible for the deterioration of glucose tolerance we found. FcRs are 
important for immune complex clearance (25) and lack of FcγRs may lead to accumulation 
of immune complexes in tissues and subsequent induction of pro-inflammatory responses 
and pathology (26). Indeed, we show that FcγRI/II/III/IV-/- mice had increased systemic 
inflammation as evidenced by more cytotoxic T cells in blood. To our knowledge, deficiency 
of all four FcγR in relation to obesity has not been studied to date. We have previously 
shown that in mice lacking the FcRγ-chain, the γ-subunit necessary for signaling and cell 
surface expression of activating FcγR and FcεRI, the development of obesity and glucose 
intolerance was reduced. However, these effects could be due to IgE (the ligand for FcεRI) 
or other non-IgG-effects, as the y-subunit is not exclusively associated with Fc-receptors 
(27). The FcγRI/II/III/IV-/- model is Fc-receptor-specific and therefore suitable to study 
specific effects of IgG signaling. FcγRIIb deficient mice did not show abnormal glucose 
62
3
tolerance, indicating that the stimulating FcγRs were responsible for the deteriorated 
glucose metabolism that we observed in FcγRI/II/III/IV-/- mice.
Since absence of FcγRs did not improve glucose tolerance in obese mice, we studied 
whether complement C3 is the pathway mediating the pathogenic effects of IgG. We found 
decreased body weight and fat mass due to less fat in several WAT depots in C3-/- mice, 
which is in accordance with previous reports establishing that C3-/- mice on an HFD have 
reduced weight of the WAT depots (28). We found that the decreased total body weight 
was partly due to lower lean mass of C3-/- mice compared to controls. C3-/- mice are known 
to have decreased birth weight (29), which is associated with reduced lean mass later in 
life (30) and thus coincides with our finding. Despite lower body weight, C3-/- mice did not 
exhibit different glucose tolerance compared to controls after HFD. Disparate data on the 
effects of C3 deficiency on glucose tolerance have been reported. C3-/- compared to wild-
type mice on different backgrounds (C57Bl/6 and 129Sv) displayed similar insulin but lower 
plasma glucose levels (31). Murray et al. (28) also found lower fasting glucose levels in 
female C3-/- mice on a chow diet and after 4 weeks of HFD compared to controls. However, 
after 16 weeks of HFD, fasting glucose and glucose tolerance did not differ anymore (28). 
The same group has also reported comparable fasting glucose and insulin levels in C3-/- and 
wild-type mice on a chow diet (32), which is in line with what we found and suggests that 
complement C3 does not act on glucose levels or tolerance.
Mice lacking both FcγRs and C3 showed increased plasma insulin, possibly due to 
absence of FcγRs as FcγRI/II/III/IV-/- mice also exhibited increased plasma insulin. However, 
no effects on glucose tolerance were found. This excludes the possibility that presence of 
either FcγRs or C3 is sufficient to mediate the development of glucose intolerance during 
obesity. Redundant roles for FcγR and C3 have been demonstrated before in autoimmune 
hypopigmentation. In the model for this pathology, FcR or C3 deficiency alone did not 
prevent development of antibody-mediated hypopigmentation, whereas a combined 
deficiency did (33).
Of note, all our models lacking the inhibitory FcγRIIb displayed higher IgG levels in 
adipose tissue compared to control mice. This is probably explained by the fact that 
this receptor mediates a negative feedback loop to dampen B cell activity and antibody 
production (15) and in agreement with the higher antibody titres in FcγRIIb-/- mice upon 
immunization with antigens (34). Strikingly, FcγRI/II/III/IV-/-, FcγRIIb-/- and C3-/- mice did not 
exhibit any or only showed negligible alterations in percentage of adipose tissue B cells, T 
cells and macrophages. FcγRI/II/III/IV-/- mice even had reduced numbers of SVCs in adipose 
tissue, which is unexpected given the deteriorated glucose tolerance we found and therefore 
reinforces our hypothesis that other organs besides the adipose tissue may be the cause of 
the phenotype observed. Only FcγRI/II/III/IV/C3-/- mice exhibited an appreciable increase in 
adipose tissue macrophages, but this was not accompanied by metabolic derangements. 
The lack of differences in inflammation between our immune deficient models and controls 
suggests that if obesity-associated IgG signals via FcγRs or complement, these pathways 
may be inferior to or compensated by other inflammatory processes occurring during 
obesity. Mice lacking B and T cells show a marked increase in macrophages and natural 
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killer cells in adipose tissue while the onset of obesity and the state of insulin resistance is 
unaffected compared to wild-type mice fed an HFD (21). In this light, one could argue that 
the role of B cells as a whole and therefore also IgG effector pathways are expendable in the 
development of glucose intolerance. Counter-regulatory mechanisms within the immune 
system may stretch beyond up- or downregulation of entire immune cell populations, as 
elevated inflammatory cytokine responses can already rescue deficiency of others (35). 
The higher cytotoxic T cell percentages we observed in blood of FcγRI/II/III/IV-/-and C3-/- 
mice may be the result of such compensatory inflammatory mechanisms.
In conclusion, our data demonstrate that B cells and IgG in adipose tissue increase in 
diet-induced obesity, and lack of FcγRIIb further increases IgG in adipose tissue. However, 
FcγR and/or complement C3 deficiency does not ameliorate the development of HFD-
induced glucose intolerance. These data suggest that if HFD-induced IgG contributes to the 
development of glucose intolerance, this is not mediated by FcγRs or complement. Future 
research is necessary to identify the antigens that IgG in adipose tissue binds and will also 
reveal whether IgG-induced pathology in obesity is mediated by other mechanisms, for 
example the deposition of immune complexes.
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Supplementary figure 1. FcγRI/II/III/IV-/- and wild-type control mice were fed an HFD for 15 weeks. Plasma 
triglycerides (A) and free fatty acids (B) were analysed at the indicated time points. Basal, 8b-cAMP-stimulated 
and insulin inhibition of 8b-cAMP-stimulated ex vivo glycerol release (index of lipolysis) from isolated 
gonadal white adipocytes were determined (C). GWAT mRNA expression of the indicated inflammatory 
genes was determined (D). Within the CD45+ cell population in blood, the percentages of B cells (CD19+) 
and T cells (CD3+) were determined (E). Within the CD3+ T cell fraction in blood, the percentages of CD4+ 
and CD8+ cells were determined (K). Values represent means ± SD. *p<0.05, ***p<0.001 vs. control (n=7-8) 





































































































































Supplementary figure 3. Complement C3-/- and wild-type control mice were fed an HFD for 15 weeks. 
Plasma triglycerides (A) and free fatty acids (B) were analysed at the indicated time points. Basal, 8b-cAMP-
stimulated and insulin inhibition of 8b-cAMP-stimulated ex vivo glycerol release (index of lipolysis) 
from isolated gonadal white adipocytes were determined (C). GWAT mRNA expression of the indicated 
inflammatory genes was determined (D). Within the CD45+ cell population in blood, the percentages 
of B cells (CD22.2+) and T cells (CD3+) were determined (E). Within the CD3+ T cell fraction in blood, the 
percentages of CD4+ and CD8+ cells were determined (K). Values represent means ± SD. *p<0.05, **p<0.01 


























































































Supplementary figure 2. FcγRIIb-/- 
and FcγRIIbfl/fl control mice were 
fed an HFD for 15 weeks. Plasma 
triglycerides (A) and free fatty acids 
(B) were analysed at the indicated 
time points. Basal, 8b-cAMP-
stimulated and insulin inhibition of 
8b-cAMP-stimulated ex vivo glycerol 
release (index of lipolysis) from 
isolated gonadal white adipocytes 
were determined (C). GWAT mRNA 
expression of the indicated 
inflammatory genes was determined 
(D). Values represent means ± SD. 
gWAT, gonadal white adipose tissue.
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Supplementary figure 4. FcγRI/II/III/IV/C3-/- and wild-type control mice were fed an HFD for 15 weeks. 
Plasma triglycerides (A) and free fatty acids (B) were analysed at the indicated time points. Basal, 8b-cAMP-
stimulated and insulin inhibition of 8b-cAMP-stimulated ex vivo glycerol release (index of lipolysis) 
from isolated gonadal white adipocytes were determined (C). GWAT mRNA expression of the indicated 
inflammatory genes was determined (D). Within the CD45+ cell population in blood, the percentages 
of B cells (CD22.2+) and T cells (CD3+) were determined (E). Within the CD3+ T cell fraction in blood, the 
percentages of CD4+ and CD8+ cells were determined (K). Values represent means ± SD. **p<0.01 vs. 



































































































































South Asians have lower expression 
of interferon signaling genes in white 
adipose tissue and skeletal muscle 
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South Asians have a higher risk of developing type 2 diabetes compared to white 
Caucasians. Since inflammation plays an important role in type 2 diabetes development, 
we assessed inflammatory state in South Asians compared to white Caucasians. We 
assessed transcriptomic levels of 144 inflammatory, immune-regulating and immune cell 
subset markers in blood, skeletal muscle and white adipose tissue (WAT) of overweight pre-
diabetic Dutch South Asian and matched white Caucasian men using a focused multiplex 
gene expression profiling technique. In South Asians, expression of especially interferon 
signaling genes was lower, both in muscle (IFIT3, IFI44; -45-51%) and in WAT (IFI35, IFI44, 
IFIT2, IFIT3, IFIT5, OAS1, STAT1; -13-40%). Of note, IL5 expression was also lower in WAT 
(-66%). In conclusion, South Asians have lower expression levels of interferon signaling 
genes in skeletal muscle and WAT. Future studies should investigate the relevance of 




South Asians, who originate from the Indian subcontinent, make up 20% of the world 
population and have a higher risk of developing type 2 diabetes when compared to white 
Caucasians (1). Albeit central obesity and insulin resistance are more prevalent in South 
Asians than in white Caucasians (1), these predisposing classical risk factors cannot fully 
explain their excess risk of developing type 2 diabetes. Despite the clear link between 
inflammation and the pathogenesis of type 2 diabetes (2), comprehensive data on the 
inflammatory state in South Asians are lacking. Therefore, the aim of the current study was 
to compare transcriptomic levels of a large panel of inflammatory, immune-regulating and 
immune cell subset markers in blood, skeletal muscle and WAT of overweight, pre-diabetic 
South Asian and matched white Caucasian men.
MATERIALS AND METHODS
Participants
Ten Dutch overweight (body mass index (BMI) between 25 and 35 kg/m²), pre-diabetic 
middle-aged (35-55 y) South Asian males and ten BMI- and age-matched Dutch white 
Caucasian males were included in this study. Pre-diabetes was defined as fasting plasma 
glucose levels between 5.6 and 6.9 mmol/L or plasma glucose levels between 7.8 and 11.1 
mmol/L at 2 hours after an oral glucose tolerance test. Ethnicity was specified as having four 
grandparents of white Caucasian or South Asian origin. Exclusion criteria included type 2 
diabetes, smoking, vigorous exercise, liver or kidney dysfunction, hypo- or hyperthyroidism, 
uncontrolled hypertension and the use of beta-blockers. Three South Asians used 
antihypertensive medication before and during the study. The study was originally designed 
to assess the effect of L-arginine on energy expenditure and mitochondrial function, for 
which a part of this study will be published elsewhere (Hanssen & Boon).
Study approval
This study was approved by the Ethics Committee of Maastricht University Medical Center 
and the Leiden University Medical Center (The Netherlands). Procedures were conducted 
according to the principles of the Declaration of Helsinki. All participants provided written 
informed consent. Trial registration number: NCT02291458 (Hanssen & Boon).
Study design
Subjects were given placebo or L-arginine (Argimax®, Hankintatukku Oy) for six weeks (9 g/day, 
divided over three quantities per day after breakfast, lunch and dinner) in a randomized 
double-blind cross-over design with a four-week washout period in between. Subjects were 
instructed to abstain from heavy physical exercise during the last 2 days of the treatment 
period, and standardized evening meals were consumed before the experimental days. 
Each intervention period was followed by 2 study days. On the first study day, a 4h-fasted 
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blood sample was drawn and resting energy expenditure was measured during 45 min at 
thermoneutrality (i.e. 29.9±0.1°C) and during 90 min of cold exposure (i.e. 23.9±0.4°C) via a 
face-mask connected to an indirect calorimeter (EZcal, IDEE). Furthermore, a cold-induced 
[18F]fluorodeoxyglucose (FDG) PET-CT scan was conducted to assess brown adipose tissue 
(BAT) volume and activity. On the second day, skeletal muscle biopsies (approx. 75-100 mg) 
were taken from the musculus vastus lateralis and subcutaneous white adipose tissue (WAT) 
biopsies were taken from the umbilical region under localized anesthesia in the morning 
after an overnight fast. Dual-energy X-ray absorptiometry (DEXA) was performed to assess 
body composition. The study was performed between November 2014 and October 2015 
in Maastricht, The Netherlands (Hanssen & Boon). From all subjects, measurements after 
placebo treatment were used to study the transcriptomic levels of inflammatory, immune-
regulating and immune cell subset markers in South Asians vs. white Caucasians.
RNA isolation and dual-color RT-MLPA assay
Muscle and WAT biopsies were homogenized in 1 mL TriPure RNA Isolation reagent (Roche, 
The Netherlands) and RNA was extracted according to manufacturer’s instructions. Whole 
blood was collected in venipuncture PAXgene collection tubes and total RNA was extracted 
and purified using the PAXgene Blood miRNA kit (PreAnalytix). A dual-color Reverse 
Transcriptase Multiplex Ligation-dependent Probe Amplification (dcRT-MLPA) assay (3, 4) 
was performed on blood, WAT and skeletal muscle tissue. Briefly, for each target-specific 
sequence, a specific RT primer was designed located immediately downstream of the left 
and right hand half-probe target sequence. Following reverse transcription, left and right 
hand half-probes were hybridized to the cDNA at 60°C overnight. Annealed half-probes 
were ligated and subsequently amplified by PCR. PCR amplification products were 1:10 
diluted in HiDi formamide-containing 400HD ROX size standard and analysed on an Applied 
Biosystems 3730 capillary sequencer in GeneScan mode (Baseclear). Trace data were 
analyzed using the GeneMapper 5.0 software package (Applied Biosystems). The areas of 
each assigned peak (in arbitrary units) were exported for further analysis in Microsoft Excel. 
Data were normalized to GAPDH and signals below the threshold value for noise cutoff in 
GeneMapper (log2 transformed peak area 7.64) were assigned the threshold value for noise 
cut-off (5, 6).
Statistical analysis
All data are expressed as means ± SEM. If some but not all subjects within a group showed 
an expression level below the detection limit, the value corresponding to the limit of 
detection divided by 2 was used for calculation of the mean and statistical analysis. If data 
were normally distributed as assessed by a Shapiro-Wilk test, log-transformed data were 
compared with a two-tailed unpaired Student’s t-test and if not normally distributed with a 
Mann-Whitney U test. Correlations were analysed by linear regression analysis. IBM SPSS 
Statistics 23.0 was used for analyses and differences and correlations were considered 





White Caucasians and South Asians had comparable age, BMI and fasting glucose, though 
South Asians tended to be shorter (-2.8%; p=0.06) (Table 1).
Markers of inflammation in blood
Transcriptomic profiles of immune markers in blood are listed in Supplementary Table 
1. Several markers were expressed higher in South Asians, including GNLY (+79%), 
NOD2 (+40%), IL2RA (+33%), CCL5 (+32%), NLRP3 (+27%) and PRF1 (+23%). In contrast, 
expression of CCL19 (-47%), IL6 (-30%), FPR1 (-29%), DSE (-24%), CXCL10 (-22%) and 
TGFBR2 (-12%) was lower in the blood of South Asians.
Markers of inflammation in muscle and WAT
In muscle, the expression of many immune markers was below the detection limit 
(Supplementary Table 1). Nevertheless, expression levels of individual genes like LAG3 
(+79%), TNIP1 (+49%), IL23A (+39%) and NLRC4 (+32%) were higher in South Asians. The 
two genes most significantly lower expressed in South Asians were interferon signaling 
genes IFI44 (-51%) and IFIT3 (-45%) (Fig. 1A). In addition, CTLA4 (-44%), CXCL10 (-39%), 







Age (years) 47.5 ± 2.0 46.5 ± 2.3 0.744
Height (m) 1.81 ± 0.02 1.76 ± 0.02 0.061
Weight (kg) 99.9 ± 4.0 93.0 ± 3.8 0.223
BMI (kg/m²) 30.7 ± 1.2 30.1 ± 1.1 0.723
Fasting glucose (mmol/L) 5.7 ± 0.2 5.6 ± 0.2 0.939
OGTT2h glucose (mmol/L) 7.4 ± 0.6 6.6 ± 0.5 0.282
HbA1c (%; mmol/mol) 5.4 ± 0.1; 36.0 ± 0.9 5.7 ± 0.1; 38.3 ± 1.3 0.149
Total cholesterol (mmol/L) 5.60 ± 0.29 5.51 ± 0.24 0.819
TG (mmol/L) 1.72 ± 0.20 1.95 ± 0.41 0.628
Fat percentage (%) 30.1 ± 1.0 31.2 ± 1.3 0.540
Lean mass percentage (%) 67.6 ± 1.0 66.3 ± 1.3 0.458
Trunk/limb fat mass ratio 1.2 ± 0.1 1.2 ± 0.1 0.698
Visceral adipose tissue mass (g) 714 ± 79 689 ± 36 0.771
Visceral adipose tissue volume (cm³) 772 ± 86 745 ± 39 0.768
Table 1. Baseline metabolic characteristics and body composition after 6 weeks placebo treatment of 
white Caucasians and South Asians. Body composition was determined by DEXA. BMI, body mass index; 




































































































Figure 1. Interferon signaling gene expression is lower in muscle and white adipose tissue of South 
Asians compared to white Caucasians. Relative interferon signaling gene expression in (A) muscle and 
(B) white adipose tissue of white Caucasians and South Asians. N.d., not detectable; WAT, white adipose 
tissue. Data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 compared to white Caucasians, 
#Gene expression of 4 or more individuals was not detectable. (C) Ingenuity Pathway Analysis (IPA) was 
performed on the list of genes with a (tendency for; p<0.1) different expression between South Asians 
and white Caucasians, which are marked with grey symbols in the network. Genes in uncoloured symbols 
were not analysed or identified as differentially expressed in our experiment and were integrated into the 
computationally generated network based on the evidence stored in the IPA knowledge memory indicating 
relevance to this network. The top canonical pathway was interferon signaling. Gene and gene relationship 
symbols: square, cytokine; vertical diamond, enzyme; horizontal diamond, peptidase; double circle, group 
or complex; dashed square, growth factor; triangle, kinase; horizontal oval, transcription factor; vertical 
oval, transmembrane receptor; single circle, other; arrow, acts on; continuous line, direct interaction; 
dashed line, indirect interaction.
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In WAT, several immune markers having a diverse range of immunological functions 
were differentially expressed between ethnicities including GNLY (+58%), BPI (-46%), 
CCL22 (-34%), CXCL9 (-28%) and TGFBR2 (-17%) (Supplementary Table 1). Interestingly, 
in line with skeletal muscle, out of the 12 genes with significantly lower expression in South 
Asians, 7 were interferon signaling genes, including IFI35 (-22%), IFI44 (-40%), IFIT2 (-22%), 
IFIT3 (-23%), IFIT5 (-28%), OAS1 (-33%) and STAT1 (-13%). IFI6 (-17%) and IFIH1 (-23%) 
expression also tended to be reduced (Fig. 1B).
To identify the signaling pathways that are differently regulated in WAT, genes with a 
tendency for different expression between South Asians and white Caucasians (p<0.1) 
were fed into Ingenuity Pathway Analysis (IPA). The top canonical pathway enriched 
with differentially expressed genes between the two ethnicities was interferon signaling 
(Fig. 1C), confirming our analysis of individual genes that are differentially expressed in WAT 
of South Asians and white Caucasians.
Of note, the most differently expressed gene in WAT of South Asians was IL5 (-66%), 
which was mainly due to a lack of IL5 expression in most South Asians (Fig. 2A). Remarkably, 
IL5 expression in WAT of only white Caucasians (as expression was undetectable in South 
























































Figure 2. IL5 gene expression is lower in white adipose tissue of South Asians compared to white 
Caucasians. (A) Relative IL5 mRNA expression in white adipose tissue (WAT) of white Caucasians and 
South Asians. Data are presented as mean ± SEM. *p<0.05 compared to white Caucasians. Correlation of 
(B) body mass index (BMI) and (C) fat mass with IL5 mRNA expression in WAT of white Caucasians. WAT, 




We demonstrate that many immune markers involved in a range of immunological functions 
in blood, muscle and WAT are differentially expressed in South Asians compared to white 
Caucasians. The most pronounced differences included lower expression of interferon 
signaling genes (skeletal muscle and WAT) and IL5 (WAT) in South Asians.
Despite the high risk of type 2 diabetes in South Asians and the clear link between 
inflammation and type 2 diabetes, inflammation in South Asians has not been extensively 
studied. South Asians have higher plasma CRP levels compared to white Caucasians, 
suggesting a more pro-inflammatory state. Moreover, South Asians generally have more 
visceral adipose tissue, which is an important source of pro-inflammatory cytokines (7). 
One previous study observed similar CD68 protein content but lower CCL2 levels in muscle 
of South Asians compared to white Caucasians (8). Although we did not determine CD68 
expression, many macrophage markers including CCL2 were undetectable in muscle of 
both ethnicities.
The most striking finding of the current study was that in both WAT and muscle, interferon 
signaling genes were consistently lower expressed in South Asians. Ingenuity pathway 
analysis corroborated the finding that the anti-inflammatory type 1 interferon signaling 
pathways, i.e. interferon α and β, were lower expressed in South Asians. Interestingly, 
adipose tissue-specific knockout of interferon (α+β) receptor 1 in mice deteriorates high-fat 
diet induced weight gain, insulin resistance and glucose intolerance (9). On the other hand, 
IFNβ1 induces cellular glucose uptake via the PI3K/Akt pathway (10) and overexpression of 
Ifnβ1 suppresses adipose tissue inflammation and protects against diet-induced obesity 
and glucose intolerance (11). Together, this indicates that impaired interferon signaling in 
South Asians may, at least partly, cause their predisposition for development of obesity as 
well as type 2 diabetes.
In addition, IL5 expression was markedly lower expressed in WAT of South Asians. 
IL5 is produced by group 2 innate lymphoid cells (ILC2s) and is essential for mobilizing 
eosinophils in the bone marrow and regulating homing and migration of eosinophils into 
tissues. IL5 transgenic mice are hypereosinophilic and have reduced fat mass and improved 
glucose tolerance (12), which is in accordance with our data showing that IL5 expression in 
adipose tissue of white Caucasians negatively correlates with fat mass. ILC2s also promote 
browning of WAT (13) and may thereby enhance energy expenditure and protect against 
obesity and associated disorders. Based on the findings in rodents, we speculate that low 
IL5 expression in South Asians may be accompanied by low adipose tissue eosinophils, 
reduced browning and its unfavorable consequences such as higher fat mass and reduced 
glucose tolerance.
Limitations of our study are the small sample size and the placebo treatment that 
participants received in the context of the L-arginine treatment this trial was originally 
designed for. As we only assessed gene expression levels, further research into the immune 
system of South Asians would also benefit from performing analysis of protein levels and 
flow cytometry. Strengths of our study are the extensiveness of the panel of immune 
79
4
markers measured, not only in blood, but also in two important metabolic tissues within the 
same individuals. Furthermore, the individuals of different ethnicities were well-matched for 
metabolic parameters that could interfere with inflammation, such as age and BMI.
In conclusion, the immune system in blood, muscle and WAT is differently primed in South 
Asians compared to white Caucasians, with a consistent lower expression of interferon 
signaling genes in metabolic tissues of South Asians as the most prominent feature. 
Whether interferon signaling in metabolic tissues directly influences glucose metabolism 
in humans and whether this could be a target to treat insulin resistance or reduce the risk of 
type 2 diabetes in South Asians is an interesting field of future investigation.
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Immune cell subset markers
BLR1 1.00 ± 0.10 1.20 ± 0.11 1.00 ± 0.15# 0.87 ± 0.11# 1.00 ± 0.15 1.12 ± 0.18
CD19 1.00 ± 0.10 1.09 ± 0.12 n.d.# n.d.# n.d.# n.d.#
NCAM1 1.00 ± 0.20 1.27 ± 0.17 1.00 ± 0.13 0.62 ± 0.10#* 1.00 ± 0.19 0.86 ± 0.17
T cell subsets
CD3E 1.00 ± 0.13 1.22 ± 0.07 n.d.# n.d.# 1.00 ± 0.20# 1.38 ± 0.18
CD4 1.00 ± 0.06 0.97 ± 0.04 n.d.# n.d.# 1.00 ± 0.07 0.89 ± 0.05
CD8A 1.00 ± 0.26 1.38 ± 0.24 n.d.# n.d.# n.d.# n.d.#
CCR7 1.00 ± 0.16 1.14 ± 0.09 1.00 ± 0.17# 1.80 ± 0.38 1.00 ± 0.00# 1.14 ± 0.14#
PTPRCv1 1.00 ± 0.09 1.17 ± 0.08 n.d.# n.d.# 1.00 ± 0.21# 0.78 ± 0.16#
PTPRCv2 1.00 ± 0.11 1.08 ± 0.06 n.d.# n.d.# 1.00 ± 0.14 0.92 ± 0.10
AIRE 1.00 ± 0.13 0.80 ± 0.09 n.d.# n.d.# 1.00 ± 0.11 1.06 ± 0.09
Th1 response
CXCL10 1.00 ± 0.10 0.78 ± 0.06* 1.00 ± 0.11 0.61 ± 0.08#* 1.00 ± 0.10 0.93 ± 0.13
IFNG n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
IL1B 1.00 ± 0.10 0.88 ± 0.04 n.d.# n.d.# 1.00 ± 0.17# 1.29 ± 0.19#
IL2 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
IL15 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.13# 0.81 ± 0.00#
TBX21 1.00 ± 0.18# 0.95 ± 0.16# n.d.# n.d.# n.d.# n.d.#
TNF 1.00 ± 0.07 0.94 ± 0.04 1.00 ± 0.07 1.11 ± 0.10 1.00 ± 0.05 0.91 ± 0.07
Th2 response
GATA3 1.00 ± 0.11 1.23 ± 0.08 n.d.# n.d.# 1.00 ± 0.13# 1.30 ± 0.18#
IL4 1.00 ± 0.41# 0.38 ± 0.00# n.d.# n.d.# 1.00 ± 0.16# 0.77 ± 0.00#
IL4d2 1.00 ± 0.18 0.98 ± 0.13 n.d.# n.d.# 1.00 ± 0.19# 0.94 ± 0.13
IL5 1.00 ± 0.16 0.80 ± 0.05 n.d.# n.d.# 1.00 ± 0.22 0.34 ± 0.06#**
IL6 1.00 ± 0.09 0.70 ± 0.05* 1.00 ± 0.10# 1.04 ± 0.14# 1.00 ± 0.16 0.98 ± 0.09
IL9 1.00 ± 0.12 0.84 ± 0.07 n.d.# n.d.# 1.00 ± 0.09 1.04 ± 0.10
IL13 n.d.# n.d.# 1.00 ± 0.09 0.64 ± 0.10* 1.00 ± 0.00# 1.23 ± 0.23#
Supplementary Table 1. Relative gene expression levels of immune markers in blood, skeletal muscle 
and white adipose tissue (WAT) of white Caucasians and South Asians. N.d., not detectable. Data are 
presented as mean ± SEM, n=10 per group. *p<0.05, **p<0.01, ***p<0.001 compared to white Caucasians, 












IL17A n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.00# 2.21 ± 0.99#
RORC 1.00 ± 0.26# 0.74 ± 0.00# 1.00 ± 0.14 0.80 ± 0.06 n.d.# n.d.#
NEDD4L 1.00 ± 0.06 1.19 ± 0.09 1.00 ± 0.14 0.91 ± 0.08 1.00 ± 0.07 0.95 ± 0.08
IL22RA1 1.00 ± 0.11 1.10 ± 0.05 n.d.# n.d.# n.d.# n.d.#
Treg markers
CTLA4 1.00 ± 0.06 1.02 ± 0.04 1.00 ± 0.14 0.56 ± 0.22* 1.00 ± 0.08 1.04 ± 0.08
FOXP3 1.00 ± 0.14 1.15 ± 0.07 n.d.# n.d.# 1.00 ± 0.15 1.04 ± 0.12
IL10 1.00 ± 0.12 1.12 ± 0.08 n.d.# n.d.# 1.00 ± 0.11 0.94 ± 0.08
IL2RA 1.00 ± 0.08 1.33 ± 0.08** n.d.# n.d.# 1.00 ± 0.22# 1.06 ± 0.19#
IL7R 1.00 ± 0.11 1.11 ± 0.06 n.d.# n.d.# 1.00 ± 0.11 0.96 ± 0.08
LAG3 1.00 ± 0.00# 1.33 ± 0.33# 1.00 ± 0.33 1.79 ± 0.24* n.d.# n.d.#
TGFB1 1.00 ± 0.05 1.00 ± 0.03 1.00 ± 0.04 0.86 ± 0.06* 1.00 ± 0.04 0.95 ± 0.04
TNFRSF18 1.00 ± 0.08 0.90 ± 0.14 n.d.# n.d.# 1.00 ± 0.19# 1.11 ± 0.17#
Cytotoxicity markers
GNLY 1.00 ± 0.17 1.79 ± 0.19** 1.00 ± 0.00# 1.37 ± 0.19# 1.00 ± 0.23 1.58 ± 0.23*
GZMA 1.00 ± 0.16 1.08 ± 0.13 n.d.# n.d.# 1.00 ± 0.07 0.97 ± 0.09
GZMB 1.00 ± 0.21 1.32 ± 0.11 n.d.# n.d.# 1.00 ± 0.13 1.37 ± 0.15
PRF1 1.00 ± 0.19 1.23 ± 0.08* n.d.# n.d.# 1.00 ± 0.15 1.04 ± 0.18
Antimicrobial activity
LTF 1.00 ± 0.22 0.58 ± 0.13 n.d.# n.d.# 1.00 ± 0.40# 0.69 ± 0.25#
Macrophage markers
CD14 1.00 ± 0.07 0.84 ± 0.04 1.00 ± 0.15 0.96 ± 0.25 1.00 ± 0.07 0.87 ± 0.08
CD163 1.00 ± 0.08 0.80 ± 0.04 1.00 ± 0.23 0.72 ± 0.33# 1.00 ± 0.07 0.83 ± 0.08
CD209 1.00 ± 0.08 0.99 ± 0.05 1.00 ± 0.15 1.10 ± 0.07 1.00 ± 0.09 0.99 ± 0.07
CCL2 1.00 ± 0.19# 0.92 ± 0.18# n.d.# n.d.# 1.00 ± 0.12 1.17 ± 0.24
CCL3 1.00 ± 0.08 1.07 ± 0.09 1.00 ± 0.51 0.38 ± 0.10 1.00 ± 0.07 1.23 ± 0.27
CCL4 1.00 ± 0.07 0.95 ± 0.04 n.d.# n.d.# 1.00 ± 0.03 0.94 ± 0.04
CCL5 1.00 ± 0.11 1.32 ± 0.09* 1.00 ± 0.17# 0.96 ± 0.14# 1.00 ± 0.11 1.07 ± 0.12
CCL22 1.00 ± 0.15 0.87 ± 0.05 n.d.# n.d.# 1.00 ± 0.08 0.66 ± 0.07**
CXCL13 1.00 ± 0.13 0.75 ± 0.22# n.d.# n.d.# 1.00 ± 0.20# 1.27 ± 0.27
IL12A 1.00 ± 0.15# 0.92 ± 0.14# 1.00 ± 0.25# 0.75 ± 0.00# 1.00 ± 0.16# 1.04 ± 0.20#
IL12B 1.00 ± 0.11 0.96 ± 0.05 1.00 ± 0.00# 1.14 ± 0.14# 1.00 ± 0.09 1.03 ± 0.10
IL23A 1.00 ± 0.03 1.05 ± 0.03 1.00 ± 0.09 1.39 ± 0.10** 1.00 ± 0.04 1.00 ± 0.03
Scavenger receptors












CLEC7A 1.00 ± 0.09 0.86 ± 0.07 n.d.# n.d.# 1.00 ± 0.15 0.79 ± 0.07
MRC1 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.09 0.91 ± 0.09
MRC2 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.11 1.00 ± 0.09
NOD1 1.00 ± 0.11 1.22 ± 0.09 n.d.# n.d.# 1.00 ± 0.06 0.94 ± 0.06
NOD2 1.00 ± 0.14 1.40 ± 0.06** n.d.# n.d.# n.d.# n.d.#
TLR1 1.00 ± 0.10 0.98 ± 0.07 n.d.# n.d.# 1.00 ± 0.09 0.90 ± 0.10
TLR2 1.00 ± 0.12 0.91 ± 0.05 n.d.# n.d.# n.d.# n.d.#
TLR3 1.00 ± 0.22# 0.90 ± 0.13 n.d.# n.d.# 1.00 ± 0.04 0.98 ± 0.07
TLR4 1.00 ± 0.09 0.95 ± 0.06 n.d.# n.d.# 1.00 ± 0.05 0.95 ± 0.05
TLR5 1.00 ± 0.14 0.85 ± 0.08 1.00 ± 0.47# 0.97 ± 0.16 1.00 ± 0.19# 2.68 ± 1.66#
TLR6 1.00 ± 0.09 0.88 ± 0.06 n.d.# n.d.# 1.00 ± 0.12 1.19 ± 0.12
TLR7 1.00 ± 0.11 1.11 ± 0.07 1.00 ± 0.18# 0.96 ± 0.15# 1.00 ± 0.06 1.06 ± 0.09
TLR8 1.00 ± 0.20 1.06 ± 0.18 n.d.# n.d.# 1.00 ± 0.25# 1.36 ± 0.16
TLR9 1.00 ± 0.51# 0.37 ± 0.30# 1.00 ± 0.10 1.21 ± 0.09 1.00 ± 0.11 0.96 ± 0.09
TLR10 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
Inflammasome components
NLRC4 1.00 ± 0.07 0.99 ± 0.04 1.00 ± 0.10 1.32 ± 0.10* 1.00 ± 0.05 1.07 ± 0.08
NLRP1 1.00 ± 0.10 1.06 ± 0.06 1.00 ± 0.00# 1.54 ± 0.23# 1.00 ± 0.06 0.94 ± 0.08
NLRP2 1.00 ± 0.16 0.90 ± 0.07 1.00 ± 0.16 1.22 ± 0.12 1.00 ± 0.09 1.01 ± 0.12
NLRP3 1.00 ± 0.07 1.27 ± 0.06* n.d.# n.d.# 1.00 ± 0.14# 0.63 ± 0.09#
NLRP4 1.00 ± 0.10 0.76 ± 0.10 n.d.# n.d.# 1.00 ± 0.10 1.05 ± 0.13
NLRP6 1.00 ± 0.13# 0.90 ± 0.09# n.d.# n.d.# n.d.# n.d.#
NLRP7 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
NLRP10 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
NLRP11 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
NLRP12 1.00 ± 0.10 0.92 ± 0.05 n.d.# n.d.# n.d.# n.d.#












CD274 1.00 ± 0.09 1.03 ± 0.11 1.00 ± 0.25# 1.46 ± 0.23 1.00 ± 0.13# 1.06 ± 0.15#
FCGR1A 1.00 ± 0.15 1.37 ± 0.51 n.d.# n.d.# 1.00 ± 0.16# 1.33 ± 0.24#
GBP1 1.00 ± 0.26 1.12 ± 0.20 n.d.# n.d.# 1.00 ± 0.19# 0.98 ± 0.31#
GBP2 1.00 ± 0.11 1.10 ± 0.11 1.00 ± 0.14 0.90 ± 0.18 1.00 ± 0.08 0.90 ± 0.07
GBP5 1.00 ± 0.19 1.17 ± 0.17 n.d.# n.d.# 1.00 ± 0.13 0.97 ± 0.14
IFI6 1.00 ± 0.42 0.72 ± 0.09 1.00 ± 0.18 0.99 ± 0.19 1.00 ± 0.07 0.83 ± 0.05
IFI16 1.00 ± 0.10 1.04 ± 0.09 1.00 ± 0.17 0.93 ± 0.18 1.00 ± 0.06 0.96 ± 0.05
IFI35 1.00 ± 0.14 0.99 ± 0.11 1.00 ± 0.14 0.80 ± 0.18# 1.00 ± 0.07 0.78 ± 0.07*
IFI44 1.00 ± 0.48 0.54 ± 0.10 1.00 ± 0.15 0.49 ± 0.08#** 1.00 ± 0.12 0.60 ± 0.05**
IFI44L 1.00 ± 0.54 0.45 ± 0.09 1.00 ± 0.24# 0.58 ± 0.09# 1.00 ± 0.19 0.66 ± 0.09
IFIH1 1.00 ± 0.21 0.98 ± 0.09 1.00 ± 0.69 0.47 ± 0.30 1.00 ± 0.09 0.77 ± 0.07
IFIT2 1.00 ± 0.26 0.77 ± 0.09 1.00 ± 0.19# 0.75 ± 0.18# 1.00 ± 0.11 0.78 ± 0.13*
IFIT3 1.00 ± 0.29 0.73 ± 0.11 1.00 ± 0.09 0.55 ± 0.07*** 1.00 ± 0.06 0.77 ± 0.08*
IFIT5 1.00 ± 0.26 0.79 ± 0.10 1.00 ± 0.16 0.64 ± 0.14# 1.00 ± 0.06 0.72 ± 0.08**
IFITM3 1.00 ± 0.28 0.57 ± 0.10 1.00 ± 0.18 0.83 ± 0.14 1.00 ± 0.06 0.94 ± 0.07
INDO 1.00 ± 0.13 0.73 ± 0.10 n.d.# n.d.# 1.00 ± 0.12# 0.88 ± 0.00#
IRF7 1.00 ± 0.16 0.80 ± 0.07 n.d.# n.d.# 1.00 ± 0.15# 0.94 ± 0.17#
OAS1 1.00 ± 0.36 0.68 ± 0.09 n.d.# n.d.# 1.00 ± 0.10 0.67 ± 0.05**
OAS2 1.00 ± 0.37 0.68 ± 0.06 n.d.# n.d.# 1.00 ± 0.16 0.70 ± 0.12#
OAS3 1.00 ± 0.48 0.50 ± 0.07 n.d.# n.d.# 1.00 ± 0.14 0.77 ± 0.09
SOCS1 1.00 ± 0.07 0.87 ± 0.07 1.00 ± 0.22# 0.92 ± 0.24# 1.00 ± 0.08 0.91 ± 0.09
STAT1 1.00 ± 0.16 1.18 ± 0.10 1.00 ± 0.09 0.87 ± 0.16 1.00 ± 0.05 0.87 ± 0.12*
STAT2 1.00 ± 0.16 1.07 ± 0.10 1.00 ± 0.14# 0.98 ± 0.12# 1.00 ± 0.05 0.97 ± 0.12
TAP1 1.00 ± 0.11 1.08 ± 0.10 1.00 ± 0.23# 0.95 ± 0.15# 1.00 ± 0.09 0.90 ± 0.10
TAP2 1.00 ± 0.12 1.08 ± 0.12 n.d.# n.d.# 1.00 ± 0.08 0.92 ± 0.16
Apoptosis / Survival
CASP8 1.00 ± 0.05 1.09 ± 0.07 n.d.# n.d.# 1.00 ± 0.07 0.95 ± 0.06
BCL2 1.00 ± 0.12 1.19 ± 0.12 1.00 ± 0.21 0.47 ± 0.08 1.00 ± 0.06 1.08 ± 0.11
FASLG 1.00 ± 0.00# 1.13 ± 0.13# n.d.# n.d.# n.d.# n.d.#
FLCN1 1.00 ± 0.16# 1.03 ± 0.22# n.d.# n.d.# 1.00 ± 0.07 0.81 ± 0.09
TNFRSF1A 1.00 ± 0.07 0.99 ± 0.04 1.00 ± 0.14 0.62 ± 0.12#* 1.00 ± 0.02 1.02 ± 0.06
TNFRSF1B 1.00 ± 0.06 0.93 ± 0.05 n.d.# n.d.# 1.00 ± 0.09 0.86 ± 0.06
Small GTPases / (Rho)GTPase activating proteins
ASAP1 1.00 ± 0.05 1.08 ± 0.05 1.00 ± 0.24 1.05 ± 0.31 1.00 ± 0.05 0.87 ± 0.09
RAB13 1.00 ± 0.19 1.11 ± 0.24 1.00 ± 0.14# 0.86 ± 0.14# 1.00 ± 0.05 0.90 ± 0.05
RAB24 1.00 ± 0.07 1.20 ± 0.24 1.00 ± 0.00# 1.21 ± 0.14# 1.00 ± 0.06 0.93 ± 0.08
RAB33A 1.00 ± 0.21 0.85 ± 0.05 1.00 ± 0.15# 0.92 ± 0.14# 1.00 ± 0.16# 2.20 ± 0.80#
TAGAP 1.00 ± 0.08 1.12 ± 0.07 n.d.# n.d.# 1.00 ± 0.17 0.88 ± 0.13












CCL11 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.46# 2.51 ± 1.97#
CCL13 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.37 0.96 ± 0.23
CCL19 1.00 ± 0.08 0.53 ± 0.10* 1.00 ± 0.10# 1.17 ± 0.19# 1.00 ± 0.15 1.17 ± 0.18
CXCL9 1.00 ± 0.13# 0.84 ± 0.10# n.d.# n.d.# 1.00 ± 0.09 0.72 ± 0.11*
CX3CL1 n.d.# n.d.# 1.00 ± 0.22# 0.69 ± 0.00# 1.00 ± 0.14 0.86 ± 0.10
Cell growth / proliferation
BMP6 1.00 ± 0.06 0.94 ± 0.06 1.00 ± 0.15 0.88 ± 0.25 1.00 ± 0.11 1.03 ± 0.09
TGFBR2 1.00 ± 0.05 0.88 ± 0.09* 1.00 ± 0.13# 0.96 ± 0.16# 1.00 ± 0.06 0.83 ± 0.04*
AREG n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
EGF 1.00 ± 0.18 0.85 ± 0.14 1.00 ± 0.16 1.23 ± 0.40# 1.00 ± 0.12 1.06 ± 0.16
VEGF 1.00 ± 0.22# 0.50 ± 0.00# 1.00 ± 0.27 1.09 ± 0.33 1.00 ± 0.15 0.70 ± 0.06
Cell activation
HCK 1.00 ± 0.04 0.92 ± 0.03 n.d.# n.d.# 1.00 ± 0.11 0.92 ± 0.11
LYN 1.00 ± 0.06 1.02 ± 0.04 n.d.# n.d.# 1.00 ± 0.08 0.89 ± 0.10
SLAMF7 1.00 ± 0.16 1.23 ± 0.10 n.d.# n.d.# 1.00 ± 0.11 1.02 ± 0.15
Transcriptional regulators / activators
CAMTA1 n.d.# n.d.# n.d.# n.d.# n.d.# n.d.#
TWIST1 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.16# 1.05 ± 0.12
ZNF331 1.00 ± 0.25# 0.84 ± 0.12 n.d.# n.d.# 1.00 ± 0.07 0.88 ± 0.06
ZNF532 1.00 ± 0.18 1.06 ± 0.28# n.d.# n.d.# 1.00 ± 0.05 0.92 ± 0.05
Intracellular transport
SEC14L1 1.00 ± 0.05 0.95 ± 0.08 1.00 ± 0.12 0.67 ± 0.07* 1.00 ± 0.10 0.86 ± 0.04
KIF1B 1.00 ± 0.04 1.05 ± 0.06 1.00 ± 0.12 0.94 ± 0.20 1.00 ± 0.04 0.93 ± 0.05
Inflammation
DSE 1.00 ± 0.09 0.76 ± 0.06* 1.00 ± 0.21 0.67 ± 0.16# 1.00 ± 0.09 1.07 ± 0.07
MMP9 1.00 ± 0.22 0.67 ± 0.10 n.d.# n.d.# 1.00 ± 0.19 1.33 ± 0.43
SPP1 n.d.# n.d.# n.d.# n.d.# 1.00 ± 0.30 0.82 ± 0.30
TIMP2 1.00 ± 0.06 0.97 ± 0.04 1.00 ± 0.13 0.68 ± 0.07 1.00 ± 0.07 1.02 ± 0.06
TNIP1 1.00 ± 0.07 1.01 ± 0.05 1.00 ± 0.31 1.49 ± 0.41* 1.00 ± 0.08 0.92 ± 0.07
FPR1 1.00 ± 0.05 0.71 ± 0.06** 1.00 ± 0.24# 0.47 ± 0.00# 1.00 ± 0.08 0.83 ± 0.09
BPI 1.00 ± 0.13 0.88 ± 0.05 1.00 ± 0.21# 0.55 ± 0.08# 1.00 ± 0.14 0.54 ± 0.06**
Mitochondrial Stress / Proteasome
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Salsalate improves glucose intolerance and dyslipidemia in type 2 diabetes patients, but 
the mechanism is still unknown. The aim of the present study was to unravel the molecular 
mechanisms involved in these beneficial metabolic effects of salsalate by treating mice 
with salsalate during and after development of high fat diet-induced obesity. We found 
that salsalate attenuated and reversed high fat diet-induced weight gain, in particular fat 
mass accumulation, improved glucose tolerance and lowered plasma triglyceride (TG) 
levels. Mechanistically, salsalate selectively promoted the uptake of fatty acids from 
glycerol tri[3H]oleate-labeled lipoprotein-like emulsion particles by brown adipose tissue 
(BAT), decreased the intracellular lipid content in BAT and increased rectal temperature, 
all pointing to more active BAT. Treatment of differentiated T37i brown adipocytes with 
salsalate increased uncoupled respiration in cells. Moreover, salsalate upregulated Ucp1 
expression and enhanced glycerol release, a dual effect that was abolished by inhibition 
of protein kinase A (PKA). In conclusion, salsalate activates BAT, presumably by directly 
activating brown adipocytes via the PKA pathway, suggesting a novel mechanism that may 




Salsalate is a nonsteroidal anti-inflammatory drug belonging to the salicylate class of 
drugs. Salicylates are originally derived from plants, in which they function as part of the 
immune system to combat infections. Nowadays, synthetic compounds that break down 
to salicylates in vivo, including aspirin and salsalate, have largely replaced salicylate (1). In 
humans, salicylates have strong anti-inflammatory effects and have therefore been applied 
in the clinic for several decades to treat pain and inflammation caused by rheumatoid 
arthritis (2, 3).
Studies have shown that salicylates exhibit beneficial metabolic effects as well. A 
recent trial has demonstrated that salsalate lowers HbA1c levels, fasting blood glucose 
and circulating triglycerides (TG) in type 2 diabetes patients (4). Furthermore, salsalate 
increases energy expenditure in human subjects (5). In contrast to aspirin, salsalate is not 
associated with an increased risk of gastrointestinal bleeding and therefore relatively safe 
for long-term clinical experience. Thus, it is considered a promising anti-diabetic drug (3). 
The mechanisms underlying the beneficial metabolic effects of salsalate remain largely 
unknown, partly because its receptor has not been identified yet (6). Salicylates have been 
shown to activate AMP-activated protein kinase (AMPK) in liver, muscle and white adipose 
tissue (WAT), suggesting a role of this energy-sensing kinase in the mechanism of action 
of the drug (1). However, salicylate still improves glucose metabolism in mice lacking the 
regulatory AMPK-β1 subunit, suggesting involvement of other pathways as well (1).
The objective of the current study was to investigate the mechanism(s) underlying 
the beneficial effects of salsalate on lipid and glucose metabolism by treating 
APOE*3-Leiden.CETP (E3L.CETP) transgenic mice, a well-established model for human-
like lipoprotein metabolism (7-9), with salsalate mixed through the high fat diet (HFD). We 
found that salsalate both prevented and reduced HFD-induced weight gain by lowering 
fat mass accumulation, and improved glucose and lipid metabolism. Mechanistic studies 
showed that these effects were accompanied by increased activity of brown adipose tissue 
(BAT). Taken together, our data indicate that BAT may contribute to the beneficial effects of 
salsalate on lipid and glucose metabolism and corroborate previous findings that targeting 
BAT may be a valuable strategy to correct metabolic derangements.
MATERIALS AND METHODS
Mice, diet and salsalate treatment
APOE*3-Leiden cholesteryl ester transfer protein (E3L.CETP) mice were obtained as 
previously described (7-9). To assess the effect of salsalate on progression of obesity, 
dyslipidemia and hyperglycemia, 10-week old male E3L.CETP mice were randomized to 
receive an HFD (Research Diets, 45% kcal lard fat) without or with 0.5% (w/w) salsalate 
(2-carboxyphenyl salicylate, TCI Europe N.V.) for 12 weeks. To assess the effect of salsalate 
on regression of obesity and associated metabolic disorders, 10-week old male diet-
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induced (12 weeks HFD) obese E3L.CETP mice received salsalate (0.5% w/w) for 4 weeks. 
To investigate the effect of salsalate independent of the E3L.CETP background in a 
progression setting, 10-week old male wild-type (WT) mice (C57Bl/6J background; Charles 
River, USA) were randomized to receive an HFD without or with salsalate for 4 weeks.
Mice were individually housed at 21°C or 28°C (WT mice). To mask the bitter taste 
of salsalate, anise (3.33%, w/w) was added to the diet of both groups in all studies (10). 
Mouse experiments were performed in accordance with the Institute for Laboratory Animal 
Research Guide for the Care and Use of Laboratory Animals and have received approval 
from the University Ethical Review Board (Leiden University Medical Center, Leiden, The 
Netherlands).
Body weight and body composition measurements
Body weight was measured with a scale and body composition using EchoMRI (EchoMRI-100, 
Houston, Texas, USA).
Determination of plasma parameters
Upon randomisation and at 4 week intervals during treatment, 6 h fasted blood was 
collected and assayed for triglycerides (TG), total cholesterol (TC) and free fatty acids 
(FFA) as described before (11, 12). Glucose was measured using an enzymatic kits from 
Instruchemie (Delfzijl) and insulin by ELISA (Crystal Chem. Inc., Downers Grove, IL).
Intravenous Glucose Tolerance Test (ivGTT)
Mice were fasted for 6 h, a baseline blood sample was obtained, and mice were intravenously 
injected with 10 µl/g body weight of glucose dissolved in PBS (200 mg/mL). Additional blood 
samples were taken at t = 5, 15, 30, 60, 90 and 120 min. Capillaries were placed on ice and 
centrifuged, and glucose levels were measured as described above.
In vivo clearance of radiolabeled lipoprotein-like emulsion 
particles
Lipoprotein-like TG-rich emulsion particles (80 nm) labeled with glycerol tri[3H]oleate 
(triolein, [3H]TO) were prepared and characterized as described previously (13). Mice were 
fasted for 6 h (from 7.00 am to 13.00 pm) and injected with 200 μl of emulsion particles 
(1.0 mg TG per mouse) via the tail vein (t = 0). After 15 min, mice were sacrificed by cervical 
dislocation and perfused with ice-cold PBS through the heart. Thereafter, organs were 
harvested, weighed and the uptake of [3H]TO-derived radioactivity was quantified and 
expressed per gram wet tissue weight.
Rectal temperature measurement
Rectal temperature was measured between 3.00 and 4.00 p.m. using a rectal probe attached 




Interscapular BAT and gonadal WAT were removed and fixed in 4% paraformaldehyde, 
dehydrated in 70% EtOH and embedded in paraffin. Haematoxylin and eosin (H&E) staining 
was done using standard protocols. The area of intracellular lipid vacuoles in BAT was 
quantified using Image J (NIH, US).
Quantification of TG content in BAT
Lipids were extracted from BAT following a modified protocol from Bligh and Dyer (14). BAT 
samples (~50 mg) were homogenized in 10 µL of ice-cold CH3OH per mg tissue. Lipids were 
extracted into an organic phase by addition of 1800 µL of CH3OH:CHCl3 (1:3 v/v) to 45 µL 
homogenate and subsequent centrifugation. The lower organic phase was evaporated, 
lipids were resuspended in 2% Triton X-100 and TG content was assayed (see above). BAT 
lipids were reported per mg protein (Pierce BCA Protein Assay Kit).
Isolation of stromal vascular fraction and flow cytometry
Gonadal WAT was removed, rinsed in PBS and minced. Tissues were digested in a 
collagenase mixture (DMEM with 20 mM HEPES, Collagenase XI and Collagenase I, Sigma) 
for 45 min at 37°C and passed through a 70-µm nylon mesh. The suspension was centrifuged 
(6 min, 1,250 rpm) and the pelleted stromal vascular fraction (SVF) was resuspended in 
FACS buffer. Fc blocking (CD16/32 antibody) was performed prior to a 30 min staining with 
fluorescently labeled primary antibodies for CD45, CD11b, Ly6G, F4/80, CD11c, CD206, 
Gr-1, CD19, CD3, CD4, CD8, CD25 and FoxP3 (BioLegend, e-Bioscience or BD). SVF was 
analyzed by flow cytometry with a BD FacsCANTO II flow cytometer and FlowJo software.
Analysis of DNA content
DNA content in gonadal WAT samples was quantified as previously described (15).
Culture and differentiation of white and brown adipocytes
3T3-L1 (American Type Culture Collection, Manassas, VA) and T37i cells (16, 17) were 
cultured and differentiated as described before. Differentiated cells were treated with 
salsalate (SML0070, Sigma), sodium salicylate (S2007, Sigma), AICA riboside (AICAR; 
ab120358, Abcam), noradrenalin (A7257, Sigma), CL316243 (Tocris Bioscience, Bristol, UK) 
or vehicle (DMSO) for 15 min or 8 h. H89 (H-5239, LC Laboratories) was added 1 h before 
initiation of salsalate treatment. Supernatant was collected for determination of glycerol 
concentration (Instruchemie, Delfzijl) and cells were harvested for RNA or protein analysis 
as described below.
Oxygen consumption measurements
A Seahorse Bioscience XF96 extracellular flux analyzer (Seahorse Biosciences, North 
Billerica, MA) was used to measure oxygen consumption rate (OCR) in differentiated T37i 
cells. On day 8 of differentiation, cells were trypsinized and seeded in a 96-well Seahorse 
assay plate. The next day, the ATP synthase inhibitor oligomycin, vehicle, salsalate and 
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Primary antibody Residue Supplier Reference Dilution 
ACC - Cell Signaling #3662 1:1000 
pACC Ser79 Cell Signaling #3661 1:1000 
AMPKα - Cell Signaling #2532 1:1000 
pAMPKα Thr172 Cell Signaling #2535 1:1000 
pHSL Ser563 Cell Signaling #4139 1:1000 
pHSL Ser565 Cell Signaling #4137 1:1000 
PKA substrates Ser/Thr Cell Signaling #9621 1:1000
UCP1 - Sigma U6382 1:5000
α/β Tubulin - Cell Signaling #2148 1:1000 
Table 1: Primary antibodies for Western blot.




















Table 2: Primer sequences of forward and reverse primers (5’ → 3’).
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CL316243 were preloaded in the reagent delivery chambers and pneumatically injected 
into the wells. Oligomycin was injected to a final concentration of 1.5 µM and the OCR was 
measured 3 times after mixing. Then, vehicle (0.1% DMSO), salsalate and/or CL316243 
were injected and the OCR was measured 6 times in 30 minutes. All OCR measurements 
were normalized to cell count using Cyquant (Invitrogen).
Western blot analysis
Pieces of snap-frozen mouse tissues (approx. 50 mg) or T37i cells (grown in 3.8 cm2 wells) 
were lysed, protein was isolated and Western blots were performed as previously described 
(11). Primary antibodies and dilutions are listed in Table 1. Protein content was corrected 
for a control mix on each blot and for the housekeeping protein tubulin.
RNA purification and qRT-PCR
RNA was extracted from snap-frozen mouse tissues (approx. 25 mg) or T37i cells (grown in 
3.8 cm2 wells) using Tripure RNA Isolation reagent (Roche). Total RNA (1-2 µg) was reverse 
transcribed using Moloney Murine Leukemia Virus (M-MLV) Reverse Transcriptase (Sigma) 
for qRT-PCR to produce cDNA. mRNA expression was normalized to β2-microglobulin (β2m) 
and 36b4 mRNA content and expressed as fold change compared to control mice using the 
ΔΔCT method. The primers sequences used are listed in Table 2.
Statistical analysis
All data are expressed as mean ± SEM, unless stated otherwise. Groups were compared 
with a two-tailed unpaired Student’s test and considered statistically significant if p<0.05.
RESULTS
Salsalate prevents high fat diet-induced obesity
To investigate the effect of salsalate on the development of obesity, male E3L.CETP mice 
were fed an HFD with or without salsalate for 12 weeks (i.e. progression study). Salsalate 
prevented the HFD-induced increase in body mass seen in the control group (-80%, 1.6±2.6 
vs. 7.9±5.5 g, p<0.01; Fig. 1A), which was due to a decreased gain in fat mass (-60%, 3.1±2.4 
vs. 7.8±4.2, p<0.05; Fig. 1B) rather than lean mass (Fig. 1C). Although salsalate persistently 
prevented mice from gaining fat mass throughout the treatment period, salsalate decreased 
food intake only during the first three days (Fig. 1D).
Salsalate prevents high fat diet-induced deterioration of glucose 
and triglyceride metabolism
Next, we assessed whether salsalate protects mice from developing HFD-induced glucose 
intolerance and dyslipidemia. Although salsalate did not affect fasting glucose levels 
(Fig. 2A), it reduced insulin levels after 4 weeks (-41%, p<0.05), 8 weeks (-47%, p=0.07) 
and 12 weeks (-67%, p<0.05; Fig. 2B) of treatment. In addition, salsalate improved glucose 
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tolerance (Fig. 2C), as evidenced by a reduction of the area under the curve of glucose 
concentrations during an ivGTT (AUC -25%, p<0.05; Fig. 2D). Salsalate did not affect 
plasma TC levels (Fig. 2E) throughout the treatment period but decreased plasma TG levels 
at 8 weeks (-43%, p<0.01) and 12 weeks (-47%, p<0.05; Fig. 2F).
To elucidate which metabolic organs were involved in the TG-lowering effect of 
salsalate, the tissue-specific uptake of FA derived from intravenously injected [3H]TO-
labeled lipoprotein-like emulsion particles was determined. Salsalate tended to increase 
the uptake of [3H]TO-derived activity by dorsocervical BAT (dcBAT), although significance 
was not reached, probably due to the substantial interindividual variation (Fig. 2G).
Salsalate reverses high fat diet-induced obesity and improves 
glucose and triglyceride metabolism
We investigated the potential of salsalate to reverse diet-induced obesity (DIO) in E3L.CETP 
mice (regression study). In this setting, salsalate lowered body weight (Fig. 3A) mainly due 
to a reduction in fat mass (Fig. 3B). Furthermore, salsalate reduced fasting glucose (-30%, 
p<0.01; Fig. 3C) and TG levels (-46%, p<0.05; Fig. 3D). Salsalate increased the uptake of 
[3H]TO-derived activity predominantly by iBAT (+156%, p<0.01) and dcBAT (+102%, p<0.05) 
and to some extent by the liver (+38%, p<0.01) (Fig. 3E). These data suggest that salsalate 
p=0.05





































































Figure 1. Salsalate prevents obesity and fat mass accumulation in E3L.CETP mice fed a high fat diet. 
10-week old male E3L.CETP mice were fed a high fat diet (HFD) without (open circles) or with (closed circles) 
salsalate for 12 weeks (A-D). Body weight (A), fat mass (B) and lean mass (C) were monitored throughout the 
experiment. Food intake was measured daily in the first two weeks and in the 6th week of the experiment (D). 
Values represent means ± SEM (n=9-10). * p<0.05, ** p<0.01, *** p<0.001 vs control.
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activates BAT, which is further supported by the observation that rectal temperature was 
raised (+0.5°C, p<0.05; Fig. 3F) upon salsalate treatment. Moreover, salsalate reduced 
interscapular BAT weight (-50%, p<0.01; Fig. 3G), indicating reduced fat accumulation 
within the tissue. Indeed, lipid droplet content was lower (Fig. 3H, I, J), pointing to higher 
intracellular lipolysis (18).














































































































































































Figure 2. Salsalate prevents high fat diet-induced deterioration of glucose and triglyceride metabolism 
in E3L.CETP mice fed a high fat diet. 10-week old male E3L.CETP mice were fed a high fat diet (HFD) 
without (open bars/circles) or with (closed bars/circles) salsalate for 12 weeks (A-G). Blood samples from 
6 h-fasted mice were collected by tail vein bleeding at different time points and plasma glucose (A), insulin 
(B), total cholesterol (E) and triglyceride (F) levels were determined. After 4 weeks, 6 h-fasted mice were 
injected i.v. with glucose and additional blood samples were taken at 5, 15, 30, 60, 90 and 120 min after 
injection (C-D). A clearance experiment was performed in which 6 h-fasted mice were i.v. injected with [3H]
TO-labeled lipoprotein-like emulsion particles. After 15 min, mice were sacrificed and uptake of [3H]TO-
derived activity was determined in the organs (G). AUC = area under the curve. Values represent means 




























































































































































































Figure 3. Salsalate reverses high fat diet-induced obesity and deterioration of glucose and triglyceride 
metabolism and enhances lipoprotein-TG derived fatty acid uptake by liver and brown adipose tissue 
in E3L.CETP mice fed a high fat diet. 10-week old male E3L.CETP mice were fed an HFD for 12 weeks to 
render them obese and subsequently fed an HFD without (open bars/circles) or with (closed bars/circles) 
salsalate for 4 weeks (A-I). Body weight (A) and fat mass (B) were monitored throughout the treatment 
period. After the treatment period, blood samples from 6 h-fasted mice were collected by tail vein bleeding 
and plasma glucose (C) and triglyceride (D) levels were determined. A clearance experiment was performed 
in which 6 h-fasted mice were i.v. injected with [3H]TO-labeled lipoprotein-like emulsion particles. After 15 
min, mice were sacrificed and uptake of [3H]TO-derived activity was determined in the organs (E). Rectal 
temperature was determined after 4 weeks of treatment (F). Upon sacrifice, interscapular brown adipose 
tissue (iBAT) was collected and weighed (G). Lipids were extracted from BAT and TG content was measured 
(H). Haematoxylin and Eosin (H&E) staining of BAT sections was performed and relative content of lipid 
vacuoles in BAT tissue sections were quantified (I), representative pictures are shown (J). Values represent 
means ± SEM (n=9-10). * p<0.05, ** p<0.01, *** p<0.001 vs control. sWAT, subcutaneous white adipose 
tissue; vWAT, visceral white adipose tissue.
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Salsalate prevents body weight gain and activates brown adipose 
tissue irrespective of the transgenic background
To exclude that the effects of salsalate were specific to the E3L.CETP transgenic model, 
male WT mice were fed an HFD with or without salsalate for 4 weeks. We confirmed that 
salsalate treatment had similar effects on body weight, body composition and food intake 
(Suppl. Fig. 1A-D). Prevention of adiposity despite equal food intake suggests that either 
physical activity or energy expenditure is enhanced. Indeed, salsalate increased EE during 
the dark phase (+10%, p<0.05; Suppl. Fig. 1E). This was especially due to a higher glucose 
oxidation (+29%, p<0.001; Suppl. Fig. 1F), whereas fat oxidation did not differ (Suppl. Fig. 
1G). Accordingly, respiratory exchange ratio (RER) was higher during the dark phase (Suppl. 
Fig. 1H). Physical activity was not affected (Suppl. Fig. 1I), suggesting that the energetic 
loss is mainly explained by increased energy expenditure.
Comparable to our findings in E3L.CETP mice, salsalate reduced plasma insulin levels 
(Suppl. Fig. 2A) and improved glucose tolerance (Suppl. Fig. 2B-D). This was probably 
achieved via an insulin-independent mechanism, as no differences in glucose levels were 
found between the treatment groups upon an insulin challenge (Suppl. Fig. 2E). Of note, 
AMPK phosphorylation in muscle was enhanced upon salsalate treatment (+43%, p<0.05), 
as was phosphorylation of its downstream target ACC (+75%, p<0.05; Suppl. Fig. 2F).
In WT mice, salsalate also reduced plasma triglyceride levels (Suppl. Fig. 2G). This 
was not due to lowered intestinal TG absorption, since salsalate-treated mice did not have 
significantly lower plasma TG levels in response to an oral olive oil gavage (Suppl. Fig. 2H) 
and FFA content in feces collected in the third week of treatment was unaltered (Suppl. 
Fig. 2I). Neither VLDL-TG (Suppl. Fig. 2J) nor VLDL[35S]apoB production (Suppl. Fig. 2K) 
were affected upon 4 weeks of salsalate treatment, further supporting a role for BAT in the 
TG-lowering effect of salsalate. Indeed, comparable to the effects seen in E3L.CETP mice, 
salsalate reduced interscapular BAT weight (-42%, p<0.001; Fig. 4A), lowered lipid content 
(-29%, p<0.05; Fig. 4B, C) and tended to increase the uptake of [3H]TO-derived activity by 
the BAT depots (Suppl. Fig. 3C).
Under thermoneutral conditions, salsalate still prevented the development of high fat 
diet-induced obesity (Suppl. Fig. 3A,B). However, thermoneutrality ablated the salsalate-
induced tendency towards an increased TG uptake by BAT (Suppl. Fig. 3C) and prevented 
the reduction in plasma TG levels seen at room temperature (Suppl. Fig. 3D). Thus, 
noradrenergic input (i.e. slight cold sensing at room temperature) seems necessary to bring 
about salsalate-induced TG uptake by BAT.
To further elucidate the mechanisms by which salsalate activates BAT and regulates 
intracellular lipolysis, we measured mRNA and (phosphorylated) protein levels in BAT of 
mice housed at 21°C upon treatment. Salsalate did not affect Ucp1 mRNA expression 
(data not shown) nor UCP1 protein content (Fig. 4D). Salsalate tended to increase the 
PKA-mediated lipolysis-stimulating phosphorylation of HSL on the Ser563 residue (+77%, 
p=0.06) but not AMPK-mediated phosphorylation of HSL on the Ser565 residue (19) (Fig. 
4D), suggesting increased PKA signaling in BAT. Despite the fact that phosphorylation 
of ACC, the downstream target of AMPK, was increased, we did not observe significant 
differences in AMPK expression or phosphorylation (Fig. 4D).
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Salsalate reduces WAT cell size and lowers inflammation in wild 
type mice fed a high fat diet
Since salsalate massively reduced fat mass, we assessed the phenotype of WAT in more 
detail. In line with the decreased total fat mass (Figs. 1B, 3B, S1B), salsalate reduced the 
weight of the gonadal WAT (gWAT) fat pad (-49%, p<0.001; Fig. 5A). Histological analysis 
showed that salsalate reduced adipocyte size (-44%, p<0.01; Figs. 5B, C), while total cell 
number, as assessed by DNA content, did not differ (data not shown).
Since salsalate is an anti-inflammatory compound, we investigated the immune cell 
composition of gWAT by flow cytometry. We did not observe a change in the percentage 
of CD45+ cells within the stromal vascular fraction (SVF), nor in relative monocyte, 
macrophage, granulocyte, T- and B-cell content (data not shown). However, we found 
less pro-inflammatory (CD11c+) M1 macrophages and more anti-inflammatory (CD206+) 
M2 macrophages within the F4/80+ fraction (Fig. 5D, E). Accordingly, salsalate decreased 
F4/80 and Mcp1 mRNA expression in gWAT (Fig. 5F), confirming fewer pro-inflammatory 
















































































Figure 4. Salsalate activates brown 
adipose tissue in wild type mice 
fed a high fat diet. 10-week old male 
C57Bl/6J mice were fed a high fat diet 
(HFD) without (open bars) or with (closed 
bars) salsalate for 4 weeks. Upon 
sacrifice, interscapular brown adipose 
tissue (iBAT) was collected and weighed 
(A). Haematoxylin and Eosin (H&E) 
staining of BAT sections was performed 
and relative content of lipid vacuoles 
in BAT tissue sections were quantified 
(B), representative pictures are shown 
(C). Protein content was determined 
by Western blot (D). Values represent 
means ± SEM (n=6-8). * p<0.05, 
*** p<0.001 vs control.
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of salsalate treated mice. Thus, besides preventing fat accumulation in WAT, salsalate 
prevented HFD-induced skewing of macrophages towards a pro-inflammatory phenotype.
Next, we studied whether the diminished adipocyte size following salsalate treatment 
could be the result of increased TG lipolysis. Phosphorylation levels of HSL on the Ser563 
residue (phosphorylated by PKA; Fig. 5G) in gWAT did not differ, nor did plasma free fatty acid 
(FFA) levels (data not shown). Moreover, in vitro stimulation of 3T3-L1 cells with salsalate did 
not influence Ser563-HSL phosphorylation (Suppl. Fig. 4A) and even repressed the glycerol 
concentration in the supernatant (Suppl. Fig. 4B). Of the oxidation genes we measured in 
gWAT, only Acc2 was upregulated upon salsalate treatment, suggesting slightly enhanced 
oxidation in gWAT (Suppl. Fig. 5A). The phosphorylation state nor the expression of AMPK 
was altered (Fig. 5G) in gWAT. We also investigated markers of lipogenesis in gWAT, but only 
found an upregulation of Acc1 expression (Suppl. Fig. 5B). Collectively, these data indicate 
that it is unlikely that lipolysis, oxidation or lipogenesis in WAT is the primary mechanism 
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Salsalate
Figure 5. Salsalate reduces white adipocyte cell size and lowers inflammation in WAT of wild type mice 
fed a high fat diet. 10-week old male wild type mice were fed a high fat diet (HFD) without (open bars) or 
with (closed bars) salsalate for 4 weeks. Gonadal white adipose tissue (gWAT) was collected and weighed 
(A). Haematoxylin and Eosin (H&E) staining of gWAT sections was performed and relative cell size of white 
adipocytes in gWAT tissue sections was quantified (B), representative pictures are shown (C). Percentage 
of macrophages (%CD11b+Ly6G-F4/80+) of CD45+ cells in stromal vascular fraction (SVF) of gWAT were 
determined by flow cytometry. Within the macrophage fraction, pro-inflammatory M1 macrophages 
(CD11c+) (D) and anti-inflammatory M2 macrophages (CD206+) (E) were measured. mRNA expression in 
of inflammatory markers (F) in gWAT was determined by qRT-PCR. Protein content was determined by 
Western blot (G). Values represent means ± SEM (n=6-8). * p<0.05, ** p<0.01, *** p<0.001 vs control.
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Salsalate directly activates brown adipocytes in vitro
Since our collective data suggested that the improvement in triglyceride metabolism by 
salsalate could be due to activation of BAT, we investigated whether salsalate directly 
activates brown adipocytes and which intracellular mechanism(s) are involved. Strikingly, 
treatment of differentiated T37i adipocytes with salsalate increased uncoupled respiration 
(Fig. 6A). In line with this, increasing concentrations of salsalate resulted in a dose-
dependent increase in Ucp1 expression (up to +227%, p<0.001; Fig. 6B) as well as glycerol 
release (up to +92%, p<0.001; Fig. 6C). Accordingly, salsalate decreased lipid content in 
the cells, as shown by Nile Red staining (-18%, p<0.05; Suppl. Fig. 6A). Decreased de novo 
lipogenesis found upon treatment with salsalate (Suppl. Fig. 6B) could also contribute 
to this finding. Besides Ucp1, salsalate upregulated several other genes involved in BAT 
function (Fig. 6D).
The majority, but not all, of orally administered salsalate is metabolized to salicylate 
in vivo, resulting in plasma concentrations of 1-3 mM (1). Like salsalate, salicylate (1 mM) 
enhanced Ucp1 expression in T37i brown adipocytes (+53%, p<0.01, Suppl. Fig. 6C). 
Salicylate (1 and 3 mM) also enhanced expression of Pparα (up to +304%, p<0.01) and its 
target gene (22) Elovl3 (up to +224%, p<0.05; Suppl. Fig. 6C), while the higher dosage of 
salicylate (3 mM) enhanced glycerol release (+80%, p<0.01; Suppl. Fig. 6D).
Since salsalate is known to directly activate AMPK (1), we investigated this in brown 
adipocytes. However, salsalate did not increase phosphorylation of AMPK (Fig. 6E) nor ACC 
(data not shown) after stimulation for 15 min, 1 h or 8 h (data not shown). We therefore 
searched for another route by which salsalate may activate BAT.
As both AMPK and PKA regulate lipolysis in BAT by phosphorylation of HSL (23, 24), and 
our in vivo data indicated PKA-mediated phosphorylation of HSL on the Ser563 residue, 
we investigated whether salsalate activates the PKA-HSL route in brown adipocytes. 
Salsalate enhanced phosphorylation of the 30 kDa PKA substrate in brown adipocytes 
Figure 6 (right page). Salsalate directly activates T37i brown adipocytes. T37i cells were cultured and 
differentiated into mature brown adipocytes. Cells were treated with salsalate (300 µM) after addition of 
oligomycin and oxygen consumption rate was directly measured with an extracellular flux analyzer. Values 
represent means ± SEM of 11-13 independent wells (A). Cells were treated with increasing concentrations 
of salsalate for 8 h and Ucp1 mRNA expression (B) and glycerol release (C) were determined. Cells were 
treated with salsalate (300 µM) for 8 h and mRNA expression was determined (D). Cells were treated with 
salsalate (300 µM) or AICAR for 15 min and protein content was determined (E). Cells were treated with 
salsalate (300 µM) for 8 h and protein content was determined (F). Cells were treated with salsalate (300 
µM) in the presence of H89 for 8 h and Ser563-HSL phosphorylation (G), Ucp1 mRNA expression (H) and 
glycerol release (I) were determined. Cells were treated with salsalate (300 µM) and CL316243 (10µM) 
after addition of oligomycin and oxygen consumption rate was directly measured with an extracellular flux 
analyzer. Values represent means ± SEM of 11-13 independent wells (J). Protein content was determined 
by Western Blot and mRNA expression was determined by qRT-PCR. OCR = oxygen consumption rate, 
OM = oligomycin. Values represent means ± SD of 3-6 independent sets of RNA, supernatant or protein. 
* p<0.05, ** p<0.01, *** p<0.001 vs control or CL316243, # p<0.05, ## p<0.01 vs salsalate.
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after 8 h of stimulation (+69%, p<0.05) and increased phosphorylation of HSL on Ser563, 
the PKA phosphorylation site of this lipolytic enzyme (+108%, p<0.05; Fig. 6F), while 
phosphorylation of HSL on Ser565, the AMPK phosphorylation site, was unaffected. 
To investigate the involvement of the PKA pathway for BAT activation by salsalate, we 
stimulated brown adipocytes with salsalate in the presence of the PKA inhibitor H89 (25 µM). 
H89 blunted the salsalate-induced Ser563-HSL phosphorylation (Fig. 6G), upregulation of 
Ucp1 expression (Fig. 6H) and glycerol release (Fig. 6I), indicating that the PKA pathway is 
required for brown adipocyte activation by salsalate. These data are consistent with our 
observation that salsalate only increased TG uptake by BAT in vivo when mice are housed 
at room temperature, i.e. when adrenergic signalling is present.
Since PKA is a downstream target of β-adrenergic signalling, we investigated whether 
salsalate acts in synergism with β-adrenergic stimulation in T37i brown adipocytes. 
Although salsalate in combination with the β3-agonist CL316243 enhanced uncoupled 
respiration as compared to CL316243 alone, no synergistic effect was found (Fig. 
6J). Furthermore, salsalate and NA showed an additive effect on Ucp1 expression 
(Suppl. Fig. 6E). This suggests that increased β-adrenergic signalling is not required for 
the effects of salsalate, but since inhibition of PKA abolishes the effects of salsalate, basal 
β-adrenergic signalling is. Taken together, both our in vitro and in vivo data point to an 




Previous studies in humans and animals have shown that salsalate has beneficial metabolic 
effects by improving glucose tolerance and lowering plasma triglycerides (3, 4). The 
mechanisms responsible for these changes, however, remained unclear. In the present 
study, we show that chronic treatment of E3L.CETP and WT mice with salsalate recapitulates 
these beneficial metabolic effects and in addition prevents and reduces body weight gain, 
mainly by lowering fat mass accumulation. Moreover, we provide evidence from both in vivo 
and in vitro studies that salsalate activates BAT, an important player in energy metabolism. 
To the best of our knowledge, this is the first study reporting that activation of BAT may, at 
least partly, underlie the beneficial metabolic effects of salsalate.
The finding that salsalate prevented body weight gain and fat mass accumulation 
accompanied by a reduced white adipocyte size has been reported before in rats (25). 
Lower fat accumulation may be the consequence of a lower food intake or higher energy 
expenditure. Although we noticed that food intake was transiently reduced upon salsalate 
treatment in mice, the preventive effect on fat mass accumulation persisted throughout the 
studies. We found increased energy expenditure in our study, which is in line with studies 
in humans showing that salsalate treatment increases energy expenditure by +18% (2, 5), 
suggesting that the long term inhibiting effects of salsalate on body weight gain are caused 
by increased resting energy expenditure.
In our study, salsalate improved glucose tolerance via an insulin-independent mechanism 
and lowered plasma glucose and triglyceride levels, which is in line with findings in humans 
(2, 3). Recently, it has been shown that salicylate acutely stimulates phosphorylation of 
AMPK and simultaneously increases glucose transport, independent of insulin, into muscle 
in rat skeletal muscles ex vivo (26). Correspondingly, in our study, AMPK phosphorylation in 
muscle was enhanced upon salsalate treatment, as was phosphorylation of its downstream 
target ACC. Taken together, our data suggest that salsalate improves glucose tolerance 
by enhancing glucose oxidation and glucose uptake via an insulin-independent pathway. 
BAT, a metabolically active tissue that contributes to energy metabolism by uncoupling 
the electron transport chain from ATP synthesis through uncoupling protein-1 (UCP1), 
also has a key role in systemic glucose homeostasis by enhancing glucose clearance (27, 
28). Although we do not have evidence for the possibility that salsalate improves glucose 
tolerance through BAT activation, we did show that the TG-lowering effect of salsalate 
was due to higher uptake of lipoprotein-TG-derived FA by BAT as intestinal TG absorption 
and hepatic VLDL production were unaffected in our experimental settings. We provide 
strong evidence that BAT was activated upon salsalate treatment, since we found reduced 
intracellular lipid content and higher rectal temperature in vivo, and higher uncoupled 
respiration, upregulation of the expression of thermogenic markers Ucp1 and Elovl3 and 
increased glycerol release upon salsalate treatment in vitro.
Regarding the mechanism through which salsalate activates BAT, we found slightly 
increased phosphorylation of AMPK’s downstream target ACC in BAT in vivo, but not of 
AMPK itself. In T37i brown adipocytes in vitro, phosphorylation statuses of AMPK and ACC 
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were also unaffected. Although a recent study by Hawley et al. (1) showed that salicylate 
activates AMPK in the liver, muscle and adipose tissue, they also observed that the potency 
of salicylate to improve fasting glucose and insulin, glucose tolerance and insulin resistance 
were retained in mice lacking the β1 subunit of AMPK, demonstrating that other pathways 
are more important than the AMPK-mediated beneficial metabolic effects of salicylates.
Our data point more profoundly towards activation of the PKA-HSL pathway in BAT. We 
found that salsalate increased Ser563-HSL phosphorylation in BAT in vivo and in brown 
adipocytes in vitro, which points to an increase of PKA-mediated lipolysis. Indeed, salsalate 
treatment enhanced glycerol release in vitro and reduced the intracellular lipid content 
in BAT in vivo. The enhanced intracellular release of FA results in increased availability 
of substrate for oxidation that can also induce allosteric activation of UCP1 (29), both 
resulting in enhanced uncoupling, which we also demonstrated in brown adipocytes in 
vitro. Importantly, the fact that PKA inhibition blunted the salsalate-induced Ser563-HSL 
phosphorylation, Ucp1 expression and glycerol release in vitro supports a necessity for 
this pathway in brown adipocyte activation.
Besides improving metabolism, salsalate is an effective anti-inflammatory agent in 
the clinic. With the current knowledge of a profound link between obesity, inflammation 
and type 2 diabetes, we also investigated the effects of salsalate on the inflammatory 
state of WAT. In gWAT, salsalate lowered Mcp1 expression, an attraction factor of pro-
inflammatory M1 macrophages, and prevented HFD-induced skewing of macrophages 
towards this phenotype. Previous research showed that high concentrations of salicylates 
inhibit NF-ĸB activity in vitro, a key transcription factor that regulates inflammation (30). In 
obese humans, salsalate lowers the inflammatory state, with a 34% reduction in circulating 
levels of C-reactive protein and declined NF-ĸB activity in WAT (31, 32). This reduction in 
inflammation might contribute to the improved glucose metabolism upon salsalate.
Since it is becoming increasingly clear that BAT activation and subsequent elevation 
of energy expenditure can lower body fat mass in human adults (33), drugs that target 
BAT are of great interest in the combat against obesity. Although some human studies 
suggested that salsalate does not affect body weight (4, 34), effects on fat mass have not 
been reported. As mice have a relatively larger amount of BAT compared to humans (35, 
36), activation of BAT by salsalate in humans might translate into improved fat distribution, 
glucose and lipid metabolism without substantially affecting total body weight.
In conclusion, we show that salsalate exerts beneficial metabolic effects by directly 
activating BAT through modulation of the PKA pathway in BAT (Fig. 7). Further studies are 
warranted to investigate whether salsalate activates BAT in humans, thereby preventing 
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Figure 7. Proposed mechanism by which salsalate activates brown adipose tissue. Salsalate improves 
intracellular lipolytic capacity of the brown adipocyte by increasing PKA-mediated HSL phosphorylation, 
thereby enhancing FA release from TG stored in lipid droplets. This leads to activation of UCP1, which 
uncouples ATP synthesis. Moreover, salsalate results in enhanced expression of Pparα, Ppargc1α, and 
Ucp1, altogether resulting in increased activity and uncoupling of ATP synthesis in BAT. A reduction in 
intracellular lipid content and upregulation of Cd36 in BAT enhances uptake of TG-derived FA from the 
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Supplementary figure 1. Salsalate prevents obesity and fat mass accumulation in wild type mice fed a 
high fat diet. 10-week old male wild type mice (C57Bl/6J background) were fed a high fat diet (HFD) without 
(open circles) or with (closed circles) salsalate for 4 weeks (A-D). Body weight (A), fat mass (B) and lean mass 
(C) were monitored throughout the experiment. Food intake was measured daily in the first week of the 
experiment (D). From day 5 to day 9 of salsalate treatment, mice were housed in fully automatic metabolic 
cages (LabMaster System; TSE Systems, Bad Homburg, Germany), which measured oxygen uptake (VO2), 
carbon dioxide production (VCO2) and caloric intake. Total energy expenditure (E) was calculated from VO2 
and VCO2 using the Weir equation, and glucose oxidation (F) and fat oxidation (G) were calculated from VO2 
and VCO2 as described previously (37). Respiratory exchange ratio (H) was also calculated from VO2 and VCO2. 
Physical activity (I) was measured with infrared sensor frames. Measurements (E-H) were corrected for lean 
mass as determined by EchoMRI (EchoMRI-100, Houston, Texas, USA). EE = energy expenditure. Values 
represent means ± SEM (n=7-8). * p<0.05, ** p<0.01, *** p<0.001 vs control.
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Supplementary figure 2. Salsalate improves glucose and triglyceride metabolism in wild type mice fed 
a high fat diet. 10-week old male wild type mice were fed a high fat diet (HFD) without (open circles/bars) 
or with (closed circles/bars) salsalate for 4 weeks. Blood samples from 6 h-fasted mice were collected 
by tail bleeding at different time points and plasma insulin (A), glucose (B) and triglyceride (G) levels were 
determined. After 4 weeks, 6 h fasted mice were i.v. injected with glucose and additional blood samples 
were taken at 5, 15, 30, 60, 90 and 120 min after injection (C-D). After 4 weeks, an insulin tolerance test 
was performed by injecting 6 h fasted mice i.p.with insulin (NovoRapid, Novo Nordisk, Denmark; 1 U/kg 
whole body mass) and measuring glucose at t = 15, 30, 60 and 90 min (E). Protein content in muscle was 
determined by Western blot (F). Postprandial triglyceride (TG) response was measured after 3 weeks of 
salsalate treatment. Animals were fasted for 6 h and a basal blood sample was drawn before an intragastric 
load of 200 µL olive oil (Carbonell, Traditional, Cordoba, Spain) was given. Blood samples were drawn 1, 
2, 4, 6 and 8 h after the bolus via tail vein bleeding and plasma TG levels were measured (H). Feces was 
collected during the 3rd week of salsalate treatment. Feces was then weighed, freeze-dried and ground, 
and fecal fatty acids were determined by methyl esterification. To this end, 750 µL CH3OH/NaOH (10 M)/H2O 
(3:1:1 v/v) was added to the feces and samples were incubated and mixed in a thermomixer (600 rpm, 90°C) 
for 1 h. Then, 1050 µL of HCl (6 M)/hexane (3:7.7 v/v) was added before samples were vortexed and spun 
down 1 min at 14,000 rpm. The upper hexane layer was dried using N2 and redissolved in 2% Triton X-100. 
Fatty acids were measured using the NEFA C kit (Wako Diagnostics, Instruchemie, Delfzijl) (I). After 4 weeks 
of salsalate treatment, hepatic VLDL production was determined. Mice were fasted for 4 h and anesthetized 
by intraperitoneal injection of 6.25 mg/kg acepromazine (Alfasan, Weesp), 6.25 mg/kg midazolam (Roche, 
Mijdrecht), and 0.31 mg/kg fentanyl (Janssen Pharmaceuticals, Tilburg). Mice were injected intravenously 
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with Tran[35S] label (20 µCi/mouse; MP Biomedicals, Eindhoven) to label newly produced apolipoprotein B 
(apoB). After 30 min, at t = 0 min, Triton WR-1339 (Sigma-Aldrich) was injected intravenously (0.5 mg/g body 
weight, 10% solution in PBS) to block serum VLDL clearance. Blood samples were drawn before (t = 0) and 
at 15, 30, 60, and 90 min after injection of Triton and used for determination of plasma TG concentration (J). 
After 120 min, mice were exsanguinated via the retro-orbital plexus. VLDL was isolated from serum after 
density gradient ultracentrifugation at d < 1.006 g/ml by aspiration (38) and examined for incorporated 
35S-activity as a measure of ApoB production rate (K). AUC = area under the curve; FFA = free fatty acids. 
Values represent means ± SEM (n=5-8). * p<0.05, ** p<0.01 vs control.





































































































Supplementary figure 3. Effect of salsalate at thermoneutrality. 10-week old male wild type mice 
were housed at 21°C (black circles/bars) or 28°C (grey circles/bars) and fed a high fat diet (HFD) without 
(open circles/bars) or with (closed circles/bars) salsalate for 4 weeks. Body weight (A) and fat mass (B) 
were monitored throughout the experiment. A clearance experiment was performed in which 6 h-fasted 
mice were i.v. injected with [3H]TO-labeled lipoprotein-like emulsion particles. After 15 min, mice were 
sacrificed and uptake of [3H]TO-derived activity was determined in the organs (C). After 4 weeks of 
treatment, blood samples from 6 h-fasted mice were collected by tail bleeding and plasma triglyceride 
levels were determined (D). Values represent means ± SEM (n=7-8). * p<0.05 vs control. (g,s,v)WAT, gonadal, 















































Supplementary figure 4. Effect of salsalate on 3T3-L1 cells. 3T3-L1 cells were cultured and differentiated 
into white adipocytes. White adipocytes were treated with 300 µM salsalate for 8 h. Protein content was 
determined by Western blot (A) and glycerol concentration in the culture medium was measured (B). Values 











































Supplementary figure 5. Effect of salsalate on genes involved in beta-oxidation and lipogenesis in 
gWAT of wild type mice fed a high fat diet. 10-week old male wild type mice were fed a high fat diet 
(HFD) without (open bars) or with (closed bars) salsalate for 4 weeks and gonadal white adipose tissue 
(gWAT) was collected. mRNA expression was determined by qRT-PCR (A-B). Values represent means ± SEM 








































































































































Supplementary figure 6. In vitro effects of salsalate and salicylate on T37i brown adipocytes. T37i 
cells were cultured and differentiated into mature brown adipocytes. Cells (grown in 0.32 cm2 wells) were 
treated with salsalate (300 µM) for 8 h, stained with 0.1 mg/mL Nile Red solution (Molecular probes, N-1142) 
for 2 h at 37°C and measured with a fluorimeter (Ex. 485 nm, Em. 590 nm). Values represent means ± SEM 
of 11 independent wells (A). To assess de novo lipogenesis, cells (grown in 3.8 cm2 wells) were incubated 
at 37°C with HEPES buffer (29.8 g HEPES, 8.78 g NaCl, 4.66 g KCl, 1.12 g D-glucose, 18.8 g BSA, 0.132 
g CaCl2 in 1.125 L H2O, pH 7.3), 100 nM insulin and [3H]glucose (~500,000 cpm). Cells were either pre-
incubated with vehicle or salsalate for 6 h or the compound was added together with the [3H]glucose. After 
2 h, cells were washed and 600 µL cold CHCl3/CH3OH (1:1 v/v) was added. Cells were left on ice for 30 min, 
upon which the supernatant was isolated. Next, 125 µL H2O was added and the samples were mixed and 
spun for 10 min at 3,500 rpm. The CHCl3 layer was isolated and evaporated under N2 and incorporation of 
[3H]glucose-derived radioactivity was quantified. Values represent means ± SEM of 4-5 independent wells 
(B). Cells were treated with salicylate (1 or 3 mM) for 8 h and mRNA expression was determined by qRT-PCR 
(C). In addition, glycerol concentration in the medium was assessed (D). Cells were treated with salsalate 
(300 µM) in the presence of increasing concentrations of noradrenalin (0.1 – 1 µM) for 8 h and Ucp1 mRNA 
expression was determined (E). NA = noradrenalin. Values represent means ± SD of 3-4 independent sets 
of RNA. * p<0.05, ** p<0.01 vs control , $ p<0.05, $$ p<0.01 vs NA, ~ p<0.10 vs NA and salsalate.
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The free fatty acid receptor GPR120 is highly expressed in white adipose tissue and brown 
adipose tissue (BAT), both of which play a major role in triglyceride metabolism. However, 
the effects of GPR120 on lipid metabolism and substrate utilization have not been studied 
to date. The aim of our current study was to assess the role of GPR120 in lipid metabolism. 
To this end, GPR120-/- and wild-type mice (C57BL/6 background) received a high-fat diet 
(HFD) for 8 weeks. Body composition was monitored by EchoMRI and fully automated 
metabolic cages were used to measure energy expenditure and substrate utilization. 
GPR120-/- mice had higher fat mass (+25%, p=0.05), lower physical activity (-49%, p<0.05) 
and lower energy expenditure during the dark phase (-5%, p<0.05), albeit that substrate 
utilization was not different (similar respiratory exchange ratio) compared to wild-type 
mice. GPR120 deficiency reduced the expression of Ucp1, Prdm16 and Pparα in BAT 
(-38 to -59%, p<0.05) without reducing uptake of fatty acids derived from intravenously 
injected lipoprotein-like particles labeled with glycerol tri[3H]oleate ([3H]TO) by BAT. When 
wild-type mice were fed a HFD for 6 weeks and orally treated with the GPR120 agonist 
TUG891 (10 mg/kg daily) during the last 3 weeks of HFD feeding, TUG891 reduced fat mass 
after 2.5 weeks (-40%, p<0.05). To assess acute effects of the GPR120 agonist, wild-type 
mice on a chow diet were treated with i.p. TUG891 (35 mg/kg daily) for 5 days. Although i.p. 
TUG891 treatment did not increase total energy expenditure, the GPR120 agonist acutely 
increased fat oxidation (+331%, p<0.01) while reducing glucose oxidation (-18%, p<0.05), 
which was accompanied by a tendency for reduced fat mass already after 5 days (-19%, 
p=0.06). In conclusion, GPR120 deficiency increases fat mass without evident effects on 
triglyceride-rich lipoprotein turnover and GPR120 agonism reduces fat mass accompanied 





G protein-coupled receptors (GPCRs) represent the largest family of transmembrane 
signaling receptors (1). A subclass of the GPCR family specifically binds free fatty acids 
(FFAs), which can act as signaling molecules to regulate various physiological processes. 
GPR120, also known as free fatty acid receptor 4 (FFAR4), is activated by medium and long 
chain fatty acids (2). Recent studies have revealed an important role for GPR120 in immune 
regulation, hormonal secretion and energy metabolism. For example, several studies 
showed that GPR120 mediates anti-inflammatory actions of ω-3 fatty acids (3-5). In white 
adipose tissue (WAT), GPR120 plays a role in adipocyte differentiation (6) and enhances 
glucose uptake, which contributes to improved insulin sensitivity (3). GPR120 deficiency 
leads to obesity, glucose intolerance and hepatic steatosis in mice fed a high-fat diet (7). 
In humans, individuals carrying a mutation associated with decreased GPR120 signaling 
have an increased risk of obesity (7). Together, these negative effects of reduced GPR120 
signaling have led to high interest in the development of pharmacological compounds to 
activate this receptor (8, 9).
GPR120 is expressed in both WAT and brown adipose tissue (BAT). WAT is the most 
abundant adipose tissue type, found throughout the body in different subcutaneous and 
visceral depots (10). WAT is a major participant in energy regulation of the body, by storing 
excess ingested glucose and fatty acids in the form of triglycerides within adipocytes and 
by releasing fatty acids to meet the energy needs of other organs (11). In contrast to WAT, 
BAT combusts fatty acids to generate heat for maintenance of body temperature, defined as 
non-shivering thermogenesis. Brown adipocytes are smaller than white adipocytes, contain 
many mitochondria and typically contain multiple small lipid droplets (10). Thermogenesis 
is dependent on the presence of uncoupling protein 1 (UCP1), which is present in 
mitochondria and “uncouples” electron transport from ATP synthesis. As a consequence, 
heat is generated instead of ATP (12, 13). Interestingly, GPR120 is highly expressed in BAT 
and cold exposure even further increases its expression in BAT and subcutaneous (s)WAT 
(14), indicating a role for GPR120 in thermogenesis. Also, GPR120 expression increases in 
WAT of mice on a high-fat diet (6). Collectively, these data suggest GPR120 plays a role in 
both BAT and WAT physiology.
Although previous studies have focused on the metabolic effects of GPR120 
signaling, most focused on the effects of GPR120 on gut hormone secretion and glucose 
metabolism. The aim of our current study was to assess the role of GPR120 in lipid 
metabolism and the therapeutic potential of a selective GPR120 agonist. To this end, we 
studied lipid metabolism in GPR120-/- mice and treated wild-type mice with the GPR120 
agonist TUG891. We found that GPR120 deficiency increases fat mass, reduces physical 
activity and reduces the expression of BAT-specific genes, but does not have pronounced 
effects on lipid metabolism. Interestingly, we found that specific stimulation of GPR120 with 
TUG891 increases fat oxidation and reduces fat mass. Taken together, our data indicate 
that GPR120 deficiency increases fat mass without evident effects on triglyceride-rich 
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lipoprotein turnover and GPR120 agonism reduces fat mass accompanied by increased fat 
oxidation. Therefore, GPR120 may be a promising target to reduce obesity.
MATERIALS AND METHODS
Animals, diet and treatment
All mice were approximately 12 weeks of age at the start of each experiment and individually 
housed under standard conditions with a 12:12 h light-dark cycle (from 7:00 h to 19:00 
h) and free access to food and water. To assess the effect of GPR120 deficiency on the 
development of obesity, male GPR120-/- mice and wild-type mice on a C57Bl/6 background 
were acquired from Taconic Biosciences. Mice received a high-fat diet (HFD; 45% kcal from 
lard fat, Research Diets) for 8 weeks, upon which they were sacrificed by cervical dislocation. 
Two wild-type mice were excluded due to severe infection during the study. One GPR120-/- 
mouse was excluded because of unexplained weight loss after 4 weeks of HFD.
To investigate the effect of oral treatment with a GPR120 agonist on obesity, male 
C57Bl6/J mice (Charles River Laboratories) were fed a HFD for 3 weeks before initiation 
of treatment with TUG891 at 12 weeks of age. TUG891 was synthesized as described 
previously (15). Mice were treated with vehicle or TUG891 (10 mg/kg body weight, dissolved 
in 10% v/v DMSO, 10% w/v cremophor and 5% w/v mannitol in water, all from Sigma-Aldrich) 
by oral gavages daily at 15:00 h. Treatment lasted for 3 weeks, upon which the mice were 
sacrificed by cervical dislocation.
The acute effects of TUG891 on energy expenditure were assessed in male C57Bl6/J 
mice. First, mice were i.p. injected twice daily at 9:00 h and 16:00 h with vehicle or increasing 
doses of TUG891 (dissolved in 10% v/v DMSO in PBS) ranging from 15-50 mg/kg body 
weight as indicated over a period of 5 days. Thereafter, mice were i.p. injected once daily 
at 17:00 h with 35 mg/kg body weight TUG891 for 5 consecutive days. Mouse experiments 
were performed in accordance with the Institute for Laboratory Animal Research Guide for 
the Care and Use of Laboratory Animals and had received approval from the University 
Ethical Review Board (Leiden University Medical Center, The Netherlands).
Food intake, body weight, and body composition
At indicated time points, food intake and body weight were measured with a scale, and body 
composition was measured using an EchoMRI-100 analyzer (EchoMRI, TX, USA).
Energy metabolism
GPR120-/- and wild-type control mice were housed in fully automatic metabolic cages 
(LabMaster System; TSE Systems) in the second week of HFD-feeding. Wild-type mice 
that received i.p. treatment with TUG891 were housed in metabolic cages during the entire 
treatment period. Metabolic cages measured oxygen uptake (VO2) and carbon dioxide 
production (VCO2). Respiratory exchange ratio (RER), glucose oxidation and fat oxidation were 
calculated from VO2 and VCO2 as described previously (16). Total energy expenditure was 
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calculated from VO2 and VCO2 using the Weir equation (17). Physical activity was measured 
with infrared sensor frames.
Histology of WAT and BAT
Subcutaneous WAT and interscapular BAT (iBAT) were removed, fixed in 4% 
paraformaldehyde, dehydrated in 70% EtOH, and embedded in paraffin. Hematoxylin-eosin 
(HE) stainings were performed on sections (5 µm) using standard protocols. The cell size of 
adipocytes in WAT and the area of intracellular lipid vacuoles in BAT were quantified using 
ImageJ software.
RNA purification and quantitative RT-PCR
RNA was extracted from snap-frozen iBAT using Tripure RNA Isolation reagent (Roche) 
according to manufacturer’s instructions. RNA concentrations were measured using 
NanoDrop and RNA was reverse transcribed using Moloney Murine Leukemia Virus Reverse 
Transcriptase (Promega) for quantitative RT-PCR (qRT-PCR) to produce cDNA. Expression 
levels of genes were determined by qRT-PCR, using gene-specific primers (Table 1) and 
SYBR green supermix (Biorad). mRNA expression was normalized to B2m and Gapdh mRNA 
content and expressed as fold change compared with control mice using the ΔΔCT method.


















Table 1. Primer sequences of forward and reverse primers (5’ → 3’).
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Plasma lipids and glucose
At the indicated time points, 4 h-fasted (from 8:00 to 12:00) blood samples were collected 
from GPR120-/- and wild-type control mice and 6 h-fasted (from 8:00 to 14:00) blood samples 
were collected from mice that were orally treated with TUG891 or vehicle. This was done by 
tail vein bleeding into chilled capillaries that were coated with paraoxon (Sigma-Aldrich) to 
prevent ongoing lipolysis (18). Isolated plasma was assayed for triglycerides, glucose, and 
free fatty acids. Triglyceride and glucose levels were measured by commercially available 
enzymatic kits (from Roche Diagnostics and Instruchemie, respectively). Free fatty acids 
were measured using the NEFA C kit (Wako Diagnostics; Instruchemie).
Olive oil tolerance test
Postprandial triglyceride response was measured in GPR120-/- and wild-type control mice 
after 6 weeks of HFD. Animals were fasted for 4 h (from 7:00 h to 11:00 h) and a basal blood 
sample was drawn before an intragastric load of 200 µL olive oil (Carbonell, Traditional, 
Spain) was given. Blood samples were drawn 1, 2, 4 and 8 h after the bolus via tail vein 
bleeding and plasma triglyceride and free fatty acid levels were measured as described 
above.
In vivo clearance of lipoprotein-like emulsion particles and 
glucose
Lipoprotein-like emulsion particles were prepared from 100 mg of total lipid, including 
glycerol trioleate (triolein; TO; 70 mg), egg yolk phosphatidylcholine (22.7 mg), 
lysophosphatidylcholine (2.3 mg), cholesteryl oleate (3.0 mg) and cholesterol (2.0 mg), with 
addition of [3H]TO (3.7 MBq). Lipids were sonicated and resulting particles fractionated by 
sequential density gradient ultracentrifugation steps (19). The emulsion fraction containing 
lipoprotein-like particles of 80 nm was isolated and mixed with 2-[1-14C]deoxy-D-glucose 
([14C]DG; 4:1 ratio, based on radioactive count). Mice were fasted for 6 h (from 7:00 h to 
13:00 h) and injected with 200 µL of [14C]DG and [3H]TO-labeled lipoprotein-like particles 
(1.0 mg triglycerides per mouse) via the tail vein. Blood samples were drawn from the tail 
vein at 2, 5, 10 and 15 minutes after injection to determine the plasma decay of [3H]TO 
and [14C]DG. After 15 min, mice were sacrificed by cervical dislocation and perfused with 
ice-cold PBS through the heart. Organs were harvested and weighed, dissolved in Tissue 
Solubilizer (Amersham Biosciences) overnight at 56°C and analyzed for 3H- and 14C-activity.
Statistical Analysis
All data are expressed as means ± SEM. Groups were compared with a two-tailed unpaired 
Student’s t-test or a two-way ANOVA for repeated measurements, as indicated. Probability 




GPR120 deficiency increases HFD-induced fat accumulation and 
reduces physical activity
To investigate the consequences of GPR120 deficiency on the development of obesity, 
GPR120-/- and wild-type control mice were fed a HFD for 8 weeks. Body weight (Fig. 1A) was 
comparable between the groups throughout the study, although GPR120-/- mice exhibited 
less lean mass (23.5 vs. 25.7 g, p<0.05; Fig. 1B) and more fat mass (2.8 vs. 1.0 g, p<0.01; 
Fig. 1C) at the beginning of the HFD. The difference in lean mass disappeared while the 
difference in fat mass in GPR120-/- enlarged during the time course of HFD feeding. The 
increased fat mass was mainly due to an increase in the sWAT depot, while gWAT mass 
was comparable between GPR120-/- and control mice after 8 weeks of HFD (Fig. 1D). The 
iBAT depot was also larger but this does not contribute substantially to total body fat or 
weight. The increase in fat mass could not be explained by differences in food intake as 
cumulative food intake was lower in GPR120-/- mice compared to controls (Fig. 1E). Instead, 
total energy expenditure was lower in GPR120-/- animals during the dark phase (Fig. 1F, G). 
The latter could possibly be due to the markedly lower physical activity levels observed in 
GPR120-/- mice as compared to controls (Fig. 1H, I). Despite a lower energy expenditure, 
GPR120 deficiency did not affect substrate utilization, as the respiratory exchange ratio 
(RER) was similar in GPR120-/- and control mice (Fig. 1J).
GPR120 deficiency reduces BAT-specific gene expression
To further investigate the cause of the increased fat mass observed in GPR120-/- mice, 
we more closely assessed the sWAT and iBAT depots. In line with the increased sWAT 
depot weight, the average size of adipocytes in the sWAT depot of GPR120-/- mice tended 
to be larger than in controls (Fig. 2A, B). Albeit that lipid droplet content in iBAT was not 
significantly higher in GPR120-/- mice (Fig. 2C, D), markers of active BAT including Ucp1, 
Elovl3, Prdm16, Ppara and Vegf were all lower in GPR120-/- mice compared to controls 
(Fig. 2E). Of the markers involved in differentiation and mitochondrial function, only aP2 was 
significantly lower in GPR120-/- mice (Fig. 2F). Interestingly, also many of the genes involved 
in substrate uptake were lower in GPR120-/- mice, including Lpl, Angptl4, Glut1 and Glut4 
(Fig. 2G).
GPR120 deficiency does not affect plasma lipid metabolism
Since GPR120-/- mice displayed higher fat mass and lower markers of BAT activity, we 
studied whether the unfavorable metabolic phenotype of GPR120-/- mice coincided 
with deterioration of plasma lipid metabolism. After 8 weeks of HFD, plasma triglyceride 
(Fig. 3A), free fatty acid (Fig. 3B) and glucose levels (Fig. 3C) did not significantly differ 
between GPR120-/- and control mice. Likewise, GPR120 deficiency did not affect excursions 
of plasma triglyceride (Fig. 3D) and free fatty acid (Fig. 3E) levels in response to an oral olive 
oil gavage, suggesting unaltered plasma clearance of chylomicrons. To evaluate the relative 
contribution of organs in the plasma clearance of triglyceride-derived fatty acids, we next 
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Figure 1. GPR120 deficiency increases HFD-induced fat accumulation and reduces physical activity. 
GPR120-/- and wild-type (WT) mice were fed a high-fat diet (HFD) for 8 weeks. Body weight (A), lean mass 
(B), fat mass (C) and food intake (E) were measured weekly. At the end of the study, mice were sacrificed and 
organs were collected and weighed (D). In the second week of HFD, mice were housed in fully automatic 
metabolic cages (LabMaster System; TSE Systems), which measured oxygen uptake (VO2) and carbon 
dioxide production (VCO2). Total energy expenditure was calculated from VO2 and VCO2 using the Weir 
equation (F) and the average energy expenditure over the entire week was calculated for the light and 
dark phase separately (G). Physical activity was measured with infrared sensor frames (H) and the average 
physical activity over the entire week was calculated for the light and dark phase separately (I). Respiratory 
exchange ratio was calculated as the VCO2 / VO2 ratio (J). Values are presented as mean ± SEM (n=8-9). 
*p<0.05, **p<0.01 vs. WT.
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assessed the plasma clearance and organ distribution of [3H]TO-labeled triglyceride-rich 
lipoprotein-like emulsion particles (Fig. 3F). While the clearance of [3H]TO from plasma 
was unaffected, the uptake of [3H]TO-derived oleate was higher in sWAT of GPR120-/- mice 
(Fig. 3G). This was due to the larger amount of sWAT in GPR120-/- mice, since uptake per 
gram sWAT was similar in both groups (data not shown). While the plasma clearance of [14C]
deoxyglucose (DG) also did not differ between GPR120-/- mice and controls (Fig. 3H), the 
uptake of [14C]DG by the kidneys and iBAT of GPR120-/- mice was higher (Fig. 3I). Although 
this could suggest that deficiency of the lipid sensor GPR120 directs BAT to take up 
glucose, GPR120 deficiency does not have major impact on lipid metabolism.
Figure 2. GPR120 deficiency reduces BAT-specific gene expression. GPR120-/- and wild-type (WT) mice 
were fed a high-fat diet (HFD) for 8 weeks. Haematoxylin and Eosin staining of sWAT and iBAT sections 
was performed, and representative figures are shown (A, C). The cell size of adipocytes in sWAT (B) and 
the lipid content of iBAT (D) were quantified and representative pictures are shown. mRNA expression of 
the indicated genes was determined in iBAT (E-G). Values are presented as mean ± SEM (n=7-9). *p<0.05, 

























































    




















































































































Figure 3. GPR120 deficiency does not affect plasma lipid metabolism. GPR120-/- and wild-type (WT) 
mice were fed a high-fat diet (HFD) for 8 weeks. At the end of the study, 6 h fasted blood samples were 
drawn and plasma triglycerides (A), free fatty acids (B) and glucose (C) were determined. After 6 weeks of 
HFD, a basal blood sample was drawn from 4 h-fasted mice upon which they received an oral bolus of olive 
oil. Subsequently, at 1, 2, 4 and 8 hours after the olive oil gavage, blood samples were taken and assayed for 
plasma triglycerides (D) and free fatty acids (E). After 8 weeks of HFD, mice were injected i.v. with glycerol 
tri[3H]oleate-labeled lipoprotein-like particles and [14C]deoxy-D-glucose, and clearance from plasma (F, H) 
and uptake by organs at 15 min after injection (G, I) were determined by analyzing 3H- and 14C-activity. 
































































































































































































































































































































































































































































Figure 4. Oral treatment with GPR120 agonist TUG891 reduces fat mass. Wild-type mice were fed a 
high-fat diet (HFD) for 6 weeks and treated orally with vehicle or 10 mg/kg body weight TUG891 during 
the last 3 weeks of HFD feeding. Body weight (A), lean mass (B) and fat mass (C) were measured once to 
twice weekly. At the end of the study, mice were sacrificed and organs were collected and weighed (D). 
Haematoxylin and Eosin staining of gWAT, sWAT and iBAT sections was performed, and the cell size of 
adipocytes in gWAT (E) and sWAT (F), and the lipid content of iBAT (G) were quantified. mRNA expression of 
the indicated genes was determined in iBAT (H). Before the start of TUG891 treatment and after 3 weeks, 
6 h fasted blood samples were drawn and plasma triglycerides (I) and glucose (J) were determined. Values 
are presented as mean ± SEM (n=7-8). *p<0.05 vs. vehicle.
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Oral treatment with GPR120 agonist TUG891 reduces fat mass
To assess the therapeutic potential of targeting GPR120 to reduce fat mass, we next 
treated HFD-fed mice orally with the GPR120 agonist TUG891 (10 mg/kg daily) or vehicle for 
3 weeks. Total body weight (Fig. 4A) and lean mass (Fig. 4B) were not affected by TUG891 
treatment. However, fat mass was slightly reduced after 2.5 weeks of treatment (Fig. 4C). 
This was not due to a decrease in a specific adipose tissue depot, as gWAT, sWAT and iBAT 
weights were similar between TUG891-treated animals and vehicle-treated controls (Fig. 
4D). Accordingly, TUG891 did not affect adipocyte cell size in gWAT (Fig. 4E) or sWAT (Fig. 
4F), nor did it alter lipid droplet content (Fig. 4G) or gene expression (Fig. 4H) in iBAT. Plasma 
triglyceride (Fig. 4E) and glucose (Fig. 4F) levels were also unaffected by TUG891.
GPR120 agonist TUG891 acutely increases fat oxidation
Since GPR120 deficiency increased fat mass and reduced energy expenditure, and 
treatment with the GPR120 agonist TUG891 reduced fat mass in HFD-fed mice, we wanted 
to gain more insight into the mechanism behind the effect of GPR120 on energy utilization 
and fat mass. We first assessed the acute effects of TUG891 on energy expenditure and 
substrate utilization. Since the oral availability of compounds is often hindered by low and/
or slow intestinal absorption but no data on optimal dosing was available yet, we chose 
to treat mice on a normal chow diet i.p. with increasing doses of TUG891 (twice daily). 
Strikingly, TUG891 injection before onset of the dark phase acutely decreased RER (Fig. 
5A), increased fat oxidation (Fig. 5B) and decreased glucose oxidation (Fig. 5C), whereas 
TUG891 treatment at the beginning of the light phase did not have pronounced effects 
on these parameters. No differences were observed in total energy expenditure (Fig. 5D) 
or physical activity (Fig. 5E). Based on these initial results, we selected the intermediate 
dose of 35 mg/kg TUG891 and administration time 2 h before the initiation of the dark 
phase because of the prominent effects on fat oxidation. We then investigated in a larger 
number of mice (n=8) on a chow diet the effects of this dose of TUG891 i.p. once daily for a 
period of 5 consecutive days on RER and fat mass. While TUG891 did not affect total energy 
expenditure (Fig. 6A, B) or physical activity (Fig. 6C, D), the GPR120 agonist reduced RER 
(Fig. 6E, F), increased fat oxidation (Fig. 6G, H) and decreased glucose oxidation (Fig. 6I, J) 
during the dark phase. Total body weight (Fig. 7A) and lean mass (Fig. 7B) were unaffected. 
However, in accordance with the increased fat oxidation, fat mass tended to be reduced 


























































































































































































































Figure 5. I.p. treatment with 35 mg/kg GPR120 agonist TUG891 acutely increases fat oxidation when 
injected before onset of the dark phase. Wild-type mice were fed a chow diet and housed in fully 
automatic metabolic cages (LabMaster System; TSE Systems), which measured oxygen uptake (VO2) and 
carbon dioxide production (VCO2). Mice were i.p. injected (dotted line) twice daily at 9:00 and 16:00 with 
vehicle or increasing doses of TUG891 ranging from 15-50 mg/kg body weight as indicated over a period 
of 5 days. Respiratory exchange ratio (A), fat oxidation (B) and glucose oxidation (C) were calculated from 
VO2 and VCO2. Total energy expenditure was also calculated from VO2 and VCO2 using the Weir equation (D). 





























































































































































































Figure 6 (left page). GPR120 agonist TUG891 acutely increases fat oxidation. Wild-type mice were 
fed a chow diet and housed in fully automatic metabolic cages (LabMaster System; TSE Systems), which 
measured oxygen uptake (VO2) and carbon dioxide production (VCO2). Mice were i.p. injected once daily 
(dotted line) at 17:00 with 35 mg/kg body weight TUG891 for 5 consecutive days. Total energy expenditure 
was calculated from VO2 and VCO2 using the Weir equation (A) and the average energy expenditure over the 
treatment period was calculated for the light and dark phase separately (B). Physical activity was measured 
with infrared sensor frames (C) and the average physical activity over the treatment period was calculated 
for the light and dark phase separately (D). Respiratory exchange ratio was calculated as the VCO2 / VO2 ratio 
(E) and the average respiratory exchange ratio over the treatment period was calculated for the light and 
dark phase separately (F). Fat oxidation (G) and glucose oxidation (I) were also calculated from VO2 and VCO2 
and the average fat and glucose oxidation over the treatment period was calculated for the light and dark 


















































Figure 7. GPR120 agonist TUG891 tends to reduce fat mass. Wild-type mice were fed a chow diet and i.p. 
injected once daily at 17:00 with vehicle or 35 mg/kg body weight TUG891 for 5 consecutive days. Body 
weight (A), lean mass (B) and fat mass (C) and were measured before and after TUG891 treatment. Values 
are represented as mean ± SEM (n=8).
DISCUSSION
In the current study, we assessed the role of GPR120 in obesity development and lipid 
metabolism. We demonstrated that GPR120 deficiency, although not evidently influencing 
plasma lipid metabolism, increases HFD-induced fat mass and reduces energy expenditure. 
This coincided with lower physical activity and lower BAT-specific gene expression. In 
addition, GPR120 agonism reduced fat mass related to increased fat oxidation, which 
highlights the therapeutic potential of targeting GPR120 to reduce obesity.
We established that GPR120-/- mice exhibited higher fat mass as compared to wild-type 
control mice. This corroborates previous findings by Ichimura et al. (7), who reported that 
GPR120-/- mice on a HFD store more fat than wild-type controls. In our study, this increased 
fat mass of GPR120-/- mice was not reflected by higher body weight. This is in contrast to 
the previous study in which the authors did find that GPR120 deficiency increased HFD-
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induced body weight gain (7). This discrepancy may be explained by differences in age or 
strain of the mice, or even the facility in which experiments were performed. We found that 
GPR120-/- mice had lower energy expenditure in the dark phase, which could contribute to 
their higher fat mass. Remarkably, lower energy expenditure in young GPR120-/- mice was 
also reported previously, but only during the light phase (7).
The most striking effect of GPR120 deficiency we observed was lower physical activity 
levels during both the light and the dark phase, which may partly underlie the lower energy 
expenditure of GPR120-/- mice. Although physical activity has not been investigated 
in relation to GPR120 before, reduced physical activity is often reported in mice that 
underwent orchidectomy (20, 21) or with androgen deficiency (21). Besides in adipose 
tissue, GPR120 is also highly expressed in the pituitary gland (6, 22). Moreover, GPR120 
protein colocalizes with LHβ and FSHβ, being subunits of the gonadotropin hormones LH 
and FSH, respectively, in the pituitary gland (23). This suggests that GPR120 may stimulate 
gonadotropin secretion in the pituitary and thereby indirectly stimulate androgen production 
in the testes. In line with this hypothesis, fatty acids increase LH release from pituitary cells 
(22). However, it has also been described that the GPR40/120 agonist GW9508 does not 
induce LH release and the GPR40/120 antagonist GW1100 fails to inhibit fatty acid-induced 
LH release from pituitary cells, arguing against a role for GPR120 in the fatty acid-induced 
release of LH from the pituitary (22). Whether GPR120 regulates pituitary gonadotropin 
secretion in vivo and what the effect of GPR120 deficiency is on androgen levels is an 
interesting field of future investigation. As androgen deficiency exacerbates HFD-induced 
metabolic derangements in mice (21), low androgen levels could well be the mechanism 
behind the deteriorated metabolic phenotype (i.e. increased fat mass, less active BAT) we 
found in GPR120 deficient animals.
Another important contributor to energy expenditure is BAT. GPR120-/- mice in our study 
exhibited increased iBAT mass and reduced gene expression of BAT markers and genes 
involved in substrate uptake by BAT, indicating that GPR120 deficiency indeed renders BAT 
less active. Surprisingly, GPR120 deficiency was not accompanied by higher plasma lipid 
levels, worsened olive oil tolerance or slower plasma lipid clearance. Others have found high 
and inducible mRNA expression of Gpr120 in BAT upon cold, and impaired cold-induced 
browning in GPR120-/- mice, both of which do suggest an important role of GPR120 in BAT 
activation (24). Thus, besides the lower physical activity we found in GPR120-/- mice, lower 
BAT activity may in part underlie the higher fat accumulation in WAT. However, even though 
GPR120 agonism activates BAT, is involved in browning of WAT (24), and both BAT and 
browned WAT are important regulators of lipid metabolism (25), the presence of GPR120 
on BAT does not seem to contribute to fatty acid uptake by BAT or to regulate plasma lipid 
levels in our study.
In line with the observation that deficiency for GPR120 increased fat mass, agonism of 
GPR120 using the agonist TUG891 decreased fat mass. We selected TUG891 because of 
its high selectivity for GPR120 over GPR40 compared to other agonists such as GW9508 
and NCG21 (15, 26). An oral dose of 10 mg/kg daily reduced fat mass after 2.5 weeks of 
treatment, whereas an i.p. dose of 35 mg/kg daily already tended to reduce fat mass after 
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5 days of treatment. Obviously, the higher dose in the latter experiment is probably mainly 
responsible for this difference, although the fact that the orally treated mice were on a 
HFD and the dissimilar bioavailability of the compound upon oral vs. i.p. treatment (lower 
absorption of compounds upon oral administration decreases their bioavailability) likely 
also contributed to the varying effects on fat mass. Only one study describing treatment 
of rodents with TUG891 has been published to date. In this study, mice received a daily 
dose of 20 mg/kg TUG891 through the drinking water for 2 weeks, upon which reduced 
fat mass, improved glucose and insulin tolerance were observed (27). A disadvantage 
of this administration route is that GPR120, which is also expressed on the tongue, may 
be involved in taste preference (28, 29). When treating mice i.p. twice daily, we observed 
larger effects of TUG891 on substrate utilization when administered at the end of the 
light phase than when administered at the beginning of the light phase. Besides dose and 
administration route, it is becoming increasingly common to take into account the circadian 
timing of administration to maximize therapeutic efficacy (30). Since lipid metabolism is 
also under circadian regulation (31), we believe that timing of TUG891 administration is of 
great importance to optimize the intended effect and minimize possible (toxic) side effects 
associated with administration of many exogenous compounds.
When further investigating the mechanism behind the potential of TUG891 to decrease 
fat mass, increased fat oxidation directly after administration of TUG891 was observed. 
This increase in fat oxidation is likely due to increased BAT activity, as previous studies 
have demonstrated that BAT activation increases fatty acid uptake by BAT (25, 32), and 
stimulates lipid oxidation rather than glucose oxidation (25). Others have shown that the 
GPR40/120 agonist GW9508 activates BAT and increases oxygen consumption in mice. 
Whether TUG891 actually increases triglyceride-derived fatty acid uptake by BAT and 
whether the stimulation of fat oxidation is mediated by GPR120 should be assessed in 
future studies.
In humans, GPR120 is well expressed in both subcutaneous and omental adipose tissue 
(7). Besides, branched fatty acid esters of hydroxy fatty acids (FAHFAs), a novel class of 
endogenous lipids, signal through GPR120 and positively correlate with insulin sensitivity 
in humans (33). These findings strengthen the possibility that the metabolic effects of 
GPR120 activation are translatable to humans.
In conclusion, absence of the fatty acid receptor GPR120 deteriorates metabolic 
phenotype, evidenced by increased fat mass and reduced physical activity in HFD-fed 
mice, without evidently altering plasma lipid metabolism. The GPR120 agonist TUG891 
increases fat oxidation and reduces fat mass, demonstrating that GPR120 agonism, and 
this specific compound, hold therapeutic potential to reduce obesity. Further research into 
the mechanisms behind the beneficial metabolic effects of TUG891 is warranted to further 
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
The current worldwide obesity epidemic requires novel preventive and curative strategies. 
These strategies should not only aim at reducing obesity, but above all combat its related 
morbidities including type 2 diabetes and cardiovascular disease. Obesity leads to higher 
plasma lipid levels (i.e. cholesterol and triglycerides) and systemic inflammation. An exciting 
challenge within the dynamic field of immunometabolism is unraveling the molecular 
mechanisms connecting accumulation of adipose tissue, the subsequent increase in 
plasma lipids and systemic inflammation, and ultimately the development of type 2 diabetes 
and cardiovascular disease. A better understanding of these mechanisms will provide novel 
therapeutic targets and possibilities to improve treatment options.
To gain more insight into the role of the immune system in obesity, insulin resistance, 
dyslipidemia and atherosclerosis, we studied the effects of a bacterial infection and 
antibodies (IgG) on these parameters in several mouse models. We also investigated 
mediators of inflammation in blood and tissues of South Asians, a population with a 
particularly high risk of developing type 2 diabetes. Furthermore, we determined the 
potential of an anti-inflammatory compound and a fatty acid receptor agonist to reduce 
obesity and inflammation, and to ultimately improve glucose and lipid metabolism in mice.
From this thesis, various novel perceptions on the link between obesity, the immune 
system, and development of type 2 diabetes and cardiovascular disease have arisen which 
will be discussed and interpreted in this final chapter. Furthermore, therapeutic implications 
and future options for the management of metabolic disease will be addressed. The figure 
in this chapter is a graphical representation of the results obtained in this thesis (Fig. 1).
INFLAMMATION, LIPID METABOLISM AND 
ATHEROSCLEROSIS
Obesity is associated with high plasma levels of low density lipoprotein (LDL) cholesterol 
(1, 2) and inflammation (3, 4). Together with inflammation, cholesterol is a main risk 
factor for atherosclerosis as excess cholesterol initiates plaque formation in the arterial 
wall. Oxidized LDL (oxLDL) cholesterol is taken up by macrophages, upon which the 
macrophages turn into foam cells. Moreover, oxLDL triggers inflammation, e.g. by activating 
endothelial cells of the vessel wall to express adhesion molecules and chemokines such as 
the monocyte chemoattractant protein-1 (MCP-1), and thereby further enhancing plaque 
development (5-8). In chapter 2, we discovered that mycobacterial infection with  BCG in 
APOE*3-Leiden.CETP (E3L.CETP) mice, despite overall immune activation, reduced plasma 
cholesterol levels and ultimately tended to reduce atherosclerosis development. This 
is a peculiar finding since alterations in levels of plasma lipids and plasma inflammatory 
mediators usually go hand in hand. As reviewed by Van Diepen et al. (7), various classes 
of lipid-lowering drugs have anti-inflammatory properties that are mainly attributable to 
the reduced presence of lipids, although lipid-lowering drugs also directly interfere with 
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inflammatory pathways. In turn, some anti-inflammatory drugs alter lipids levels, although 
the effects are ambiguous. For example, the inhibitor of NF-κB salicylate lowers plasma 
triglycerides in type 2 diabetes patients but not in individuals with pre-type 2 diabetes, 
and IL-6 signaling inhibitors raise plasma triglycerides in patients with rheumatoid arthritis. 
More investigations are needed to unravel the specific effects of anti-inflammatory drugs 
on lipid metabolism (7).
Even though inflammation and lipid levels usually go up or down together, other 
conditions exist in which an immune response is associated with lower lipid levels. Hepatitis 
C virus (HCV) infection causes hypolipidemia (9, 10), but the mechanism by which HCV 
deregulates lipid metabolism is different from what we think the mechanisms behind the 
cholesterol lowering effects of BCG are. While we observed that BCG increased cholesterol 
clearance and reduced intestinal cholesterol absorption, without evidence for reduced 
hepatic cholesterol synthesis, HCV interferes with host cholesterol metabolism by exploiting 
the lipoprotein machinery during replication in the hepatocyte (11, 12), resulting in lower 
synthesis of cholesterol (13). Despite the cholesterol-lowering effects of HCV infection, 
HCV infection was often reported to be associated with atherosclerosis (14, 15). One of the 
possible mechanisms mediating this link could be the activation of inflammatory processes 
and cytokine imbalance. It must be noted however that the results of studies describing 
the association between HCV infection and atherogenesis are not uniform and controversy 
still exists on the direction of the association (16). Knowing the relative contribution of 
inflammatory processes and lipid metabolism is a prerequisite to justify the development 
and application of anti-inflammatory drugs for the treatment of atherosclerosis, but lipid 
metabolism and inflammatory processes are so intertwined that it is nearly impossible to 
dissect what their relative contributions to atherogenesis are.
To accurately assess the relative contribution of cholesterol and inflammation in 
atherosclerosis development, superior mouse models than the currently available ones are 
needed. E3L and E3L.CETP mice express a mutation of the human APOE*3 gene besides 
their endogenous apoE. This attenuates clearance of cholesterol-enriched lipoprotein 
remnants via the LDLR pathway, resulting in a humanized lipoprotein profile (17-19). Most 
studies performed in E3L and/or E3L.CETP mice to date investigated the effect of lipid 
level-modulating compounds on atherosclerosis (20-22). In most studies, the plasma total 
cholesterol exposure correlated with measures of the atherosclerotic lesion area (as in 
(17)), which underscores the high degree of dependence of atherogenesis on cholesterol 
levels in these models. Only few studies demonstrated a reducing effect of a compound 
on atherosclerosis beyond and independent of the reduction achieved by lowering of 
cholesterol by the compound alone in E3L mice (23, 24). These conclusions were drawn 
from an experimental set-up in which a separate cholesterol-fed control group was taken 
along with lower cholesterol intake that resulted in plasma cholesterol levels that were 
comparable to the cholesterol-fed group that was treated with the compound. In mice 
treated with rosuvastatin, the expression of MCP-1 and tumor necrosis factor (TNF) was 
lower than in the group with matched plasma cholesterol levels, and atherosclerosis was 
also lower than in the group with matched plasma cholesterol levels, indicating an additional 
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anti-inflammatory and inhibitory effect of rosuvastatin on atherogenesis (23). In another 
study, salicylate reduced hepatic NF-κB activity and macrophage content in plaques further 
than matched cholesterol feeding did, also pointing to an effect of salicylate independent 
of its cholesterol-lowering effect (24). Only one study in E3L.CETP mice showed increased 
rather than decreased inflammatory state without any effect on plasma lipid levels upon 
parasympathetic denervation of the spleen, evidenced by increased dendritic cells, B 
cells and T cells in the spleen, increased expression of inflammatory cytokines in the liver 
and in peritoneal leukocytes and increased levels of the cytokines IL-1β and IL-6 in the 
circulation. Nevertheless, this did not aggravate atherosclerosis development (25). Taken 
together, modulation of inflammation independently of lipid metabolism has hardly been 
studied in E3L and/or E3L.CETP mice and since many interventions modulate both lipids 
and inflammation, these models are not recommended if one wants to assess a pro- or 
anti-inflammatory effect on atherosclerosis development independent of alterations in lipid 
levels.
Apoe-/- and Ldlr-/- mice are the most widely used mouse models for atherosclerosis. 
Since these mice lack a functional hepatic ApoE-LDLR axis, the predominant route by 
which cholesterol-enriched lipoprotein remnants are cleared from the circulation (17), 
they do not respond to lipid-lowering therapies (26). Apoe-/- mice spontaneously develop 
atherosclerosis, even on a chow diet which does not contain cholesterol. In contrast, 
Ldlr-/- mice have a modest elevation of plasma cholesterol compared to wild-type mice and 
exhibit slow atherosclerosis development. Nevertheless, when fed a diet rich in cholesterol, 
these mice also have strongly elevated cholesterol and accelerated atherogenesis 
(26). ApoE not only mediates lipoprotein clearance, but also has anti-inflammatory and 
immunomodulatory properties. Compared to wild-type mice, Apoe-/- mice have higher 
expression of immunostimulatory cell surface molecules on macrophages, which results 
in enhanced T cell activation compared to wild-type mice (27). When stimulated with 
LPS, Apoe-/- mice show a higher upregulation of the pro-inflammatory cytokines TNF, 
IL-6, IL-12 and interferon-γ in liver and spleen compared to wild-type mice. This may also 
be explained by the ability of apoE to bind and inactivate LPS (28, 29). Ldlr-/-apobec-1-/- 
mice, which also display high cholesterol levels, do not exhibit this inflated cytokine 
response upon LPS injection, indicating that the increase in pro-inflammatory cytokines 
in Apoe-/- mice upon LPS is independent of hypercholesterolemia (30). A mechanism 
explaining more inflammation in Apoe-/- mice is that lack of ApoE also reduces the uptake 
of apoptotic bodies by macrophages, resulting in more apoptotic bodies and macrophage 
recruitment in the liver, lungs, brain and possibly more organs compared to wild-type 
mice. In addition, the pro-inflammatory markers TNF and fibrinogen are higher in livers of 
Apoe-/- mice compared to wild-types. When comparing macrophage content between wild-
type, Apoe-/- mice and Ldlr-/- mice, which have a similar lipoprotein profile as Apoe-/- mice, 
Ldlr-/- mice do not show increased macrophages in the lungs and only exhibit a ~1.5-fold 
upregulation of hepatic macrophages that does not reach significance compared to wild-
type mice. In contrast, Apoe-/- mice have a ~3-fold higher macrophage content in both liver 
and lungs compared to wild-type mice, which equals ~2-fold increases compared to Ldlr-/- 
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mice (31). The augmented immune activation and ectopic macrophage recruitment in 
Apoe-/- mice possibly contributes to atherosclerosis.
These differences in clearance of cholesterol-enriched lipoprotein remnants and 
inflammatory state between mouse models for atherosclerosis may explain why studies are 
sometimes conflicting. For example, BAT activation increases the selective uptake of fatty 
acids from triglyceride-rich lipoproteins into BAT, resulting in the formation of cholesterol-
enriched remnants. In Apoe-/- and Ldlr-/- mice, in which these remnants cannot be cleared 
by the liver, this leads to enhanced atherogenesis (17, 32). In contrast, BAT activation in 
E3L.CETP mice accelerates the hepatic clearance of these cholesterol-enriched remnants, 
resulting in protection from atherosclerosis development (17), an effect that may be expected 
relevant for most humans with an intact apoE-LDLr clearance pathway for lipoprotein 
remnants. As for the effect of BCG on atherosclerosis (chapter 2), different studies have 
been performed in different animal models. Subcutaneous  BCG injections in rabbits of 
which plasma cholesterol levels were maintained within a certain range by varying the 
cholesterol content of the diet per rabbit revealed more atherogenesis upon BCG treatment 
(33). A study in which Ldlr-/- and Apoe-/- mice were treated with subcutaneous injections of 
freeze-dried BCG showed less atherogenesis (34). Both of these studies justly concluded 
that the effects of  BCG on atherogenesis went through immunomodulatory mechanisms 
since the cholesterol levels between  BCG-treated and control mice were similar. The 
differences in outcome between the studies (more vs. less atherosclerosis) are possibly 
due to differences in immune responses of rabbits vs mice, the difference in BCG used (live 
attenuated vs. freeze-dried), the dosing and number of injections with BCG and the amount 
of cholesterol in the diet, since cholesterol is also a pro-inflammatory stimulus. If one would 
be interested to know whether the  BCG-induced infection and associated inflammation 
we observed upon intravenous administration of live attenuated BCG, independently of its 
cholesterol-lowering effect, accelerates atherosclerosis, a new experiment would have to 
be done in which a group with matched low cholesterol levels is included. Alternatively, the 
experiment could be repeated in Ldlr-/- mice.
Sometimes, the differences between mouse models for atherosclerosis may help to 
gain mechanistic insight. Since Ldlr-/- mice lack hepatic clearance of cholesterol-enriched 
remnants and do not show immunological abnormalities like Apoe-/- mice do, Ldlr-/- might 
be the best model to study the effect of immunomodulatory effects independent of lipid 
metabolism on atherosclerosis. However, in the end we strive for models that are as 
comparable as possible to humans, with the ultimate aim to predict how a compound acts 
in man. In this light, rabbits and E3L.CETP mice are still the best option we currently have.
ADIPOSE TISSUE INFLAMMATION AND TYPE 2 DIABETES
Inflammation is also believed to be an important link between accumulation of adipose 
tissue and development of type 2 diabetes. White adipose tissue (WAT) harbours many 
types of immune cells, of which the numbers increase during obesity (35-39). The 
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chronic inflammation associated with obesity disturbs insulin signalling in the tissue, 
since inflammatory cytokines activate JNK and IKKβ signalling pathways. This results in 
inhibitory phosphorylation of insulin receptor substrate 1 and 2 (IRS1 and IRS2), proteins 
that transmit signals from the insulin receptor to intracellular signalling pathways (40, 41). 
This inhibition of insulin signalling induces insulin resistance in white adipose tissue and 
contributes to development of type 2 diabetes. Macrophages were the first and most 
abundant type of immune cells discovered to infiltrate obese WAT (36, 42), for which 
the majority of research on immune cells in adipose tissue focuses on macrophages. 
Adipose tissue macrophages fulfil conventional functions such as clearing cellular debris 
and taking part in tissue immune surveillance. Macrophages also have a lipid buffering 
function; during lipolysis (e.g. upon fasting or adrenergic activation), macrophages take 
up and store lipids released from adipocytes in order to ensure gradual lipid release into 
the circulation (43). Recent studies have also focused on the function of other immune 
cell types in WAT inflammation, such as B cells. B cells were first reported to be present 
in adipose tissue in 2005 (44), and were subsequently found to be recruited to adipose 
tissue during high-fat diet (HFD) feeding (45). Winer et al. (46) showed that IgG, an antibody 
produced by B cells that activates complement and binds Fc receptors (FcRs), promotes 
insulin resistance and glucose intolerance. In chapter 3, we confirm that adipose tissue 
B cells and IgG are more abundant in obese compared to lean adipose tissue (also see 
graphical representation in Fig. 1 of this discussion). However, we showed that lack of FcγR 
and complement C3, the two pathways through which IgG signals, does not ameliorate 
the development of HFD-induced glucose intolerance. This implicates that presence of 
FcγR and complement C3 is not critical for the development obesity-associated glucose 
intolerance. When investigating adipose tissue inflammation, we found that mice lacking 
FcγR and complement C3 did not exhibit any or only marginal differences (i.e. increased 
number of macrophages in WAT only in mice lacking both FcγR and complement C3) in 
inflammation compared to controls. Perhaps, counter-regulatory mechanisms between 
different elements of the immune system prevent that effects on metabolic parameters are 
active in mice that lack FcγR or complement C3. Possibly, the number of natural killer cells 
or other immune cell types that we did not measure may be increased in adipose tissue, 
as has been shown in mice lacking B and T cells compared to wild-type mice fed a HFD 
(45). Counter-regulatory mechanisms within the immune system may stretch beyond up- 
or downregulation of entire immune cell populations, as elevated inflammatory cytokine 
responses can already compensate deficiency of others (47). Of note, our finding that 
deficiency of B cell-derived IgG downstream signalling pathways (i.e. FcγR and complement 
C3, chapter 3) does not ameliorate development of glucose intolerance is supported by 
the report that deficiency of B and T cells does not affect the onset of obesity and the 
state of insulin resistance in mice (45). Overall, the complexity and versatility of the immune 
system complicate the research into immune modulation of adipose tissue and metabolic 
disorders. Since removing B cells or B cell components without inducing compensatory 
effects by other constituents of the immune system is not possible, the precise role of B 
cells in WAT inflammation and insulin resistance remains obscure.
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In chapter 4, our purpose was to gain insight into the inflammatory state of WAT (and 
also skeletal muscle and blood) in a population with a high risk of type 2 diabetes. Since 
South Asians have an exceptionally high risk to develop this disorder compared to white 
Caucasians (48), we compared transcriptomic levels of a large panel of inflammatory, 
immune-regulating and immune cell subset markers in blood, skeletal muscle and WAT of 
overweight, pre-diabetic South Asian and matched white Caucasian men. It is generally 
known that obesity is associated with the infiltration of several immune cell types in WAT 
including macrophages, T cells and B cells, which are held responsible for the induction of 
chronic low-grade inflammation and development of insulin resistance (41). For this reason, 
we had expected increased expression of markers for these cell types in WAT of South 
Asians compared to white Caucasians. Surprisingly, expression levels of the main markers 
for immune cell subsets such as CD3, CD4 (T cells), CD19 (B cells) and the monocyte/
macrophage markers CD14, CD163 and CCL5 were comparable in WAT of South Asians 
and white Caucasians. Nevertheless, we revealed that South Asians have lower expression 
of interferon signalling genes in WAT than white Caucasians. These interferon signalling 
genes are transcribed by transcription factors called interferon regulatory factors (IRFs) 
(49). Interestingly, IRFs (IRF1-IRF9) were recently found to be expressed in adipose tissue, 
where they regulate adipogenesis (50). Subsequently, IRF4 was discovered to promote 
lipolysis and inhibit lipogenesis in adipocytes, indicating that this factor is involved in lipid 
handling within the adipose tissue. Moreover, lack of IRF4 increases adiposity in mice (51, 
52). In contrast to IRF4, IRF3 protects from HFD-induced obesity (53), suggesting that 
the different IRFs have opposing functions which might be explained if they compete 
for the same co-factors. Together, these data imply that altered regulation of upstream 
transcription factors for interferon signalling such as IRF3 and IRF4 could, at least in part, 
underlie the higher abdominal adiposity in South Asians compared to white Caucasians 
(48, 54). Besides, links between interferon signalling and glucose metabolism exist. Ifnβ1 
overexpression maintains healthy glucose homeostasis upon HFD feeding of mice (55) 
whereas IRF4 deficiency and adipose tissue-specific knockout of Ifnar1 deteriorate insulin 
resistance and glucose tolerance (52, 56). As South Asians are more glucose intolerant than 
white Caucasians (57), these data support the possibility of a link between the reduced 
interferon signaling in their WAT (chapter 4 and Fig. 1 of this discussion) and deteriorated 
glucose metabolism.
Obviously, interferon signaling may not be the only cause of the disadvantageous 
metabolic phenotype of South Asians. From literature it is known that South Asian newborns 
are characterized by elevated E-selectin and CRP levels in the cord blood, which suggests 
that endothelial dysfunction and enhanced inflammation are already present at birth in 
this population (58). Healthy lean adolescent South Asians have less BAT volume than 
matched white Caucasians (59), although this diminished BAT phenotype was not observed 
in the current study with overweight, pre-diabetic older South Asian and matched white 
Caucasian men (Boon & Hanssen, unpublished data). Nevertheless, the South Asians in the 
current study had reduced mitochondrial function as measured in skeletal muscle, which is 
probably the main reason for their lower energy expenditure compared to white Caucasians 
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(Boon & Hanssen, unpublished data). This finding matches the ‘mitochondrial efficiency 
hypothesis’ postulated by Bhopal and Rafnsson (60), who propose that differences in 
environmental stressors such as a cold environment for white Caucasians and a food 
shortage for South Asians have led to differences in mitochondrial coupling efficiency. 
As a result, white Caucasians produce relatively large amounts of heat during oxidative 
phosphorylation while in South Asians the conversion of energy to adenosine triphosphate 
(ATP) rather than to heat is maximised. The latter is very unfavourable in the current 
environment with abundance of food and reduced need to be physically active (60). It would 
be very exciting to assess whether evolutionary pressure led to differences in genes that 
contribute to mitochondrial function and inflammation in South Asians in genome-wide 
association studies in South Asians and white Caucasians. In addition, the relation between 
reduced interferon signalling in South Asians and their reduced mitochondrial function, 
BAT activity, energy expenditure and worsened glucose intolerance is an interesting field 
of future investigation.
THERAPEUTIC IMPLICATIONS
Obesity is associated with hyperlipidaemia (1, 2) and systemic inflammation (3, 4), which 
in turn are closely involved in the development of obesity-associated metabolic disorders 
(61, 62). In the first part of this discussion, lowering of cholesterol has already been passed 
in review and this is an effective strategy to reduce atherosclerosis and cardiovascular 
disease. In this section, additional strategies to constrain development of obesity-
associated disorders by lowering plasma lipids and/or reducing inflammation to decrease 
development of atherosclerosis and insulin resistance will be discussed.
Triglyceride combustion by BAT and beige WAT
A promising therapeutic approach to reduce plasma triglyceride levels is to increase 
combustion of fatty acids by BAT. Activation of β3-adrenergic receptors on brown adipocytes 
is the most well-known and potent way to induce thermogenesis and lipid combustion (63, 
64) and β3-adrenergic receptor agonists such as CL-316243 potently induce lipid uptake 
by BAT in mice (17). Many other compounds have also been identified to activate BAT. 
Among these, rimonabant (65), metformin (66),  glucagon-like peptide-1 receptor activation 
(67) and salsalate (chapter 5) also reduce plasma triglycerides. We showed that salsalate 
does this by directly activating BAT (Fig. 1), evidenced by increased uncoupled respiration 
and lipolysis in brown adipocytes. Although it was long thought that salicylates exert their 
beneficial metabolic effects through activation of AMPK (68, 69), we found evidence for 
an alternative intracellular mechanism dependent on the PKA pathway. A later report by 
Smith et al. (70) confirms that AMPK does not mediate the beneficial effects of salicylates. 
Although they primarily focussed on glucose metabolism rather than triglycerides, they 
showed that mice lacking the AMPK subunit that salicylates interact with still experience 
beneficial effects on glucose metabolism upon salicylate treatment. Interestingly, the same 
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group also provided evidence for a mechanism by which salicylate induces mitochondrial 
uncoupling independent of UCP1, possibly explained by the protonophoric effects of 
salicylates, i.e. the ability to move protons across lipid bilayers (70). The potential of 
salsalate to directly induce mitochondrial uncoupling in primary hepatocytes (70) may 
also explain why salsalate prevents non-alcoholic steatohepatitis (71). If salsalate indeed 
functions as a mitochondrial uncoupler in any cell type, this also clarifies how salsalate 
increases energy expenditure in human subjects (72). Other protonophoric compounds are 
probably effective to lower plasma triglycerides by activating BAT too. However, systemic 
treatment with mitochondrial uncouplers can be very dangerous; the mitochondrial 
uncoupler 2,4-dinitrophenol (DNP) induces weight loss but is associated with side effects 
like hyperthermia, tachycardia and death (73-75). In order to safely induce weight loss by 
activating BAT with mitochondrial uncouplers, improved ways to specifically target BAT 
would be warranted first.
A novel approach to activate BAT is via GPR120, a free fatty acid receptor that is 
activated by medium and long chain fatty acids (76). GPR120 is highly expressed in WAT and 
BAT and others have shown that GPR120 mediates anti-inflammatory actions of ω-3 fatty 
acids (77-79), plays a role in adipocyte differentiation (80), and enhances glucose uptake, 
which contributes to improved insulin sensitivity (77). Lack of GPR120 leads to obesity, 
glucose intolerance and hepatic steatosis (81). Our incentive to study whether stimulation 
of GPR120 could activate BAT was the fact that Gpr120 expression in BAT increases upon 
cold exposure (82), which indicates a role for GPR120 in thermogenesis. We found that lack 
of GPR120 increased fat mass and reduced energy expenditure, but did not have evident 
effects on triglyceride-rich lipoprotein turnover. Promisingly, injections with the GPR120 
agonist TUG891 increased fat oxidation and reduced fat mass (chapter 6). While we were 
performing these experiments, others already published that the GPR120 agonist GW9508 
activates BAT (Fig. 1) (83). Although these are encouraging results, future studies (which will 
soon be performed by Schilperoort et al.) will have to elucidate whether BAT activation by 
GPR120 agonists also leads to enhanced triglyceride-derived fatty acid uptake by BAT and 
consequently lower plasma lipids.
An alternative therapeutic approach is to induce the formation of beige adipocytes 
in WAT, because beige adipocytes probably also use triglycerides for nonshivering 
thermogenesis like classic brown adipocytes do. This is supported by the fact that fatty 
acid uptake in beige WAT upon β3-adrenergic stimulation increases while the WAT depots 
shrink (17). Beiging of WAT is typically induced by cold and catecholamine stimulation (17, 
84, 85), but many other stimuli that promote a beige phenotype are rapidly being discovered 
and include pharmacological activation of β3-adrenergic receptors (17, 64), thyroid 
hormone (86), glucagon-like peptide 1 receptor activation (67), fibroblast growth factor 
21 (87), and bone morphogenetic protein 7 (88). Furthermore, various components of the 
immune system have been implicated to promote beiging, such as alternatively activated 
macrophages (89, 90), eosinophils (91) and ILC2s (92, 93). Several cytokines were identified 
to be involved in the underlying mechanisms and recent evidence also points towards a 
prominent role for interferon regulatory factors in the regulation of beiging (52, 53). Thus, 
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genesis and activation of beige adipocytes is an alternative pharmacological strategy to 
combust lipids and thereby reduce lipid levels in the blood.
Although it was long thought that beige adipocytes are derived from Myf5+ precursor 
cells whereas white adipocytes are not, the current model of the differentiation process 
seems more complex as Myf5+ cells can also differentiate into white adipocytes. More 
specific factors that mark brown/beige adipogenesis (e.g. the transcription factor Ebf2) are 
presently being discovered (94). Gaining a better understanding of adipocyte development 
is a prerequisite for the development of compounds that promote beige adipocyte 
differentiation and is under investigation.
Cholesterol lowering strategies
Whether triglycerides are an independent risk factor for cardiovascular disease is still under 
debate (95), but cholesterol certainly is the main risk factor for atherosclerosis development 
(6). Therefore, cholesterol-lowering strategies are effective in battling atherosclerosis. 
In chapter 2, we found that mycobacterial  BCG infection lowered cholesterol partly 
by increasing hepatic uptake of cholesterol. We speculate that the accumulation of 
mycobacteria we detected in the liver could be responsible for this increased cholesterol 
uptake (Fig. 1 of this discussion), as mycobacteria use host cholesterol as an energy source 
(96-99). Since humans cannot use cholesterol as an energy source like triglycerides, the 
most effective strategy to lower cholesterol levels in humans is inhibition of HMG-CoA 
reductase, which decreases cholesterol synthesis in the liver. Other approaches are 
inhibition of intestinal cholesterol absorption and sequestration of bile acids. Bile acid 
sequestrants bind bile acids in the intestine, thereby preventing their reabsorption and 
leading to increased fecal excretion. This reduces the bile acid pool in the liver and thereby 
stimulates bile acid synthesis from cholesterol. Consequently, hepatic uptake of cholesterol 
is increased to replenish hepatic cholesterol levels and plasma cholesterol levels are 
lowered. The most recent addition to cholesterol lowering drugs are proprotein convertase 
subtilisin kexin type 9 (PCSK9) inhibitors. PCSK9 binds to the LDL receptor (mainly in the 
liver), resulting in intracellular degradation of the receptor and a subsequent decrease in 
LDL receptors on the plasma membrane. By preventing PCSK9 binding to LDL receptors 
with PCSK9 inhibitors, LDL receptor degradation is prevented, which results in increased 
LDL receptor expression and enhanced hepatic uptake of LDL from the circulation 
(100). As discussed above, BAT activation not only has the potential to reduce plasma 
triglyceride levels (101, 102), but activation of BAT by β3-adrenergic receptor stimulation in 
E3L.CETP mice also lowers cholesterol levels by indirectly accelerating the hepatic 
clearance of cholesterol-enriched remnants (17). Although (temporarily) introducing a 
cholesterol-consuming bacterium is far from optimal considering the pathogenic nature of 
e.g. Mycobacterium tuberculosis or Mycobacterium leprae (103), it would be neat to find a 




Taking into account the wide spectrum of inflammatory cells and cytokines that are 
elevated in obesity, targeting a single cell, factor or cytokine might not be efficient to reduce 
systemic inflammation and ways to manage the overall metabolic inflammation should be 
considered. In this light, salicylates, such as salsalate, are favourable as they inhibit the 
master regulatory protein complex of inflammation NF-κB and thereby transcription of 
many inflammatory cytokines (104). Despite the fact that salicylates were shown to lower 
glucose levels in diabetic individuals more than 100 years ago (4, 105), and since then a large 
amount of research was dedicated to the role of inflammation in both insulin resistance 
and atherosclerosis, salicylates have not been applied in the clinic to treat these disorders 
yet. In chapter 5, we show that salsalate not only improves glucose metabolism, but also 
reduces inflammation in WAT (Fig. 1 of this discussion). Although we did not demonstrate 
a causal relationship between the reduced adipose tissue inflammation and the improved 
glucose metabolism observed, it does confirm that the two effects go together. Promisingly, 
salicylate was also shown to reduce atherosclerosis partly by quenching inflammation. As 
described above, this was proven by showing that salicylate treatment reduces hepatic 
NF-κB activity and macrophage content in plaques further than low cholesterol feeding (to 
achieve similar plasma cholesterol levels in the salicylate-treated and the control group) 
did (24).
Since South Asians have reduced expression of type 1 interferon signalling in WAT 
(chapter 4) and a disadvantageous metabolic phenotype including obesity and insulin 
resistance (106, 107), one could speculate that anti-inflammatory type 1 interferons would 
qualify to treat adipose tissue inflammation and/or insulin resistance and atherosclerosis in 
this population. Interferons are currently used to treat viral infections (108) but have never 
been applied or tested to treat metabolic inflammation. Although more insight into the 
link between interferon signalling in adipose tissue and metabolic health would be useful, 
investigating whether interferon treatment would be effective to reduce metabolic disease 
in humans does not entail a high risk because interferons are approved drugs (108).
In summary, type 2 diabetes and atherosclerosis are both characterized by systemic 
inflammation and a decent amount of evidence suggests that targeting inflammation with 
pharmacological interventions may improve these metabolic disorders.
TRANSLATIONAL CHALLENGES
Large quantities of studies aimed at reducing the obesity epidemic and related morbidities 
are currently being performed in mice, which ultimately need to be translated towards the 
human situation. For instance, anti-inflammatory strategies to reduce atherosclerosis 
and insulin resistance may deserve faster implementation in the clinic if only we could 
show how and to which extent the immune system exactly contributes to these metabolic 
derangements in humans. The fact that lipid metabolism and inflammation are intertwined 
(7) complicates progress within this field of research. HMG-CoA reductase inhibitors 
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(i.e. statins) reduce C-reactive protein (CRP, a marker of inflammation) levels besides 
lowering LDL cholesterol in clinical trials (109-111). When added to statins, the cholesterol 
absorption inhibitor ezetimibe also reduces CRP (112). It was recently reported that PCSK9 
is directly involved in promoting inflammatory processes (113, 114) and thereby contributes 
to atherosclerosis independent of cholesterol, which suggests that even PCSK9 inhibition 
may reduce inflammation (114). Comparative studies into the differential effects of 
statins, ezetimibe and PCSK9 inhibitors on cholesterol levels, inflammatory markers and 
cardiovascular outcome may shed more light upon the relative contribution of inflammation 
and cholesterol on cardiovascular disease in humans. It would also be interesting to take 
along assessment of the inflammatory phenotype of WAT and skeletal muscles more often 
in clinical studies as we did in chapter 4, to gain a better understanding of potential anti-
inflammatory effects of promising compounds on these tissues.
With regards to lowering triglycerides by activating BAT and beige WAT, combusting lipids 
this way prevents obesity and atherosclerosis in mice, but the translational value of these 
promising results from different mouse models for the human situation is still uncertain. 
Interscapular classical BAT in mice does not regress with age whereas adult humans no 
longer possess this classical BAT depot. Another difficulty in extrapolating mouse data to 
the human is the fact that humans are usually situated in a thermoneutral zone (±25°C) due 
to the wearing of clothes, while mice are often housed at room temperature (18-22°C) at 
which BAT is active. Housing mice in their thermoneutral condition (30°C) would be more 
comparable to the human situation, which is not always acknowledged. Future studies BAT 
activation and beiging in mice should therefore preferably be performed at 30°C.
Interestingly, mechanisms of beiging of WAT display more similarities between mice 
and humans. Hormones, immune cells or cytokines that induce beige adipocytes in mice 
are also present in humans, suggesting that beiging via those mechanisms can also occur 
in humans. For example, presence of ILC2s in human adipose tissue has been confirmed, 
suggesting that the circuit of ILC2s, eosinophils, type 2 cytokines and anti-inflammatory 
macrophages that induce beiging in mice, is also operational in human beiging (115). Severe 
beiging of WAT is also seen in patients with pheochromocytoma, a catecholamine-secreting 
tumor. This condition indeed leads to increased energy expenditure (116). Together, these 
observations support a similar mechanism behind beiging in humans and in mice, although 
beiging capacity and its contribution to energy expenditure in humans still needs to be 
determined in detail.
Potential drugs that induce beiging of WAT in humans are currently being tested in the 
clinic (117). A possible target would be the β3-adrenergic receptor, although it is not specific 
for brown adipocytes as it is expressed in a variety of organs. Until recently, β-adrenergic 
receptor agonists had not been shown to have major effects on energy balance. In 2015, it 
was shown that a latest generation β-adrenergic receptor agonist, mirabegron (approved to 
treat the overactive bladder), activated BAT evidenced by increased [18F]fluorodeoxyglucose 
(FDG) uptake, and increased energy expenditure in healthy male subjects (118). As for 
targeting inflammation, the effects of salsalate (chapter 5) are currently being investigated 
in clinical trials (119-122). Promisingly, some studies show that salsalate improves glycemic 
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Figure 1. Immune modulation of adipose tissue and lipid metabolism. See text for explanation. BAT, 
brown adipose tissue;  BCG, Bacille-Calmette-Guérin; IFN, interferon; TRL, triglyceride-rich lipoprotein; 
WAT, white adipose tissue.
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control (123) and reduces systemic inflammation (119, 124, 125). However, salsalate did not 
reduce noncalcified coronary plaque volume in man (119), and thus the question remains 
whether reducing inflammation per se also reduces cardiovascular disease in humans.
Besides receptor-targeted drugs, diet and nutritional components can be considered as 
an alternative strategy to modulate thermogenesis and inflammation in humans. Although 
it is known that brown, beige and white adipocytes are fuelled by glucose and fatty acids, 
large knowledge gaps still exist. We still do not know whether different types of dietary fatty 
acids or carbohydrates elicit distinct effects on thermogenesis and inflammation. Whereas 
saturated fatty acids promote inflammation and are detrimental for metabolic health 
(126), n-3 fatty acids are anti-inflammatory and act beneficially (127). Whether dietary n-3 
fatty acids activate BAT or promote beiging remains to be investigated. As for specific 
carbohydrates, hardly anything is known about their effects on BAT activity or beiging. 
Almost 30 years ago, Walgren et al. (128) showed that dietary carbohydrates increase 
noradrenaline turnover in heart and/or BAT of rats, unrelated to the type of carbohydrate 
(i.e. fructose, sucrose, dextrose, corn starch) (128). These promising data have not been 
followed up. Other nutritional components of interest may be amino acids. High plasma 
concentrations of branched-chain amino acids are found in obesity and type 2 diabetes, 
and they are associated with increased cardiovascular risk (129). In mice, dietary restriction 
for the amino acid methionine activates BAT (130). Together, this suggests that altered 
intake of amino acids could modulate metabolic health. Future research might shed light on 
the underexposed aspect of modulating inflammation and thermogenesis and ultimately 
metabolic health by nutritional components.
CONCLUDING REMARKS AND FUTURE PERSPECTIVES
The immune system plays an important role in brown and white adipose tissue and lipid 
metabolism and mechanisms behind the interactions between immune cells, adipocytes 
and lipids are gradually being uncovered. These mechanisms could yield targets to 
develop novel therapeutic strategies to lower plasma lipid levels, attenuate adipose tissue 
and systemic inflammation, and ultimately reduce atherosclerosis and insulin resistance. 
Currently, the most favourable novel approach to eliminate triglycerides and possibly also 
cholesterol is by increasing combustion of fatty acids in BAT or beige adipocytes in WAT. 
Combining this with anti-inflammatory therapies to restrain systemic and adipose tissue 
inflammation will probably further improve metabolic outcome by uncoupling obesity from 
its associated disorders that are mediated by inflammation. Since the immune system 
and its functioning are very complex, targeting central mediators of inflammation (i.e. 
transcription factors or upstream regulators of main inflammatory pathways such as NF-κB 
or IRFs) are probably preferred.
In order to find novel and effective therapeutic targets, the challenge is to identify the 
metabolic crosstalk between (brown, beige and white) adipocytes and immune cells and 
the order of events that occur during obesity development. Immune modulation of adipose 
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tissue and lipid metabolism will not come down to an individual immune cell type and will 
involve significant crosstalk between different cell types. Important questions to further 
address include: What are the immune regulatory effector molecules that are secreted by 
adipocytes to attract or regulate immune cells? How are browning and the immune system 
regulated in obesity? And how do these processes change during aging? And last but not 
least, it is of great importance to translate these findings towards the clinic in favour of 
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The worldwide prevalence of obesity is steadily increasing. Obesity leads to insulin 
resistance and atherosclerosis, which are the pathologies underlying type 2 diabetes 
and cardiovascular disease, respectively. Inflammation is an important factor connecting 
obesity to these disorders, but the exact mechanisms connecting obesity, the immune 
system, type 2 diabetes and cardiovascular disease are still under investigation. The 
research described in this thesis was performed 1) to gain more insight into the role of 
the immune system in obesity, dyslipidemia, insulin resistance and atherosclerosis, 2) to 
study whether inflammation contributes to the disadvantageous metabolic phenotype of a 
human population with a particularly high risk to develop type 2 diabetes and cardiovascular 
disease, and 3) to study the therapeutic potential of decreasing inflammation by 
pharmacological strategies to reduce obesity and improve glucose and lipid metabolism in 
pre-clinical models. Chapter 1 serves as a general introduction to the different processes 
and players that are important in obesity and associated disorders, including regulation of 
lipid metabolism, the physiology of adipose tissue, and the interaction between the immune 
system and adipose tissue function.
We first studied the effect of a potent inflammatory trigger, i.e. Bacille-Calmette-Guérin 
(BCG), on lipid metabolism and atherosclerosis.  BCG is prepared from attenuated live 
Mycobacterium bovis and modulates atherosclerosis development as currently explained 
by immunomodulatory mechanisms. However, whether  BCG is pro- or anti-atherogenic 
remains inconclusive as the effect of  BCG on cholesterol metabolism, the main driver of 
atherosclerosis development, has remained underexposed in previous studies. In chapter 
2, we aimed to elucidate the effect of  BCG on inflammation in relation to cholesterol 
metabolism and atherosclerosis development in a mouse model of human-like lipoprotein 
metabolism. To this end, we fed hyperlipidemic APOE*3-Leiden.CETP mice a Western-
type diet and treated them with a single intravenous injection of BCG. We found that BCG-
treated mice had hepatic mycobacterial infection and hepatomegaly. Enlargement of 
the liver coincided with severe immune cell infiltration and a higher cholesterol content. 
Moreover,  BCG reduced plasma total cholesterol levels. This was due to accelerated 
hepatic clearance of cholesterol, as evident from clearance studies with intravenously 
injected [14C]cholesteryl oleate-labeled lipoprotein-like particles, and to reduced intestinal 
plant sterol and cholestanol absorption. Ultimately, BCG decreased the ability of peritoneal 
macrophages to become foam cells and tended to decrease atherosclerotic lesion area 
and reduced lesion severity in the aortic root of the heart:  BCG delayed atherosclerotic 
lesion progression. Consequently, we concluded that  BCG reduces the plasma levels of 
atherogenic lipoproteins and delays atherosclerotic lesion formation in hyperlipidemic 
mice.
In chapter 3, we switched our focus from immune modulation of lipid metabolism and 
atherosclerosis to glucose metabolism and type 2 diabetes. During the development of 
obesity, B cells accumulate in white adipose tissue (WAT) and produce IgG, which has 
previously been suggested to contribute to the development of glucose intolerance. 
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IgG signals by binding to Fcγ receptors (FcγR) and by activating the complement system 
(including C3). We aimed to study whether activation of FcγR and/or complement C3 
mediates the development of high fat diet-induced glucose intolerance. To this end, we 
studied high-fat diet-fed mice lacking all four FcγRs, only the inhibitory FcγRIIb, only the 
central component of the complement system C3, and mice lacking all FcγRs as well as 
C3. We found that absence of the inhibitory FcγRIIb increases adipose tissue IgG, but 
that absence of FcγRs and/or C3 does not protect against high-fat diet induced glucose 
intolerance. We therefore concluded that if obesity-induced IgG contributes to the 
development of glucose intolerance, this is not mediated by FcγR or complement activation.
In chapter 4, we studied the inflammatory state of South Asians, a human population 
with a particularly high risk to develop glucose intolerance, compared to white Caucasians. 
More specifically, we compared mRNA expression of 144 markers of immune function in 
skeletal muscle and WAT of middle-aged overweight pre-diabetic Dutch South Asian and 
matched white Caucasian men. We found that expression of especially interferon signaling 
genes was lower in South Asians, both in muscle (IFIT3, IFI44) and WAT (IFI35, IFI44, IFIT2, 
IFIT3, IFIT5, OAS1, STAT1). Ingenuity pathway analysis highlighted the anti-inflammatory 
interferon α/β signaling pathway to be lower in South Asians. From this, we concluded that 
South Asians have impaired interferon signaling in metabolic tissues. Since recent evidence 
from rodent studies shows that impaired interferon α/β signaling in adipose tissue induces 
insulin resistance and glucose intolerance, impaired interferon signaling in South Asians 
may contribute to their high risk of type 2 diabetes.
In the next part of this thesis, we focused on the treatment of metabolic inflammation. 
The anti-inflammatory compound salsalate lowers glucose intolerance and dyslipidemia 
in type 2 diabetes patients, but the mechanism was still unknown. The aim of chapter 5 
was to unravel the molecular mechanisms involved in these beneficial metabolic effects 
of salsalate by treating mice with salsalate during and after development of high-fat diet-
induced obesity. We found that salsalate attenuates and reverses high-fat diet-induced 
weight gain, in particular fat mass accumulation, improves glucose tolerance, and lowers 
plasma triglyceride levels. Mechanistically, salsalate selectively promotes the uptake of 
triglyceride-derived fatty acids by BAT, as evident from clearance studies with glycerol 
tri[3H]oleate-labeled lipoprotein-like emulsion particles, decreased the intracellular lipid 
content in BAT, and increased rectal temperature, all pointing to more active BAT. Moreover, 
treatment of T37i brown adipocytes in vitro with salsalate increased uncoupled respiration, 
expression of the uncoupling protein-1 (Ucp1) and lipolysis. These latter two effects were 
abolished by the inhibition of cAMP-dependent protein kinase A (PKA). We concluded that 
salsalate activates BAT, presumably by directly activating brown adipocytes via the PKA 
pathway. This suggests a novel mechanism that may explain its beneficial metabolic effects 
in type 2 diabetes patients.
Finally, we studied the therapeutic potential of targeting GPR120, a free fatty acid 
receptor that is highly expressed in BAT and WAT, is regulated by cold exposure, and is a 
mediator of anti-inflammatory and insulin-sensitizing effects. Since the effects of GPR120 
on lipid metabolism and substrate utilization have not been studied to date, the aims 
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of chapter 6 were to assess the role of GPR120 in lipid metabolism and to evaluate the 
therapeutic potential of a selective GPR120 agonist in energy consumption. When fed a 
high-fat diet, GPR120 deficient mice had higher fat mass, lower physical activity, and lower 
energy expenditure during the dark phase, while relative substrate utilization (i.e. glucose 
vs. fatty acids) did not differ compared to wild-type mice. GPR120 deficiency reduced 
expression of Ucp1, Prdm16 and Pparα, which are markers of BAT activity, thus suggesting 
less active BAT. Treatment with the GPR120 agonist TUG891 during high-fat diet-feeding 
reduced fat mass after 2.5 weeks. Furthermore, short-term treatment (5 days) with TUG891 
on a chow diet acutely increased fat oxidation and reduced glucose oxidation, and already 
tended to reduce fat mass. From these data we concluded that GPR120 deficiency increases 
fat mass while GPR120 agonism reduces fat mass and increases fat oxidation. Therefore, 
stimulation of GPR120 holds therapeutic potential to combat obesity.
To conclude, we evaluated the results of this thesis in chapter 7 and discussed the 
potential of targeting adipose tissue (and) inflammation to treat obesity-associated 
disorders such as type 2 diabetes and cardiovascular disease. Taken together, the studies 
described in this thesis have increased our understanding of the role of inflammation in 
adipose tissue function and lipid metabolism during the development of type 2 diabetes 
and cardiovascular disease. Moreover, novel potential therapeutic strategies were identified 
to combat obesity, metabolic inflammation and associated metabolic disorders, such as 




Obesitas komt wereldwijd steeds meer voor en leidt vaak tot insulineresistentie en 
aderverkalking. Insuline is het hormoon dat na een maaltijd door de alvleesklier geproduceerd 
wordt en suikeropname door metabole organen zoals spieren, lever en vetweefsel 
stimuleert. Als gevolg van verminderde werking van insuline (ofwel insulineresistentie) hoopt 
suiker op in het bloed en zo kan type 2 diabetes ontstaan. Aderverkalking komt juist door 
ophoping van vetten (cholesterol) en immuuncellen in de bloedvatwand. Aderverkalking 
kan uiteindelijk leiden tot een hart- of herseninfarct. Omdat type 2 diabetes en hart- en 
vaatziekten vaker voorkomen bij mensen met overgewicht, worden deze kwalen ook wel 
obesitas-gerelateerde stofwisselingsziekten genoemd.
In het geval van obesitas is niet alleen de vetstofwisseling verstoord, maar ook is 
het immuunsysteem actiever. Waarschijnlijk heeft het immuunsysteem een belangrijke 
rol bij de ontwikkeling van insulineresistentie en aderverkalking, maar hoe obesitas, 
het immuunsysteem en type 2 diabetes en hart- en vaatziekten precies met elkaar 
verbonden zijn is nog niet geheel bekend. Het onderzoek in dit proefschrift werd 
uitgevoerd om 1) meer inzicht te krijgen in de rol van het immuunsysteem in obesitas, 
een verstoorde vetstofwisseling, insulineresistentie en aderverkalking, 2) de activiteit van 
het immuunsysteem te onderzoeken in een groep mensen met een bijzonder hoog risico 
op het ontwikkelen van type 2 diabetes en hart- en vaatziekten, en 3) te onderzoeken of 
geneesmiddelen die het immuunsysteem remmen, een gunstig effect hebben op obesitas 
en de suiker- en vetstofwisseling in muizen.
Hoofdstuk 1 vormt een algemene introductie, waarin de verschillende organen en 
processen die betrokken zijn bij de ontwikkeling van obesitas en de daaraan gerelateerde 
ziekten zoals type 2 diabetes en hart- en vaatziekten, besproken worden. Obesitas ontstaat 
door een ‘positieve energiebalans’, waarbij de inname van energie (in de vorm van voedsel) 
hoger is dan het energieverbruik. De organen in ons lichaam gebruiken voornamelijk 
suikers en vetten als bron van energie, en na een maaltijd worden deze vanuit het voedsel 
via het bloed naar organen zoals het hart, spieren en vetweefsel getransporteerd. Suiker 
is oplosbaar in bloed, maar vetten niet. Daarom worden vetten uit het dieet door de darm 
in oplosbare pakketjes verpakt die we lipoproteïnen noemen, waarna ze alsnog via het 
bloed naar de organen worden gebracht. De meest voorkomende vetten in ons voedsel zijn 
triglyceriden en cholesterol. Triglyceriden zijn de vetten die door organen als energiebron 
worden gebruikt, en bij een overschot aan energie (ofwel een positieve energiebalans) 
wordt de energie (suikers én triglyceriden) na een chemische omzetting in de vorm van 
triglyceriden opgeslagen in vetcellen in ons vetweefsel. Cholesterol is geen bron van 
energie, maar een essentieel onderdeel van onze cellen en cruciaal voor de aanmaak van 
hormonen, vitamine D en galzuren.
Aangezien buitensporige opslag van vet kenmerkend is voor obesitas, is in dit 
proefschrift vooral onderzoek gedaan naar het vetweefsel. Er bestaan verschillende 
soorten vetweefsel, waaronder wit vet en bruin vet. Van wit vet heeft een mens wel 12-
35 kg en de voornaamste functie van wit vet is de opslag van overtollige triglyceriden. 
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Bruin vet verbrandt juist triglyceriden om warmte te genereren, waardoor zoogdieren hun 
lichaamstemperatuur op peil kunnen houden. Van bruin vet hebben we maar 100-200 g. 
Interessant genoeg zitten er tussen de vetcellen in het witte vetweefsel ook heel veel 
immuuncellen. Tijdens de ontwikkeling van obesitas komen er veel meer immuuncellen 
naar het witte vet, die zorgen voor ontsteking van het vetweefsel. In het bruine vet komen 
ook immuuncellen voor, maar hierover is nog maar nauwelijks iets bekend. Wel staat vast 
dat overmatige activatie van het immuunsysteem of metabole ontsteking, zoals tijdens 
obesitas optreedt, kan bijdragen aan insulineresistentie en aderverkalking. Zo remt 
ontsteking de effecten van insuline en dragen immuuncellen bij aan de ontwikkeling van 
aderverkalking. Een overactief immuunsysteem bevordert dus zowel type 2 diabetes als 
hart- en vaatziekten.
Vaccinatie kan het immuunsysteem activeren, en via deze weg de ontwikkeling van 
aderverkalking beïnvloeden. Een vaccin dat wereldwijd gebruikt wordt is het anti-tuberculose 
vaccin Bacille-Calmette-Guérin (BCG) dat gemaakt is van verzwakte tuberculose-bacteriën. 
Eerder onderzoek naar de effecten van BCG op het immuunsysteem en aderverkalking gaf 
tegenstrijdige resultaten, aangezien verergering maar ook vermindering van aderverkalking 
werd gerapporteerd. Omdat aderverkalking niet alleen van het immuunsysteem maar ook 
sterk van cholesterol afhangt, onderzochten wij of BCG behalve het immuunsysteem ook de 
cholesterolstofwisseling beïnvloedt en daarmee ook de ontwikkeling van aderverkalking. 
De resultaten hiervan staan beschreven in hoofdstuk 2. We toonden aan dat een enkele 
injectie met  BCG in muizen leidde tot een bacteriële infectie, een sterk vergrote lever en 
activatie van het immuunsysteem. In de levers van BCG-behandelde dieren zaten veel meer 
immuuncellen en cholesterol, terwijl in het bloed van de behandelde muizen juist minder 
cholesterol gemeten werd. Dit kwam doordat er meer cholesterol werd opgenomen door de 
lever, maar ook doordat de opname van cholesterol door de darm lager was. Om het effect 
op aderverkalking te meten, bestudeerden we in de grootste lichaamsslagader vanaf het 
hart de grootte van de cholesterol- en immuuncelophopingen. Deze zogenaamde ‘plaques’ 
waren kleiner, waaruit we concludeerden dat BCG, ondanks de activerende effecten op het 
immuunsysteem, de ontwikkeling van aderverkalking in muizen vertraagt.
In hoofdstuk 3 lag de nadruk van het onderzoek meer op de rol die immuuncellen in het 
vetweefsel hebben bij de ontwikkeling van insulineresistentie. Hierbij focusten we specifiek 
op een bepaald type immuuncellen, namelijk B cellen, waarvan eerder werd aangetoond 
dat de antilichamen die door deze cellen gemaakt worden (namelijk IgG) specifiek 
bijdragen aan de ontwikkeling van type 2 diabetes. IgG bindt en activeert zogenaamde Fc-
receptoren en complement eiwitten, die onderdeel uitmaken van het immuunsysteem en 
betrokken zijn bij de afweer tegen indringers van buiten, zoals bacteriën. Om te bestuderen 
via welke mechanismen IgG precies bijdraagt aan de ontwikkeling van type 2 diabetes 
tijdens obesitas, voerden we muizen die géén Fc-receptoren hadden en het belangrijkste 
complementeiwit (C3) misten een vetrijk dieet. Vervolgens wogen we de dieren en 
maten we suikerniveaus in hun bloed. We vonden dat muizen zonder Fc-receptoren of 
complementeiwit C3 meer B cellen en antilichamen in hun witte vetweefsel hadden, maar 
geen andere bloedsuikerniveaus dan de controle muizen op een vetrijk dieet. Daarom 
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concludeerden we dat als obesitas-geïnduceerde IgG productie door B cellen in het witte 
vetweefsel bijdraagt aan de ontwikkeling van type 2 diabetes, dit niet via de activatie van 
Fc-receptoren of complementeiwitten verloopt.
Vervolgens hebben we het onderzoek naar het immuunsysteem in relatie tot diabetes 
voortgezet in mensen. Hindoestanen hebben een sterk verhoogd risico op diabetes, maar 
het immuunsysteem in deze bevolkingsgroep was nog nooit uitgebreid onderzocht. Daarom 
hebben we, zoals beschreven in hoofdstuk 4, de expressie van 144 genen die betrokken 
zijn bij de werking van het immuunsysteem vergeleken tussen Hindoestaanse en blanke 
Kaukasische mannen die allemaal overgewicht en verhoogde bloedsuikers hadden. We 
vonden in het witte vet en de spieren van Hindoestanen een lagere expressie van genen 
die betrokken zijn bij interferon-afgifte ten opzichte van blanke Kaukasiërs. Interferonen 
worden door immuuncellen uitgescheiden na contact met indringers, zoals virussen. We 
concludeerden dat Hindoestanen een verminderde interferon-werking hebben in hun witte 
vet en spieren. Recent onderzoek in muizen heeft laten zien dat verminderde interferon-
werking in vet leidt tot insulineresistentie, wat erop duidt dat de lagere expressie van 
interferon-genen in Hindoestanen ten grondslag zou kunnen liggen aan hun verhoogde 
risico op het ontwikkelen van type 2 diabetes.
In het volgende deel van het proefschrift richtten we ons meer op de behandeling 
van metabole ontsteking. Zo was bekend dat de ontstekingsremmende stof salsalaat 
bloedsuikers en -vetten verlaagt in mensen met type 2 diabetes, maar het mechanisme achter 
deze effecten was nog onontdekt. Het doel van het onderzoek beschreven in hoofdstuk 5 
was om de werking achter deze positieve effecten van salsalaat te onderzoeken. Dit deden 
we door muizen een vetrijk dieet te voeren en te behandelen met salsalaat. We vonden dat 
salsalaat gewichtstoename kon voorkomen en zelfs kon verminderen. Daarnaast hadden 
de behandelde muizen inderdaad minder hoge suiker- en triglyceridenniveaus in hun 
bloed. Dit kwam doordat salsalaat bruin vet activeerde en daarmee de opname van vetten 
uit het bloed door het bruine vet stimuleerde. Als we bruine vetcellen in een kweekschaal 
behandelden met salsalaat, maten we dat de cellen meer zuurstof verbruikten en dat de 
genexpressie van bruin vet-specifieke genen hoger werd, wat erop duidt dat salsalaat 
een direct effect heeft op bruine vetcellen. Als resultaat van dit onderzoek ontdekten we 
daarom een nieuw mechanisme dat verklaart waarom salsalaat zulke gunstige metabole 
effecten heeft in mensen met type 2 diabetes.
Tot slot bestudeerden we de therapeutische mogelijkheden van activatie van het 
eiwit GPR120. GPR120 is een receptor voor vetten die in het witte en het bruine vet tot 
expressie komt. De expressie van deze receptor wordt verhoogd door kou; bekend is 
ook dat activatie van deze receptor ook remmende effecten heeft op ontsteking en 
insulinersistentie kan verminderen. Het was echter nog niet bekend of GPR120 ook een 
rol speelt in de vetstofwisseling. Daarom onderzochten we, zoals beschreven in hoofdstuk 
6, wat de rol van GPR120 in vetstofwisseling is en of een specifieke activator van GPR120 
het energieverbruik kan verhogen, om zo vetstofwisseling te verbeteren. Als we muizen 
die géén GPR120 hebben een vetrijk dieet voerden, hadden zij een hogere vetmassa, 
verminderde fysieke activiteit en een lager energieverbruik dan controle muizen. Ook 
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hadden GPR120-deficiënte muizen een lagere expressie van bruin vet-specifieke genen 
in hun bruine vet, wat suggereert dat ze minder actief bruin vet hebben. Omgekeerd 
verminderde behandeling van muizen met een GPR120 activator tijdens een vetrijk dieet 
hun vetmassa na enkele weken. Daarnaast zagen we dat een kortdurende behandeling van 
muizen gedurende 5 dagen met deze activator acuut de vetverbranding verhoogde, waarbij 
ze ook al een beetje afvielen. Hieruit concludeerden we dat een gebrek aan GPR120 een 
hogere vetmassa tot gevolg heeft, terwijl activatie van GPR120 vetverbranding verhoogt 
en vetmassa vermindert. Daarom zou activatie van GPR120 een mogelijk aangrijpingspunt 
kunnen zijn voor nieuwe therapieën tegen obesitas.
Om af te sluiten worden de resultaten van dit proefschrift bediscussieerd in hoofdstuk 
7. Hierin wordt de veelbelovendheid besproken van therapieën die aangrijpen op 
vetweefsel en/of ontsteking om obesitas-gerelateerde ziekten zoals type 2 diabetes en 
hart- en vaatziekten te behandelen. Samen hebben de studies die beschreven zijn in dit 
proefschrift ons inzicht vergroot in de rol die het immuunsysteem heeft in vetweefsel en 
de vetstofwisseling tijdens de ontwikkeling van type 2 diabetes en hart- en vaatziekten 
(beoogde doelstellingen 1 en 2). Daarnaast hebben we mogelijke nieuwe strategieën 
geïdentificeerd die obesitas, metabole ontsteking en de gerelateerde stofwisselingsziekten 
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